Kimberly-Clark Aktie

Good morning, and welcome to the Kimberly-Clark Third Quarter 2026 Earnings Call. [Operator Instructions]

I will now hand the floor over to Chris Jakubik, Vice President, Investor Relations at Kimberly-Clark. Chris, please go ahead.

Thank you, and good morning, everyone. I would like to remind everyone that during our comments today, we will make some forward-looking statements that are based on how we see things today. Actual results may differ due to risks and uncertainties, and these are discussed in our earnings release and our filings with the SEC.

We will also discuss some non-GAAP financial measures during these remarks. These non-GAAP financial measures should not be considered a replacement for and should be read together with GAAP results. And you can find the GAAP to non-GAAP reconciliations within our earnings release and the supplemental materials posted at investor.kinberly-clark.com.

With that, I'll turn it over to Mike for a few opening comments.

All right. Thank you, Chris, and thank you, everyone, for joining us. This week marks a new chapter for Kimberly-Clark. We officially completed our acquisition of Kenvue, a defining moment in our 154-year history. We're delighted to welcome the talented Kenvue team. team.

The closure of this transaction marks a major milestone in our power and care transformation, a year of rigorous integration planning and the starting point for an exciting future defined by extraordinary care. We have created a portfolio and set of capabilities uniquely positioned at the intersection of fast-moving consumer goods and health care.

Our companies share a rich heritage. We pioneered entire categories providing everyday essentials that serve billions of people around the world. Consumers have been loyal to our brands for generations because they trust us to provide better care for them and their loved ones. We formed deep life long bonds with consumers and translate that intimate relationship into significant lifetime value. And now we have a generational opportunity to do even more.

Everyday health is becoming more personal, more proactive and more essential. With the addition of the Kenvue brands, we will be there for more people in more places and across more everyday health needs. That is the aspiration that guides our new company, better care in more hands to enable smarter health.

From baby care to women's health to active aging, consumers require and deserve a higher standard of care, and we will meet that moment with exceptional science-backed innovation and best-in-class execution that continues to raise the standard. We're energized and more ready. We work to strengthen our base business, enhance our capabilities and build our combined team. And now our team is heads down focused on execution.

Near term, we will enhance performance, efficiency and effectiveness by applying our proven operating model. We'll reinvest in our brands to ensure we're delivering superior brand propositions across the value spectrum. Medium term, we will benefit from category and geographic expansion. And longer term, we will capture secular growth tailwinds. Our teams have worked hard to map out our integration, and we've implemented the leadership team and operating model for the new company. Executed critical day 1 priorities and sequenced multiyear systems and process integration road maps. We've got a running start and our priorities are clear. We will execute with excellence deliver against our synergy commitments, strengthen our core brands and businesses and see growth.

Now to deliver the value of the combination, we have a clear 3-phase plan, ready, set and grow. Ready covers the first 100 days when we will set the tone for the new company. And in this first phase, will ensure seamless operations and deliver quick wins on synergies. I'm confident that our shared commitment to care and strong execution will enable us to deliver generational value for consumers, customers and shareholders.

Now looking at the third quarter, we delivered solid results driven by our durable operating model, which overcame challenging one-off headwinds. The underlying health of our base business remains strong, and we have sustained momentum. North America continued to show strength in tissue and share gains in K-C Professional, and we are driving performance in personal care.

We also delivered across our international personal care focused markets, including South Korea, Brazil and Indonesia. And as we move into the fourth quarter, we're focused on applying our playbook across the combined company and our durable powering care growth engine will continue to power and strengthen our performance. We're confident in our ability to drive sustainable growth in 2027 and beyond.

I want to thank the teams who have made our transformation possible and executed this acquisition with such dedication and focus. We're excited for this new beginning and the future we're building. Kimberly-Clark is a new kind of health and wellness company and extraordinary starts today.

So with that, I'd like to open the line for questions.

[Operator Instructions] And your first question today Dara Mohsenian from Morgan Stanley.

so we've had some press reports that have cropped up more recently, cost pressures, even with oil coming back down on the last couple of days here. You've been dealing with the China issue. Just to maintain fiscal '26 guidance, just wanted to get a sense of what drives confidence there and maybe some of the key assumptions driving the underlying Q4 delivery. And then for '27, the opposite question, which is you've laid out adjusted earnings dilution not expected to be more than mid-single-digit dilutive versus stand-alone K-C but you've got potential synergies. It could be pretty robust. There's a couple of onetime items from '26 like the fire, the China issue that could get better. So 1 could be more optimistic. So it'd just be helpful to hear some of the puts and takes for '27. Now that the deal is officially closed, particularly synergies and reinvestment needs and any of the other key factors you would call out for next year?

Okay. Dara, maybe I'll start, and I'll ask Nelson to chime in, but I just kind of want to give you some overall perspective on how we're thinking about the balance of this year and then a little bit into '27. But I will tell you, the overall is we feel great about where we are and what our plans are shaping up to be.

In the near term, we're very focused on executing and building sustainable momentum. And part 1 for me, the priority is we're going to focus on executing the integration seamlessly. As I told the organization in multiple town halls and my perspective is I want the integration to be boring for the organization and also for our customers. And then that means is in a pragmatic way, it's exciting that we're coming together, but we want to be able to operate. And our euphemisms internally would say, "Hey, we want to be able to ship product, pay suppliers and pay people." Right? So that's kind of the paradigm that we're operating in.

We're very focused on the fundamentals. I will tell you, as of Monday, we implemented the new organization structure and the new operating model, and that's off to a great start. There's definitely lots of work ahead because obviously, as we come to the coming weeks, especially into 2027, we'll be making some staffing changes, system and reporting changes but that's all going to be very, very well sequenced and we feel great about that.

And so I mentioned this like 3 stages of how we're thinking of integration ready. That's really about flawless execution through the first 100 days. Set is really about 2027, which is making sure we're set establishing a sound foundation for growth and then grow is unlocked in the full potential of the company, right? So I think that's kind of how we're thinking about the integration.

I think part 2 is the second big priority for me and my leadership team is we're focused on improving the momentum of Kenvue and K-C brands, right? I will tell you, self care and essential care performance was solid in the quarter. You guys probably already saw that. It was up 3% organically. We take a look at a detailed by category [ pipe ] time period scorecard of the Kenvue brands every month in our monthly trading updates up until we closed. And I would say for a scorecard that looked 100% red this time last year, Nelson, I think you would agree. I think when we had our view last Thursday, it was 70% green.

And so I think the Kenvue business is turning and turning pretty well. But the other areas where we've got to get improvement is some on the K-C brands. And as you're well aware, Dara, that we had the social media crisis that was proving to be false based on false information, but it did impact our business pretty significantly. And so I think it's going to take us time to work it back. We're very confident we'll bring the business back and ultimately regain our market leadership position, but it's going to take a little time to rebuild that.

And then the last area is we were looking for improved performance in North America skincare, North American oral care. And then a little bit on the K-C side, the personal care, we'd like to improve our execution in pockets, including in North America.

So again, I think that's kind of the overall -- where the first couple of priorities are -- maybe the thing I'll click on underlying all that is we're going to stay very balanced and focused on creating shareholder value over the long term. And that means, as you might expect from us, we're not really going to sacrifice long-term value to manage to a short-term number. We want to make sure we can invest in the brands.

The China diapers is a case in point. We're -- the business is has taken a hit, but we're going to continue to invest through the cycle to make sure that we build that business back to a -- and so ultimately, we're a flywheel growth company, and that means we want to be able to invest in our brands to drive growth, and that will create a virtuous cycle of growth. And so that's kind of where our focus is. But I think Nelson, maybe we'll give you maybe some of the additional details.

Yes. Just to unpack a little bit, Dara, I mean a few things. As Mike said, we feel pretty good about where we stand today. And more importantly, we're taking a very disciplined approach to the first year of the combined company to ensure that we have sustainable profitable growth in the mid to long term. .

As a starting point, I mean we're on track or ahead across the key deal metrics that we laid out a year ago, including closing of the transaction, the synergy pacing, the cost of capital and the operating momentum across our legacy stand-alone Kenvue card business, Kenvue our new categories, and Arbex, which went live July 1 of this year with our joint venture partner, Suzano.

I think in perspective, as we head into the balance of the year and 2027, our first full year as a combined company. For a transformation of this magnitude, I mean, we remain on track on both earnings accretion and importantly, approximately getting to about a 2x leverage by the end of the second year of the transaction.

Now going into your question on 2026 and then next year. First, our outlook, and that's, again, stand-alone Kimberly-Clark, reflects stronger underlying business momentum that the headline third quarter results suggest, along with a strong global commercial agenda for the fourth quarter, that's underway. We also expect to benefit from incremental cost mitigating actions that were taken in the third quarter. This includes all the elements within our integrated margin management, [ toolkit ] revenue growth management, productivity and other measures that the team has already activated.

And the other bit to take into account is that we have an easier comp in the fourth quarter, particularly for our North America business, which, as you might remember, had a lower growth in the fourth quarter of last year.

And then the other bit, as Mike mentioned, is we will remain pretty disciplined in the balance of the year, that is in the next 2 months. and we're reserving the flexibility to pursue value-creating investments that can accelerate our longer-term agenda, if attractive opportunities emerge between now and the end of the year.

Now looking into next year, 3 things that we're focused on: first, delivering the deal synergies; second, strengthening the core of the 2 businesses; and then third, seeding future growth. As it relates to deal synergies, we are on track with our synergy plans and the actions that Kenvue took at the beginning of this year actually position us well to have a strong start as we get the 2 companies operating on a combined basis now.

The other bit on -- is on strengthening the core of the businesses. We continue to expect a gradual return towards a category level growth, particularly in the new categories that have come into the business. And this will be supported by increased investments in marketing, innovation and R&D. At the same time, we'll be sharpening the portfolio and improving execution. And this will include SKU rationalization, increased service levels improvements, all of which can create some near-term impacts as we position the business for healthier, mid- and long-term growth.

And then lastly, on seeding our future growth. We are also making targeted upfront investments behind our biggest categories and the opportunities we see, recognizing that the financial contribution will build over time. So overall, Dara, we feel pretty good about where we stand today, and we remain on track against the assumptions we established a year ago, and will preserve flexibility to invest appropriately behind the business over the next few months and in 2027.

I feel like we hit you with the fire hose.

Your next question is coming from Peter Grom from UBS.

So I wanted to just ask about North America I know there are a lot of moving pieces here, but would love to get your perspective just on the health of the business, given weaker share performance in the last couple of quarters and the pricing lower. So just any perspective there and how you see that evolving as we move forward?

Yes. Thanks, Peter. I will tell you, I'm confident in the underlying health of the North America business on the K-C side. Well, actually both sides, I think -- but I think that question was more directed on the K-C side. The underlying health of the K-C side of the business is solid. It was a soft quarter. Definitely, Peter impacted by a few key discrete impacts, the largest, I think, which is again, retailer inventory changes, which for us in the quarter was about 130 basis point headwind.

We did postpone a major new product launch. And again, that's maybe an executional issue within the house. We had a new manufacturing asset to produce the new product out, and it wasn't putting out the quality that we wanted. And so we pulled it back and we'll be launching it likely next -- early next year. And so that was probably the second big one.

And then there is some share softness, primarily due to club distribution changes in baby care, which I think you guys are all well aware of. And so those are a few of the big impacts. I do expect overall in North America, our execution to improve. I'm really confident in the innovation pipeline I think the brand investments that we have and the commercial capabilities, as you guys are well aware, we have a great customer organization.

Our e-commerce business is growing double digits, I think, north of 20%. And then the other area, Peter, is tissue is performing very strongly, both on the consumer side and on the professional side, and we feel great about the performance there.

So overall, for the year, I know you probably want to talk a little bit about promotions, but I think we expect our pricing overall for the year to be about relatively flat. And so again, while I think it's maybe 2 quarters are a little softer than what we're used to. We do expect to improve our performance in North America.

And just to add a couple of numbers, Peter, for you. I mean, one, keep in mind that the club distribution and diapers and training pants, it's about 1 point of headwind in the quarter for North America. And then also to reiterate what Mike was saying, in tissue, we gained overall 20 basis points share on a weighted basis in the quarter. And that's on the heels of 2 straight quarters of continued strong performance [indiscernible] underlying health of the business in North America is strong.

And again, as we've got strong activations and innovations in the pipeline, which will continue into next year.

Just to add 1 point there. I think as you're tracking, Peter, I think you mentioned the patterns on pricing. As you look at it, year-to-date, total company pricing is down about 70 basis points, 80 basis points in North America, and that's having lapped our least intense quarter of programming last year.

If you recall, we shifted some programming from Q3 to Q4 last year. So Q3 least intense period and we're about to lap our most intense prior year period of programming in Q4. So as Mike said, when you think about the year, we'll probably land pricing relatively flat. So you kind of get on a sequential basis, a little bit of a pickup in terms of what that pricing profile looks like.

Your next question is coming from Michael Lavery from Piper Sandler.

I just want to come back to Kenvue, your excitement over the deal is clear. And I just want to see if you can help us understand a little bit better how to think about some of the brand's health momentum. They've obviously been a little quieter since the deal was announced but you guys have been working with them closely. Can you just maybe give us a sense of -- maybe first of all, some of if or how their brand-building framework that they used, how it compares to yours, what similarities or differences there might be?

And just how to think about the opportunity for the organic growth because I think some of the cost savings potential is -- it feels a bit more straightforward. But I know there's also a real focus on just building that top line momentum. Can you help us understand how you see those building blocks there? And maybe some kind of your take on the recent color from their side.

Yes. Okay. Michael, great question. I will tell you -- I will give you a little color just recognize it's day 3 for me, officially. So I want to try to give you a little more context for how the brands are doing. I will tell you, your overall question, and I think I said this a little bit earlier, A lot of the challenges that they've had over the past few years have been, in my mind, 100% executional, and I don't think I've found any that I perceive as being structural yet, right?

And so -- and so -- but I do -- what I will say is, I think, Kirk and the leadership team at Kenvue did a phenomenal job pivoting when Kirk gotten that chair. And I think this goes back to it and this is where Kirk and I bonded because we were kind of trained by the same people. And so we have a similar philosophy on how you support brands.

And so I think Kirk made a lot of big moves to strengthen the execution. One of the most important was, at the beginning of January, he flipped the operating model, which matches almost exactly with ours, which is why we've been able to so seamlessly move to the new org structure on Monday first thing, and we're operating in a new model.

I will tell you, I'm encouraged with Kenvue's Q3 performance, as you guys probably saw organic was up about 3%, and we're seeing some positive momentum. I think there is plenty moving in the right direction. And maybe I'll note a few things, Michael.

OTC overall, I think, is performing well in my book. [ TENA ] for the year, I think up somewhere between low to mid-single digit, I think, which is a great rebound. I think in the quarter, it was up about 70 bps of share. Also in OTC, Nick -- it is up about 7% year-to-date, [indiscernible] up 5% year-to-date. Love the advertising they're doing to drive kind of category expansion with Sanjay Patia.

And then I would say, overall, hair, very good. Row gain. Surprisingly, I didn't know this, Michael, but it may be driven by some GLP adoption, GLP-1 adoption. So [indiscernible] is up 30% year-to-date. OGX, the shampoo is also performing very well. And then in Essential Care, the baby brands are up about 5% year-to-date. Band-Aid which is a great Halloween giveaway is up 4% year-to-date. And so I think there is plenty of moving in the right direction.

Again, what's driving it, and this kind of reflects maybe a personnel choice I made more recently, North America, it's clear -- Carlos and I also have a very similar training and he's very focused on the core aspects of execution, which DPSM is the shorthand, which is distribution, pricing, shelving and merchandising and focusing on execution, which I think, Michael, have been a little bit off of the focus area for Kenvue in the past.

And I think we are seeing -- really that kind of performance is really driven by better fundamental execution across all those levers. I think we're not out of the woods yet. And so the areas that we got to improve, I would say they're stabilizing, but there's plenty of work left to be done.

Skin care was down just a little bit under 1 point year-to-date, and that's versus a category that's up about 4 or -- and again, I think the team has taken steps to improve execution there. I think medium term, and this is my perspective and it still needs to be worked through the team. I think it's about resetting the assortment. I do think there's some extensions that we've done with some of the brands that will require a reset over time. And the other area for me and [ John Halverson ] knows this, and he's going to -- he's totally up to the task, and I was just with him and the agencies a couple. We've got to improve the creative execution.

And I'm looking -- while -- in skin care, the marketing investment is fine and it's competitive with the category, I think there's room to increase our investment there. And then the other area is oral care, Listerine year-to-date, down about 2 points. For me, this is in my opinion, which is I think we need to simplify and clarify the offering and the key benefits for the consumer.

Given the leadership share position that we have, I mean, a very, very strong leadership position in the category. For me, it should be similar to what we've been doing with Kleenex and the Penn and Poise, which is focus advertising on expanding penetration and frequency of the category. And so that's kind of the focus area for us.

Beyond that, Michael, I would say longer term, there's a lot more headroom in these categories than I originally thought when we made the initial announcement. It's going to take some time to get there. We're not going to take shortcuts. We will build through the fundamentals. And so what you'll probably see in '27 is A little bit of a conservative approach that we reflected in our 2027, '28 outlook. We want to create the room to accelerate investments and get the brands in a better position to grow.

And Chris tells me to tell you that we're going to share more at CAGNY.

Your next question is coming from Chris Carey from Wells Fargo.

First, Mike, just can you talk about the team's ability to deliver on this integration and synergies while continuing kind of operational excellence on the legacy Kimberly-Clark business with a key leader leaving in restore and at how you're backfilling and making sure that you don't miss a beat. That would be question number one. Just love some context on that. .

And then for Nelson. When you say mid-single-digit dilution for 2027, just to be clear about this, are earnings down mid-single digits in 2027 than [indiscernible]. That's my interpretation which I think is what you're saying, but I'd just like to confirm that. And then within that, can you just talk about the treatment around amortization going forward in the non-GAAP numbers and what's reflected in the outlook for 2027 and going into 2028?

Okay. All right. Thanks for the question. Let me start with the team. Look, I feel great about our leadership team, and I think we're really well positioned to deliver generational value. You may know that -- I may have mentioned this before, but we did detail assessments on every leadership team member for both Kenvue and K-C kind of going in as I selected the staff. .

I think Nelson told me he spent 7 hours being assessed. And so we took a very detailed approach and we used outside experts to kind of help us do that. So I feel very good about the talent that we have in the room and the selections. Certainly, I guess I will say, first and foremost, I'm excited for us and his new adventure. And I think not knowing that much about that business, but I think they found a good one, right? And so I'm excited for him.

I would tell you, his departure probably reflects a change in timing for both of us. It should be clear to all of you that within K-C, we were on a path of transition. And but when we have the opportunity to create this, I would say, combination that would create generational value, I think the timing for me change and the timing for Rus changed.

And so -- and you're only going to have this time of your life once, right? And so I'm excited for him. I will tell you, parenthetically, I love being more directly involved in all aspects of the business. I'm not sure the team enjoys that as much, but it's kind of more akin to what I'm used to doing. And so I think, hopefully, that will have a positive impact.

Let me tell you the IMO is in great hands with Jeff Melucci, who put a lot of this deal together steering the process and then Nelson, who you would really want tracking and making sure that the teams are ensuring synergy delivery, which lines up with financial delivery anyways. The big note that I should point out is we had transitioned about 60 days ago from an IMO led implementation of the synergy delivery to a, I would say, ELT led, right? So each of the ELT team members or enterprise leadership team members, whether they're a business unit owner or a functional owner are accountable for delivery versus kind of a group in the center. But Nelson is going to oversee that. So again, I feel very good about where we are at the team, and I feel great about the people we have on the team.

Yes. And then Chris, going into your questions around the modeling and the outlook we gave when we announced the transaction. First, all comparisons are against K-C stand-alone. That's the first bid. We will come out with pro formas and all that in more detail as we get into reporting actual results for full year '26. And put that forth so that then we can start comparing that in that way.

So when we talk about mid-single-digit dilution and then snapping back, that's exactly it. So for 2027, that's what we would expect, but that is against a stand-alone Kimberly-Clark EPS. And that would, of course, be reflective of the fact that we would have the amortization of the intangible assets and go into that, the treatment around amortization is, as you remember, Kenvue was adjusting out their portion of amortization of these assets, we don't. It's not in our policy. So we actually, we'll keep that within our non-GAAP metrics. So that's the element that's there for modeling purposes.

And we have that reflected also in the latest performance that we filed as part of the recent debt issuance. Then as we step into 2028, what's going to happen is we expect to have a year that's on algorithm on a 2-year compounded basis, which would be in the mid- to high single-digit EPS growth on a compounded basis, 2 years versus the baseline of 2026 stand-alone K-C.

Your next question is coming from Javier Escalante from Evercore.

Congratulations on completing the merger. I would like to double click on diapers, if I may, both in the U.S. and China. How is your diaper business performing outside club? What is the competitive dynamic overall. What we see in [ Serkan ] is these Chinese diapers are leveling off and wonder whether that opens up an opportunity to restart a premiumization cycle after 2 years of promos. .

And number two, in China, I know that is [ 11/11 ] social commerce is a big deal there. How are you using this to build trust any early reads on equity, how the messaging is landing. I know that you said that the recovery is going to take time. But anything -- tell us how you're dealing with this, and I have a follow-up, if I may.

Okay. Thanks for the question, Javier. Great to hear from you. Look, I feel great about overall our diaper business. I know it's been a choppy couple of quarters, but when you I think when you take 1 of the best performing businesses we have in the world and chop it by 70%, it's going to affect the business. But I would say the underlying kind of strength of the products, I would say, the performance relative to competition of the product, I think we feel great about and then the innovation pipeline that we have.

So we've got a proven strategy to elevate and expand the category to your point, right? And so -- and that's what we're going to continue driving. We know how to win in the most competitive markets in the world, especially China, and so our playbook is to drive that innovation that grows categories deliver superior value propositions across all value tiers.

Our strategy internally is really, Javier, best product at the lowest possible cost, right? And then when we do that, that creates the room to invest in building brand love and driving really compelling activation. I'd say -- I'll start with North America. I think I'd say we've seen solid performance in North America over the last few years, gained share 2 years in a row leading up into this year, despite increasingly intense, I would say, promotional environment.

I think we feel like we have the best innovation agenda that we've had in a very long time. To your point, I would say premiumization continues to create some tailwinds. Just for reference, I think when I joined the company, I think we were about 30% of our business overall was premium. Today, we're well over 85%. So I think what you articulated around driving premium mix through offerings that offer that better performance for consumers is the core of our strategy.

I think we have seen over the past few years, the entry of some lower-priced diapers, a lot of it coming from China. Our attitude is, while we've been -- we compete with 200 diaper brands in China, we've been beating them there. And so we feel confident we can beat them here.

And so for us, our approach is, hey, let's make sure that our value propositions are sharp and that we continue to bring the innovation. And so we have things like [ HUD Fit 360 overnight ] we're excited about 1 that will prevent diaper rash more specifically that we'll be launching in the first quarter. So we've got a lot of great news.

I would say, as you point out in the U.S. The majority of our share decline in U.S. baby care was driven by distribution changes in club, which we're working through. I would say if you look outside of it, Javier, your overall across BCC or our baby and child care, more broadly, our shares overall slightly up. And so we feel good about where that is. But we're going to stay focused on executing our playbook.

I'll pivot to China. Just to kind of give you all the context, the Chinese authorities refuted the false allegations that were -- and they declared that Huggies were safe. And so that was really important Sam or the authority that had jurisdiction there confirm the quality and safety of our products.

And I will tell you, they were very complementary of how our teams engage with them through the whole discovery process. At this point, Javier, demand has stabilized, I'd say it's improved slightly. But recovery is going to take time because here's what I've learned, which is like Bad news goes viral, and good news does not right? And what that means is like then we have to build -- put the good news out ourselves, and that's going to take a little time, right? But again, as I told the team in Shanghai, like if there's any team that knows how to do it, it's that team, right?

And so again, we're focused on rebuilding consumer trust. We're elevating transparency directly with consumers. I think we have I think a glass box look into our production facilities for consumers to look at. And then a regular update on, they can see kind of the quality coming off the line. And so I think we feel great about that innovation.

And so I think we -- it's probably no team. I'm more confident in than our China team. And I think the long-term health of our China business, I'm excited about diaper specifically, but I'm also excited about how the China team, together with the Kenvue team, will build the Kenvue brands in China as well.

This leg will pass, I guess. I interrupted you. Go ahead.

I was just going to say you asked specifically on 11/11. I mean that's a hard -- so the reality, Javier, is that it's going to take some time. And 11/11 is already, if you were pipelining and creating everything that already went through. So I -- it's something that as the news came out, it was right upon us, and we still expect the business to be subdued in the fourth quarter because of where we're at and the timing of when the government came out with the results favorable to us.

But again, we will take the time. We will make the right investments in order to make sure that Huggies gets back to its rightful place in China. And as a reminder, right before this, we were right around 20% leadership, number one, gaining share for 5 years straight at about 200 basis points a year in our business in diapers in China. And -- we're absolutely focused in making sure that we regain that.

And in this period of my comment of making the merger boring right? If you can help us because there has been a lot of detail here. In a very simple narrative, how you see the sequence of the synergy plan in 2027. So the way that I think of it in my head, perhaps is how you preserve the low-hanging fruit in terms of revenue synergies. What are you going to be tackling in terms of cost? Is it cost, is it back office, tell us a little bit kind of like in a very simple way, this is what it should be happening through 2027.

Let me start with a higher level and then Nelson can add. But Chris wants me to make sure that I say Javier, more on CAGNY. Okay. But number one, I'll just say here's how we're thinking about it. Again, I'm kind of a boring person and so I don't like drama as we operate the business. And so I think we have a very well thought out plan.

I mean we announced the leadership team back in April and then the next few levels several months ago. And so the teams had plenty of time to think through this. Maybe part 1 is there are going to be significant staffing changes, and this is the unfortunate work of kind of combining companies, but there are going to be staffing changes throughout 2027. And we feel very good about our plans there. And I think our teams know -- are very familiar with what those are. And so that's part 1.

Part 2 is I think maybe primarily on Nelson's teams, we're going to run separate systems for a while, and then we will gradually bring them in because K-C happens to have very robust -- the latest SAP S4 ERP systems for both North America and then a separate instance for the international business. And so we'll, over time, in a phased way, bringing the Kenvue businesses onto those platforms as we bring the K-C businesses forward on those.

And so in the meantime, I think it's on Nelson's team to kind of cover together reporting. I guess they're using Power BI, Javier to kind of do that. But again, that will give us, I think, the visibility we need to manage in the interim. But I think we have a very planful approach to deliver the synergy. Not sure if Chris agrees with me saying this now, but I feel very good about where we are in the synergy plan. And sitting in my chair, as you would expect, that I would say, but I think we will beat the synergies that we've talked about publicly.

Javier, a few things. I mean, obviously, we've been -- and we've been providing updates over the last 12 months, we've been very diligent in our process of looking at the synergies through the IMO, the segments and the functions and getting ready for day 1, which was earlier this week.

And we, as I said earlier, I mean we're on track with our plans. Again, the overall cost synergies for the deal are about $1.9 billion, and there's 3 sources that very clear to us. One is the overheads optimization, G&A that will drive about 1/3, and that is already incorporating, eliminating certain roles, which is part of having to do a transaction like this. It's leveraging spans and layers of controls across the organization. And then there's a series of nonpeople costs, including systems, which we are progressively going to be tackling and starting now. And that's very clearly laid out.

The second bucket is in cost of goods sold, and that's going to be closer to 40% of the overall give or take, of between 30% to 40% of the synergies. And we have clear plans with [ TENA] and our organization around optimizing our distribution network and leveraging procurement capabilities to drive savings from starting now.

And then the third bucket is in sales and marketing and trade spend optimization. Very clear plans on that, obviously, tackling duplication of roles, but also around leveraging media synergies and optimizing trade spend. So all of that is very carefully planned, and it will be orchestrated and executed starting -- executing now as we begin the first week of the merger of the 2 organizations.

We'll provide more details when we get to the CAGNY. And obviously, 1 of the things that we've talked about earlier this year is we're encouraged by Kenvue having taken a proactive approach at the end of the first quarter, getting some of these organizational changes underway which accelerates some of those synergies into 2026 and give us a good head start as we go into next year. We'll provide an update on the cadence and of how those savings will come through, but some of that has already been materialized this year.

Your next question is coming from Anna Lizzul from Bank of America.

I was wondering if you could elaborate specifically on your launch of big dreams and diapers. And where do you see this competing in the landscape? What are your aspirations for this brand specifically? And then if I can ask a bigger picture question on cost. Clearly, freight, a bigger headwind. How should we think about that in terms of some of the heightened costs, but in light of the benefits you're also seeing from the Arbex JV on input costs?

Thanks for the question, Anna. Maybe just a comment. We're really excited about Big Dreams and that's something -- I think for those who may not have the context that we've launched with Amazon in partnership with Amazon I think the team at Amazon is very, very excited about the product. I think we've put together a fantastic quality product that I think has with the attributes with our knowledge of the diaper category, we kind of know what consumers are looking for. .

And I think the unique thing there on is we want to make sure we're offering a very, very strong value proposition, particularly I would say for, I would say, middle to lower income consumers. One thing that I'll emphasize is, we saw the -- maybe a few years ago, several years ago, maybe the prospects for what everybody calls this K-shaped scenario of an economy. And so we're really, I would say, steeled or focused to be able to operate effectively in that kind of environment.

And so for us, we've been emphasizing, hey, how do we bring the best of our innovation into more value-oriented offerings. And again, that's kind of why we're looking to drive low cost in our production so that we can afford to do that. And so this is another example of that. Within the Huggies brand, we did something similar, bringing, I would say, our latest core technology on diapers and launching it into our value tier first on Snug & Dry in North America about 18 months ago. And so again, that's kind of part of our strategy, which is to adapt to the -- and kind of win in the K-shaped environment. And so we feel good about that. And then maybe I'll ask Nelson to comment on the inflation.

Anna, in terms of costs and where we stand today, as we provided the update back in September at the Barclays conference. We now project the total full year gross inflationary impacts of around $250 million of which $50 million was an impact in the second quarter. And then for the balance of the year in the second half, we expect that around $200 million of inflation. And this step up of around $50 million our prior update back in August, concurrent with our second quarter update and earnings is largely driven by the spike that we saw in spot freight rates in North America. That number, again, remains the same. There's no change right now versus what we updated you all at the Barclays conference earlier in September.

The teams are doing a great job through a combination of mitigating actions that have been undertaken, as I mentioned earlier in the call today, and that includes all elements of the integrated margin management toolkit from revenue growth management to the very strong productivity that we're delivering year-to-date we're at 6.1%, gross productivity, 5.8% for the third quarter. So those programs will continue.

And obviously, we always on cost discipline around all the structures. As it relates to Arbex, I mean, we're very pleased with the standup of the joint venture, which went live July 1. The Arbex management team and Suzano partner and along with ourselves, we're very focused on unlocking strong value creation, which will entail a very proactive measures around cost containment, cost management and driving productivity, and we're taking full advantage of that already. So that's underway. We will be providing a full update on our view for 2027 when we get to that in February of next year.

But again, we remain very disciplined in our approach to managing costs and managing over the term of the business to ensure that we deliver pricing at a cost of lease neutral, which is our philosophy that's been in place for many years now.

Next question is coming from Robert Moskow from TD Cowen.

And maybe you're going to give more details at CAGNY. But the revenue synergy target was the 1 that stuck a lot of people as the most ambitious. They are notoriously difficult to execute. And it seemed to involve a lot of international expansion of brands that had not traveled into these different regions in the past. So are your first impressions the same? Like do you still see the same kind of opportunity? And what are the first steps for enabling that, Mike maybe you could talk a little more on that.

Yes. Thanks for the question, Rob. Again, and maybe -- I'm not sure, Chris, if I do it over again, maybe I wouldn't have put revenue synergies out there because I think what I'm hearing from investors is, well, we don't care until you put them into the algorithm, okay, which I think is fair enough, right? And so however, sitting in my shoes, Rob, I think we will deliver more over time. But I wouldn't write that down because I think ultimately, it has to make its way into the growth algorithm, right? So that's part one.

But I'd say in the medium term or short term, I would say it's what you say, which is like there's some obvious distribution gaps. We had a large personal -- K-C personal care business in Europe probably about a decade ago. But we had a tough time in that business. I think Kenvue brings I think, a lot stronger distribution and capability in Europe than we ever had.

Similarly, in India, we used to be in a joint venture with Unilever where that got us very good distribution. And when that agreement ended, I think we've struggled since. And so Kenvue has a multi-hundred million dollar business there. They're in about 3.1 million points of distribution in India. And I think that's a market that I think the K-C personal care brands can make an impact in.

And so I think there's going to be some obvious, I would say, geographic distribution opportunities that while we've struggled in the past. I think there are some capabilities that are different. The [indiscernible] is the same within Kenvue, they've got a relatively, I would say, a smaller business in markets like Mexico and Korea, where we are over $1 billion in both those businesses just on the K-C side. And so I think, again, we feel like that there's some pretty good opportunity.

Longer term, -- and again, maybe there's a misnomer in terms of what's a synergy, there's really 2 buckets of what we're calling synergies. There's like integration synergy, which tends to be the smaller amount, right, in my mind, because what we have in articulate as well, and this is probably my fault, Rob, is like there's a lot more transformation opportunity, right?

And the thing is K-C, I would say we're still in the early innings of our transformation, I'd say, like the third inning. And I think Kenvue is earlier in that process. And so a lot of what I -- I guess I'm miscalling synergies really transformation opportunity. But -- what we're seeing is there's a lot of category growth, category development opportunity that hasn't -- there's still an opportunity for us to market more effectively.

And again, maybe the example I'll give you, if you think about on the K-C side, what we've been doing with Kleenex, what we've been doing with Poise the pen, which is advertising to expand category consumption penetration frequency, and by the way, on the Kenvue side, they're seeing great results. The reason why allergy [indiscernible] is up this year is because they've shifted to that strategy at the beginning of this year, and I think it's really working effectively. I mean, the facts are which is shocking, less than 20% of the population that suffers from seasonal allergies ever treat it.

And so kind of that's the insight that we're going after. And so that's kind of why we have a lot of conviction. And I would just say what the growth is going to be.

And just to be clear, when you gave that $1.9 billion number, were you talking about transformation opportunity also or 2 different things?

Well, I would probably say, no. I mean some of it is pure synergy stuff, but some of it is more efficiency that we saw. So I think it's been -- it was a blended number.

But the $1.9 million is cost. That does not have anything related to revenue synergies, robin. As you remember, I mean, it was minimal in terms of the operating profit or EBIT that we would see out of the revenue synergies in what we valued because we reinvested over close to 60% in our modeling in the S-4. .

Yes. It was $1.4 billion revenue, but only $200 million in EBIT contribution.

Because of the reinvestment of around $300 million. So the when I talk about the synergies, it's really going to be on the $1.9 billion, which is the costs, Rob, that's what we're focused on.

And Rob, maybe just -- sorry to keep adding to, but I would say, hey, maybe this is a topic that investors bring up. Hey, Mike, is this cost play? Or is it a growth play. And my attitude on -- no, this is a flywheel play, meaning like the whole goal is we're getting costs out so that we can reinvest in the brands to grow the brands faster. And so that's, and that's our model of power and care that we feel really strong conviction about that's been working for us. I know we can always improve our execution, and we're going to do that, but that's kind of what we're doing with this whole transformation with both companies.

And that's how we doubled over the last 5 years, our absolute advertising spend because we applied that flywheel as we ran through power and care and the whole transformation of the portfolio. So that's the playbook that we're going to have the combined company gets underway this week. .

If we can take 1 more question.

Your final question is coming from Susan Anderson from Canaccord Genuity.

And thanks for all the details this morning. I was wondering if maybe you can just give some color, maybe I missed it on just where retailer inventories are at with your brands and categories and then also including the Kenvue brands. I think -- some of the competitors talked about a weaker start to COGS cost, which impacted retailer orders. I guess, are you seeing something similar with Kenvue OTC brands with inventory at retail and then just how you're feeling about your other categories as well going into the back half thing.

Also a great question since Nelson and I just looked at the retail inventory by geography, Kenvue last Thursday. I mean, I think it's kind of normal to within the range of what they've been carrying for the last few years. And so we feel good about that. I think there have been some changes on our side. I would say retailers have -- inventory has compressed a bit. I do think with a couple of big customers, there have been some changes in inventory strategy, inventory technology that's driven by that. But again, I think in general, I would say the retail inventory headwinds that we've experienced last year tends to be timing related. And so our underlying demand, I'll tell you, we feel it remains healthy.

Yes. And I would just add, I mean, 2 things. One, in North America for this year, it's going to represent for the close to about 1 point of growth, and that's what we have -- for us, for K-C stand-alone. As we go into Kenvue, as Mike said, I mean we've been looking at the data. We're obviously joining forces as we speak. We'll go through the integration, and we'll see what those levels are. And there obviously could be some changes in adjustments, but the 1 thing is we're going to be focusing on service levels.

And as service levels improve and whatnot, there will be further optimization in inventories. And obviously, this is 1 of the places where, as we get into the integration with our supply chain team, and we deploy, can access and some of the tools that we've got, that should drive optimization over time. But again, more to come on that as we get underway with the integration. Susan.

Great. Well, thanks, everybody, for joining us. If analysts have any further follow-up questions, myself and my team will be available to take them. But thanks, everybody, for tuning in today.

Thank You. This does conclude today's conference call. You may disconnect your lines at this time, and have a wonderful day. Thank you once again for your participation.

Good morning, everyone. We are pleased to kick off this busy day with Kimberly-Clark. We've got the full team here. We've got Mike Hsu, Chairman and CEO; Russ Torres, President and COO; and Nelson Urdaneta, CFO. And Chris, I don't know your proper title other than IR. IR. Head of Investor Relationship. Thank you for joining us, everybody.

Mike, to say a little, like a lot has changed at Kimberly-Clark over the past few years, and that's probably an understatement. Before we get into that, though, I wanted to start just with The Powering Care strategy that you introduced at the March 2024 Investor Day. For those that may not be up to speed, could you just maybe give an overview of that strategy and detail how it differed from the company's prior strategy?

Okay. All right. Thanks for having us here, Lauren. Great conference, and we're excited to be here. Yes, Powering Care, we introduced, as Lauren said, at our Investor Day back in the spring of 2024, and we've been operating on that pretty consistently. It really has 3 big planks. Plank #1, we call externally, Lauren, accelerate pioneering innovation. Internally, we call it onslaught because that's kind of really the intent of what we're looking for, which is an onslaught of pioneering innovation, marketing and activation. But I think the core idea there is, hey, to understand what consumer needs are that are kind of unmet.

We want to deliver obvious superiority and then for us, superior performance is another way to deliver superior value. So that's our big focus there. The second big plank is what we call optimize the margin structure. We felt like we had some room to improve in terms of our cost structure. We really think about that as how do we offer the best possible product at the lowest possible cost. Internally, it's not lower cost, it's lowest possible cost. We operate that way, and we've made strong progress, as you've seen over time, enhancing our margins.

Then the third plank is wire the organization for growth. Historically, Kimberly-Clark was a very decentralized company and which led to a lot of positive things, Lauren, very entrepreneurial, very agile markets, but we underleveraged our scale. A big part of wiring the organization for growth is how do we leverage our scale more effectively and enable ourselves to go faster by bringing global might to the local fight. So I'll pause there.

I would say, since '24 when we've been operating, I think it has helped us deliver consistent organic growth. I think we're in our 10th quarter of volume and mix growth. We've expanded our margins and really dramatically reduced our earnings volatility, which you may remember from the bad old days.

The many. Yes, definitely. So in that context, you gave us a little lead in. Let's dive into the business performance, just looking at the company, excluding what's now in the IFP JV. So over the medium-term, organic sales have held in well at 3.9% in 2024, 1.7% in '25 but things have slowed down again more recently. Can you just speak to how you aim to drive top line in categories that many would still say are very slow growth? And then also touch maybe on trends you've seen closer in that resulted in you taking down your fiscal year organic guidance report in August.

Yes. Thanks for that. Maybe I'll lead off, Lauren, and I'll ask Russ and Nelson to comment with a little more detail. But I would say the headline for us is the categories we operate in, I would say, are very durable and resilient. Our focus is on superior value and expanding the categories. That's really kind of how we're driving our growth.

The resilient and durable category part, I mean, the reality is if you look at our categories like diapers, adult care, bath tissue, they really kind of if left alone, grow with population growth, right? So that's kind of the thing. It's not a fast-growing category tends to grow with population, but we feel like we can accelerate that category growth by adding premiumization into the mix. That's what we've done in our 2 largest markets in North America and in China.

I think back when I started with the company, I think we were about a 70% business was mix driven by value in our value performance tiers. Today, we're over 80% premium. China, if you went back to 2019, was 6% premium. Today, it's well over 50%. So I think the -- one way we accelerate is bring value-added innovation to drive the premiumization of the category. I think it's been working.

Then the other big area is we feel like we can expand the category as category leaders by driving category consumption. So an area that we focused on more recently in the last 3 years was on Kleenex, and we've been able to successfully drive household penetration over the last 3 years by focusing on kind of the category growth drivers. I think we've seen Russ maybe about, I think, 7% compounded growth over the last 3 years on Kleenex. There are ways that we think about that we can drive it.

I would say your note on what's been happening this year, I think, one, I would say the category has been choppier. We have seen an uptick in promotional intensity by competitors over the last few quarters. Whether they're new small brands or some of our major competitors, we have seen that occur. I think our point on it is, and you've heard me say this before, Lauren, is like we're not really -- it doesn't really make sense for us to try to rent additional share through promotion.

The reason I say that in our categories, since they grow at the population, they're kind of fixed consumption in a lot of ways. When you overpromote the category, you kind of drive -- all you're doing is buying forward inventory or pantry loading consumers. That's not really that valuable for consumers or the retailers.

Yes, Mike, I'd just add, you mentioned choppiness. It is a choppy environment out there. I think our teams have demonstrated very good agility in responding to those one-off impacts. We talked about the China situation in our call in the second quarter. Just for those who didn't hear, that was going to be an impact on the full year of about 100 basis points to our organic growth rate for the total company and about $0.18 of EPS and that will come through in a more significant way in the third quarter. It's about a 250 basis point headwind for that.

But our teams have really pivoted and focused on taking the playbook and applying that to other markets internationally. We've seen very good growth and share gains accelerating in markets like India, Vietnam, Korea, Indonesia, around the world. Our teams are pretty resilient. Since the second quarter, we did, in North America, see 3 additional challenges arise that will likely cause the third quarter to come in softer than we had expected.

The first was we had an innovation launch that we postponed due to some production issues. The second is in our professional business, we saw some pretty significant distributor disruptions and that's a business that we've grown volume 7 quarters in a row. We've gained share in all of our categories in the second quarter, but that distributor disruption is going to cause a significant inventory deload for us. Each of those 2 will be about 1 point of growth in our North America business, respectively, in the third quarter.

Then third, we've seen some -- as you probably have heard from others, the freight market and logistics market in North America is tightening. We've seen the prices go up there. We're a little more exposed to that than we usually would be because of the Los Angeles distribution center fire. We had a lot more things that are being moved around, and that will also be a significant impact in the quarter of about $30 million to $40 million of incremental costs.

Our team in North America is working on offsetting all those things, but it is a choppy period. We're going to continue to execute our play and feel like we do believe at this point, the full year will be consistent with what we had talked about on the second quarter call.

Okay. All right. So Nelson, just to bringing it to you. No impact to the full year top line and bottom line. Is that correct? This is all within 3Q?

Let me unpack it a little bit more. As we've said in the past, we focus on managing to the year, the mid-term and the long-term, not really the quarter. I mean there's just a lot of moving pieces. More importantly, our focus is on profitable growth. Over time, things will move, but what Russ just explained is going to have an impact on the third quarter. That's the one thing we know. As we look at the third quarter right now, it's -- we are projecting that we're going to see our revenue contract in the low single digits with a low teens decline in our EPS versus the prior year.

There are a lot of moving pieces, and our teams are currently working through the action plans that will address some of those new news that we have, and we didn't have that at the time we reported earnings back in early August. If anything changes on the full year, Lauren, we'll provide an update concurrent with our next earnings call.

Now the important thing to highlight is that for 2027 and 2028, we're still in line with the expectations that we have laid out post acquisition in terms of our algo. For 2027, that is no more than a mid-single-digit dilution versus our baseline stand-alone EPS for 2026. Then for 2028 and an algorithm year where we would see earnings per share growth growing in the mid- to high single-digit constant currency versus -- on a compounded basis versus our baseline 2026 stand-alone EPS.

Okay. A couple of things I wanted to just come back on. One was China. I know you said specifically 250 basis points in 3Q. Just any updates there? How are things progressing? Is the 100 still probably the right ballpark for the year? Is it also go in the bucket of we'll get an update at 3Q?

Yes. We haven't seen on the consumer offtake side, any change in the situation versus what we had talked about on the second quarter call. So while we haven't seen any sequential deterioration in offtake, we haven't seen any meaningful improvement to normalize either. The team has done a very, very good job of executing the strategy, focusing on communicating our quality and safety to the stakeholders in working with the government and other retail partners to help get through the transition as quickly as we can and then obviously communicating with transparency. We don't have an update at this point. Certainly, if something changes, we'll let everyone know.

Okay. And then just in terms of category growth, we've heard generally -- I mean we're a day into this, but that consumer is generally holding in despite some macro headwinds. Just wanted to get a sense from me like why do you think your categories in particular, have been choppy? Why have things slowed? We've heard sort of a more positive stance arguably on the consumer environment.

Yes. I think, Lauren, I'd say definitely, I would still say our categories are very durable despite the environment overall, I think, being very choppy. It's pretty clear that I think middle to low-income households are under increased pressure. I think that by now, I think that's obvious. I think we've hung in better over time because I do think we made a pivot a few years ago to focus on superior value at all rungs of the good, better, best ladder.

What we've done is things like bring our best innovation. In fact, in U.S. diapers, I think our most advanced absorbent core, we launched first in our value tier product before rolling it to premium tiers. I think making the products better has helped us throughout this. However, we are seeing the choppiness is driven by, I think I mentioned earlier, increased promotional intensity. There is some shifts in our business among quarters between when a big retailer promotion kind of happened and a year ago versus this year. I think there's those kind of effects.

Then there has been some inventory changes. Generally, we don't get too obsessed over retail inventory changes because in the long run, shipments line up with consumption, they kind of have to. As kind of Nelson and Russ both point out, we're pretty, I would say, consistent in how we manage the business. We're managing the business for the long term. We recognize that the environment is a little choppy, but we're going to navigate through it.

Okay. Great. And then coming back also to cost inflation as a result of the Middle East. You discussed $150 million in incremental inflation in the second half in order to stay PNOC neutral that you'll leverage not just the tariff refunds, but also pricing. What can you tell us about pricing so far? And do you think that you'll expect to take incremental pricing in '27 to hit PNOC neutral next year as well?

Sure. Let me give you some of the context and recap what we talked about on the earnings call and build in the new news that we just shared and then Russ might chime in on pricing and how that's going through. But the first thing is we're proud of how our teams are maneuvering through what's a very dynamic environment. We've had significant experience over the last few years in managing through significant volatility and being able to deliver growth consistently over the last 4, 5 years or so.

The one thing is that at our August earnings update, we shared that we have built into our outlook for the second half, $150 million of incremental gross input cost inflation and that we expect to offset this pretty much through all the mitigating actions that are being undertaken, including pricing in several markets that is going into place or has already gone in place. The onetime benefit from the second quarter collection of a tariff refund that took place in North America.

However, as Russ shared, we now have new news in terms of some headwinds and costs, particularly in North America. The first is the one related to the spot freight transportation, which could amount to around $35 million to $40 million in the balance of the year with a meaningful impact already in the third quarter. Then the retaliatory tariffs that went into effect in Canada this week, that has the potential to add up to another $10 million of headwinds in the balance of the year.

The teams are currently working through all the mitigating actions. Again, if we see any change in our full year view, we'll provide an update at our next earnings call. As to 2027, it's important to highlight that we will benefit from the carryover impact of the actions taken in 2026. Whether or not we need to take more incremental actions or other elements, it's too early to tell at this stage.

Okay. Russ...

I'd just tag on to that quickly and just to reinforce that our strategy is to focus on growing volume mix and maintaining PNOC discipline over time. Those pricing actions are flowing through. You'll start to see that in the scanner data in North America and in other geographies that the ones we've already taken. But pricing is just one lever. We also really focus on innovation and mix and revenue growth management actions like price-pack architecture as well as driving the cost cycle over time to get to that profitable growth. We look at it as a balanced mix, but we'll use all the tools in the toolkit to help manage PNOC over time.

Lauren, if I can just add, I want to come back on the choppiness in terms of demand and the demand profile in the categories. As Mike said, I mean, we are in categories that are essentials. The variability that we've seen quarter-to-quarter has been greater than the variability that we've seen on, say, a trailing 12-month basis. Our categories have been pretty consistent between 2% and 2.5% over the last few years on a trailing 12, but we have seen more choppiness month-to-month and a bit quarter-to-quarter. But I think relative to a lot of other categories that you follow, I think our demand profile is a lot stable.

Yes. Okay. Just want to -- you've been pretty active on portfolio reshaping. So to step back a little higher level for the moment. Before we get to Kenvue, I just wanted to talk about the joint venture with Suzano. So just to refresh our people here, about 15 months ago, you announced a deal to sell 51% of your International Family and Professional Care business to Suzano. The deal finally closed on July 1 to create a company called Arbex. Can you just speak to the strategic rationale for this transaction?

Yes. I would say that a big part of it is, we're really excited to team up with Suzano to create the international tissue leader. They've been a great partner. They're our largest fiber supplier in the world. We work closely together with them. I think the rationale on this is we're going to combine Casey's great tissue-making expertise, our commercial -- global commercial acumen and marketing tissue products with Suzano, which has the lowest fiber cost in the world, right? When you put those together, what you have is a great business with inherently stable cost base. That makes it a better business than the 2 businesses being separate.

What -- I think we would expect to see is inherently in that business, a set of winning capabilities plus volatility reduction within the business. Then obviously, for our portfolio, Lauren, and you've seen this evolve over time, which is one of the things we've been focused on since I came into this role was to reduce our volatility on EPS. I think we looked at the math.

I think one of the things holding our stock back was I think the investors like in this room didn't care for the excess volatility that occurred in our stock. What was driving that volatility is the price of fiber. Certainly, by putting this business together, it reduces that volatility and then reducing the mix in our overall composition within our portfolio does as much.

Just to add a couple of things there, Lauren. Partnering with Suzano under a joint venture structure maximizes the future value of both Arbex, the new joint venture and Kimberly-Clark. 4 things that drive that. The first one is it halves our exposure to fiber-based inputs. For Arbex, fiber-based inputs will represent right around 15% of net sales, whereas for us, it will now be in the range of 6% to 8%. Secondly, it brings in a partner with significant capabilities and experience, which will allow Arbex to truly compete effectively for market share in the markets it's in.

Thirdly, we will benefit from the fact that we're expanding a strategic relationship with the world's preeminent fiber manufacturer, and that will yield benefits for our global Personal Care business as well as our North America Tissue and Professional business. Then lastly, we stand to benefit from the way we've structured the joint venture.

First, it's because we're getting a cash upfront, which we will deploy to fund part of the cash consideration for the Kenvue acquisition. Secondly, we will benefit from the upside of Arbex, which we see a lot of upside as it stands up and grows over the next 3 years. Then lastly, there's a clear exit mechanism in place in case Suzano chooses to buy our remaining stake down the road.

Great. There was one thing I wanted to follow up on with this business is the work you've been doing on forest-free fibers. So you've found an alternative to wood pulp that could be cheaper and better for the environment. Just curious on the impact that this could have on North America and IPC and then could it drive even lower volatility for Arbex? And how might it impact also the relationship with Suzano given they are the biggest wood pulp producer?

Yes. We're really excited about it. Hopefully, you can tell, Lauren, we're calling our alternative natural fiber program, I think it was going to be a huge benefit for consumers, the planet and certainly the economics of our business. It's something we've been working on, and we've been consistent in our investment. It's over 2 decades of investment. If you think about where we've been over the last -- just the last 10 years, we've been able to invest consistently to kind of drive this kind of breakthrough innovation that's new to the world.

For consumers, this fiber has a unique property that it delivers superior strength and superior softness at the same time. It kind of breaks the bounds of what traditional fibers deliver. The consumers are going to see a better product that's soft and strong. I think for the planet, I would say it's the ultimate regenerative initiative. This fiber kind of grows like grass and harvesting is like mowing grass. So you can think about it's incredibly land efficient. The fiber that we use today is harvested from millions of acres of natural forest. This will be in the tens of thousands of acres of farmed land. From that effect, it's very, very land efficient.

It also only grows in arid conditions. It's a desert plant. So it's incredibly water efficient. There's a lot of huge benefits for the planet. Then perhaps equally important, it's good for the economics of the business. We expect it will be cost neutral or better over time. We're excited about that. Then we don't expect -- it should have very low volatility in the production cost. I think overall, it's a win-win-win for consumers, the planet and certainly for the business.

If I may add, because it's important from a capital allocation standpoint, we're applying the same disciplined approach to the alternative fiber platforms as we do with the rest of the portfolio. This alternative platform has the potential to create economic value. It's likely to improve our margins over time as well as further reduce our input cost volatility. We will need to prove that it's scalable. Once we prove that, we will lay out the best path to implement it, which could include potential partners.

Okay. Great. Let's switch and talk a little bit about Kenvue. So first thing I just wanted to ask is if there's any update on the closing time line for the deal?

I think we're still very confident in our Q4 close timing. I think we've filed in all the jurisdictions. We're getting positive feedback. You may have noticed we've made a number of transactions or select divestitures, but we feel like we're on track for a Q4 close.

Okay. Great.

Then one thing on that, just to kind of highlight. We will need to do a few divestitures and some have been announced already. Just to make it clear for everyone, any potential divestiture has no impact on the potential earnings, potential of the new company. That's very important to highlight. Collectively, the divestitures will not amount to more than 1% of the aggregate revenue and profit of Kenvue. Importantly, it doesn't impact the economics or the value prop of the acquisition.

Not more than 1%, not Kenvue, but the combined company.

Okay. And then we get feedback from investors that Kenvue's categories are just fundamentally different from Casey's. We've heard things like channel mix, seasonality, competitive concentration, barriers to entry and even geographic exposure and expertise. So how would you respond to that?

Yes. Maybe I'll start with part one, Lauren, like we're really excited about the Kenvue opportunity and teaming up with the Kenvue team. One, it increases our exposure to what I would call Triple Crown categories. Triple Crown, in my parlance, I would say, higher growth, higher margin and then really highly expandable, right?

I'll just give you an inside baseball story. I think when I was selecting the leadership team of the future combined company, I was interviewing one of the Kenvue regional leaders, and I was saying, well, how are you feeling about your year? He's got this high single-digit organic growth plan for the year. I'm like, that seems like a lot. How are you feeling about that? He goes, well, pretty good since my categories are growing 6.5%. I think that's the difference.

There is some good growth in some of these categories. Then we see the opportunity because there's a huge gap between, I think, incidence of a health problem for a lot of consumers and treatment. The example I'll give you is if you think about allergy care, we've done a lot of market research and structured research in these categories, trying to understand the need states, what consumers are using these products for and then what are the opportunities to market them.

In allergy, our assessment is less than 20% of the population that has an allergy problem are actively treating it, right? I think that goes to the marketing opportunity to expand the category kind of like we've been doing with Kleenex or Depend actively trying to grow the category. We're really excited about that.

I think to your question, our view would be we recognize there are different categories, but the tenets of what we're trying to do with Powering Care apply. The core strategy of Powering Care is we want to get these brands on a virtuous cycle of growth, right? And that means we have a strong pipeline of innovation, marketing, kind of sales activation ideas that we can invest in, that we support the brands with a great cost position, right, best product, lowest cost. We drive that through an effective organization that's very agile and very focused on execution.

I think the thing about Kenvue is, one, in terms of the insights, and I think they haven't had as much maybe the time to kind of develop those levers. We've had a number of meetings with the future joint combined team which interestingly turned out to be 50-50, right, 50% KC leaders and 50% Kenvue leaders. We've been working through this.

I think in our discussions, we'd say, hey, the structured understanding of needs and then putting the resource investment behind the brands like we've done on -- or the alternative fiber for the last 20 years, I mean that's not easy to do, investing through a cycle when you got price wars happening or COVID this, but I think we've retained that executional discipline.

I think being very systematic about where you're going to put your innovation investment is something I think we feel like we're very good at, and we can help Kenvue with.

Second is on best product, lowest cost, Kenvue has fantastic margins. But however, I think they would also say -- they got great margins, but they're not low cost. The way we view it is even though you have high margins, we're going to continue to watch every nickel because every nickel that we save is a nickel that we can earmark for further investment to grow the business, right? I think that's the second part.

Then maybe the area that I think we spent maybe the most time talking about is how do we kind of create the kind of executional focus. I think that's execution for KC has been, we feel like our calling card. We have disciplined execution. We're very market-centric, locally agile. Then we've been able to, in the last couple of years, better apply our global scale. I think that's a trait that we think we bring that could really kind of help Kenvue.

I think they've kind of been -- they've kind of struggled a bit because they've been through, Lauren, maybe I think about 4 different organizational operating models over the last 7 years. So just having a consistent operating strategy, operating model, I think, will be a big benefit. We really believe the tenets of Powering Care and getting a company on a virtuous cycle is going to apply very, very well to Kenvue.

Okay. Great. Maybe we can talk a little bit about integration. So investors typically get pretty nervous about transactions of this size. So Russ, you've been leading integration efforts. It sounds like you've been doing a lot to get a running start. So you can maybe give us some color? And also, at the same time, maybe touch on cost synergies and work you've been doing on that front? And is there maybe upside? It's already a big number you've thrown out, but is there potential for upside?

Yes, sure. A few things. First of all, I would say the synergy and integration plan is going very well at this stage. In fact, we're probably ahead of where we had expected to be from the synergy planning point of view. Operationally, we're ready for day 1, and we have plans to bring the company together over time. There's a couple of X factors I would point out that give us confidence in the way we're approaching it. One is, we've got a proven leadership team that's really capable, and they've demonstrated that they can grow the company, drive cost reduction and transform at the same time. That's the same group plus some great additions on the Kenvue side that will be leading this.

The second thing is the culture. That's always a big concern of anybody who's been involved in integration. The mesh has been really, really good. In fact, I think both companies' engagement scores have gone up after we announced the transaction. Our advisers told us they hadn't really seen anything like that occur before. On the synergies specifically, though, we have very good line of sight and visibility developing. All our plans are bottoms-up, analytically based. We've been working on them for many months. We've got 50 integration teams and hundreds, if not thousands of people at this point that are working on those with the future leaders.

You're right, we're not ready to call up yet, but we have high visibility and a high degree of confidence in our ability to achieve. I'll just give you a little bit on a couple of points. In the COGS area, that's an area that as we've dug in, we have found more opportunities. You're probably going to see that be more part of the mix, and we'll keep you apprised of that going forward. The 3 big buckets we're going after really are duplication and integration activity, and that's things like just overlaps as well as leveraging the combined scale of the company. That will be kind of the first big wave.

The second one will be combining the operations commercially, route to market and supply chain. That will probably be in years 2 and 3 in terms of carrying the water there for the development. We're very excited about the potential there. Then the third one will be really transforming the company in new ways that we haven't done before, using AI or simplification and developing new processes. So we feel like we've got it lined up and have confidence we're going to hit the ground running.

Okay. Great. And then let's talk for a second about revenue synergies. You've discussed $500 million in incremental operating profit from revenue synergies and plans to reinvest about $300 million back into the business. In what sense is this like low-hanging fruit, how you describe the opportunity? Just trying to understand the short-term versus the long-term opportunity that's being captured in this.

Yes. Same thing. I think we've got both short-term and long-term opportunities, bottoms-up planning. Our teams are engaged on it. I'll just give you some texture of some of the areas that might pop out. In North America, for example, there are some things that might not be immediately obvious, but Kenvue has a great selling organization to health care professionals, which we can use in our category on the KC categories. Likewise, the KC categories have a great professional channel that Kenvue really hasn't tapped into.

I could go on. There's capabilities like e-commerce and such, but that's the types of things we'll be tapping into and applying the best of both companies. In China, we've got a great e-commerce capability on the KC side that Kenvue will benefit from. Of course, from a geographic standpoint, there's capabilities and distribution positions Kenvue has in Western Europe or India and KC has in markets like Mexico or Indonesia that we're going to be leveraging. I know we're short on time, but that's -- but we're very excited about what that holds in the future.

Well, and I'll say beyond the short-term, and I think we -- again, I think Russ and the team were feeling very good about the revenue synergies. But beyond that, I would say in the medium-term, the opportunity around category penetration is a big one, Lauren. I think the reason I flagged that is because we didn't know that as much going in, right? We've been doing a lot of market research to understand these categories. Those are some insights, I think that even Kenvue didn't understand.

I think -- and it takes a little time to kind of work to kind of develop marketing that expands the category, but I think that's something that we're going to be very, very focused on. I think in the medium-term is also product design. I think one of the reasons why maybe investors thought it was not intuitive for us to be interested in skin care, but it turns out scientifically, we have a great deal of research on skin because our products are in contact with skin 24/7. So there's still that opportunity, we feel like to put maybe their skin knowledge and our skin knowledge together that will result in breakthrough products for consumers down the road.

We just think there's a lot of great opportunities to drive that. Then the last area for us is what we're calling internally smarter health. I think this notion around how do you expand the category, having consumers treat themselves better. We do think, we've been investing a lot in our digital capability with consumers. We do think that is a really robust area for growth further down the road. So again, we remain really excited about the synergies that we have committed to, but also we think there's going to be more beyond.

Okay. Great. I did just quickly want to ask you about the Tylenol litigation because in July, the Second Circuit revived the lawsuit. So just does this change your thinking at all on deal math?

No. I think the -- one, we feel very confident in Kenvue's approach to defending Tylenol. I think the science supporting the safety and efficacy of Tylenol continues to grow. Kenvue's defense is based on sound science and legal merit. I think you may have noticed that the Second Circuit came out in July, also, I think, 5 new studies published, including one, which is a paired sibling study, which is, in our minds, maybe one of the strictest tests. So all of them confirm the safety and efficacy of Tylenol. We feel very, very good on the scientific grounds. Then also, I think we feel very good about the legal merits of the case and continue to feel very confident.

Okay. Great. We're going to have to wrap there. So please join me in thanking the Kimberly-Clark team for being with us today. Thank you.

Good morning, and welcome to the Kimberly-Clark Second Quarter 2026 Earnings Call. [Operator Instructions]

I will now hand the floor over to Chris Jakubik, Vice President, Investor Relations. Please go ahead.

Good morning, everyone. This is Chris Jakubik, Head of Investor Relations at Kimberly-Clark, and thank you for joining us.

I would like to remind everyone that during our comments today, we will make some forward-looking statements that are based on how we see things today. Actual results may differ due to risks and uncertainties, and these are discussed in our earnings release and our filings with the SEC. We will also discuss some non-GAAP financial measures during these remarks. These non-GAAP financial measures should not be considered a replacement for and should be read together with GAAP results. And you can find the GAAP and the reconciliations within our earnings release and the supplemental materials posted at investor.kimberly-clark.com.

With that, I'll turn it over to Mike for a few opening comments.

Thank you, Chris, and thank you all for joining us today. As I mentioned in our prepared remarks, our second quarter results demonstrate the durability of the growth engine we've built through Powering Care. We delivered our 10th consecutive quarter of solid volume plus mix performance, held global weighted share, posted another quarter of industry-leading gross productivity and continued to invest for impact. We did this even as consumers remain pressured and category growth is moderating.

At the same time, results were impacted by a few discrete but significant one-off items in the quarter that underpin our decision to adjust our full year outlook. Despite these headwinds, the fundamentals of our business remain strong, and we're confident in our momentum entering the second half and into 2027. Our teams are executing with speed, agility and great care to manage the business with discipline and navigate external dynamics. We're delivering superior science-backed innovation and value propositions around the world through our proven repeatable playbook that positions us to continue to win with consumers. We're advancing the next phase of Kimberly-Clark's transformation and sharpening our focus on proprietary right-to-win spaces.

Yesterday, we unveiled a proprietary alternative natural fiber innovation program, which has the potential to reshape the future of our industry. This is the culmination of more than 2 decades of materials and plant science expertise brought to life through Powering Care. We believe the program will enhance product performance for consumers, strengthen our long-term growth trajectory, reduce exposure to natural forest fiber cost volatility and advance our natural forest fiber-free ambition.

We also completed the successful launch of Arbex, our strategic joint venture with Suzano. We're making strong progress on our integration planning for Kenvue as well. We're excited and ready for what's next. We have a unique generational opportunity to create a new kind of health and wellness company, reimagine care for billions of people around the world and to create lasting value for shareholders.

With that, we'd like to open up the line for questions.

[Operator Instructions] Your first question is coming from Nik Modi from RBC Capital Markets.

So just like maybe you can unpack what exactly is going on in China in terms of like how this all started and then what the path forward is? And then I have one more question after that.

Yes, I'll take that, Nik, it's Russ. Yes, I would say the main message is that we were very confident in our products. We make high-quality products that are safe and perform well. And so we think that's going to lead the way to recovery over time, but just a little more context, I'll maybe make 3 points.

First, there really is no scientific evidence backing the claims. We did, as we noted in the remarks, make multiple independent tests conducted by certified third-party lab that confirmed that our products are safe and they were non-detect tests. Second, in terms of how we're handling it. Our team is doing an excellent job navigating the situation. We're continuing to cooperate with the Chinese authorities who are managing the issue. And our strategy really is to continue to invest aggressively behind reinforcing the fact about our products and communicating quickly with transparency to consumers. And obviously, engaging stakeholders like retailers and government agencies. And we've got an excellent support from all the stakeholders, which we're really grateful for.

And then third, in terms of the outlook and what we expect going forward, we are not seeing any sequential deterioration in our sellout in China, but it also hasn't inflected positively yet. So we think we've been appropriate in the outlook for the balance of the year, considering that uncertainty. And while we are cautiously optimistic in some areas, I think these incidents have been occurring with greater frequency and consumers are pretty smart and getting savvy about these things. We're also realistic that it's going to take a little time to kind of work through this. So hopefully, that gives you some sense.

Yes. Nik, it's Mike. I'll just tag on. One, given kind of the social media environment, this is not the first time that's occurred to us, it probably is the largest blow. But I would say, our purpose as a company is better care for a better world, and we take our responsibility to consumers as paramount in that, and we would never trade that off. And so we're very confident in the quality of our products. And so we believe we'll get this back to the right place.

I would like to add, Nik, though, that brand foundations globally remain strong in the face of some of the discrete impacts, including the China issue that we're working through. Just to point out, and I think I made this in my prepared remarks, we're still sustaining positive volume plus mix growth. I think our tenth consecutive quarter of that. And then in the -- even in the quarter, holding overall weighted share in the quarter, although on the old cohort approach, up or even in about 70% of sales across the world. So I think we feel good about our brand fundamentals, and we're confident we've been able to navigate this issue.

Great. And then, Mike, it was a really noisy quarter. A lot of stuff going on. Maybe you could just give us some perspective on how you guys performed relative to your internal expectations just so we can kind of ground ourselves?

Yes, I'll make a comment, but maybe I'll have Nelson give you that because I think he's a little prepared for that line of thinking. But also, I would agree with you, it's a choppy environment, so I'll come back to that.

Yes. So Nik, just to unpack a little bit the quarter where we're at. I mean, yes, the second quarter organic growth came in below our expectations. However, strong execution on the tariff refund that we received in the second quarter drove the better-than-expected and solid operating profit growth and EPS performance in the quarter.

If we look at organic sales in Q2, we were about 100 basis points or so below our expectations. This was driven primarily by the disruption in our China diaper business. In the back half of June, keep in mind that was only just 2 weeks as well as the trade inventory reduction in North America, which was largely concentrated in adult care and in one particular channel, and that was not something we contemplated when we gave our outlook back in April that bit as well. Lastly, as the softer category growth because as you remember, we had talked about a 2.5% category growth trailing 12 months back in April, and now we're staring at about 2%.

As it relates to adjusted operating profit and EPS, the 2 came in ahead of expectations, as I stated earlier. And this is primarily due to the tariff refund benefit and the really solid productivity we delivered in the quarter, which was 6.4%, which both more than offset the higher levels of brand investment year-over-year. And overall, despite the challenging operating environment that Mike referred to, which included maneuvering through the L.A. distribution center fire, all the Middle East incremental costs that we're managing through and the China diaper disruption. We still had strong execution across all of our markets in general, and this enabled us to deliver solid bottom line and EPS, which was again ahead of expectations.

Yes. And then, Nik, just back to the point, I would recognize that I think it is a very choppy environment generally for us globally. But I would say the category remains resilient in a choppy environment. If you go on a trailing 12-month basis, for the past few years, our categories on average have been about 2, 2.5. And I think that reflects the essential nature of our categories that yield a little more resilient, more stable demand than other categories that I worked with in my past.

That all said, though, I would say, Nik, I think you see it, too. Consumers are clearly under increased pressure. I think we're seeing sentiment among -- especially among lower consumers is weakening and we're seeing greater variability in consumption. Weighted growth across our categories in North America moderated sequentially from 3.7% last quarter to 1.9%. If you go further back Q4, I think it was plus 0.4%, right? So it is choppy.

But the thing I will tell you is at least some of that choppiness is potentially exacerbated by maybe promotional timing effects. And the reality of our categories compared to some of the food categories that Nelson and Russ and I have worked in the past is we tend to be more concentrated in a smaller number of large retailers. And so I think large promotional events can swing things. And I think we've seen that from quarter-to-quarter. And so I would say we expect promotion kind of variations and normalized over time.

Your next question is coming from Chris Carey from Wells Fargo Securities.

Thank you. The first question is a clarification question. What was the tariff refund in the quarter? And do you expect any more -- I'm trying to understand the full year guidance, tariff refund versus inflation and the mitigation efforts that you're doing. And so it will help isolate some of those key buckets. None follow-up.

Sure, Chris. So a few things. I mean in terms of the refund that we received in the quarter in North America, the U.S., it was $45 million. And that represents roughly about half of what we paid in North America as a whole. And keep in mind, that's not just the U.S. because there were some retaliatory tariffs that we paid earlier last year in Canada as well. So overall, this is reflected in our second quarter results and in our updated outlook.

For the balance of the year, we don't have anything much more material factored in. So that's largely what's included in our outlook. And right now, beyond that refund, we're continuing to monitor a policy environment and what's out there.

Great. And then going into 2027, there had been an expectation for think mid-single-digit dilution from deal activity and then there was going to be an underlying assumption for base Kimberly-Clark, just given what we're seeing in the in the backdrop for categories in North America and the competitive activity given the volatility in China and also your latest expectations for Kenvue, which sounds like it's closing in Q4 with good line of sight on synergies. Do you continue to view the 2027 construct as you have laid out as still as tangible or firm as you had done before? Just give us a sense of maybe how a thought process may be evolving as you get a bit more information about both your legacy Kimberly-Clark business and also Kenvue as you go into next year?

Yes. So Chris, let me unpack your question a little bit. So first, we remain very confident in our ability to create generational value through the Kenvue acquisition, joining forces the 2 companies.

Based on what we know today, we do not believe the factors driving our lower stand-alone '26 earnings outlook, and that's for us materially changed the underlying earnings potential of either our stand-alone businesses or the combined company going forward. Now clearly, the exact timing and pace of the recovery in China following the diaper disruption will influence how quickly results normalize. There's also some uncertainty around commodities and the broader macro environment. Given the ongoing Middle East crisis and volatility we're all managing through potential impacts on the inflation in consumers as well as the exact timing of the further mitigating actions we may need to take. But some of those are already well underway, and that's why you see the outlook that we put forth.

Given all those moving pieces, standing here today, it's early to provide a specific view on 2 even because we still have a lot of things that need to land in the back half of the year, including the exact timing of the closing of the transaction. But as I said, we remain very confident in the underlying earnings power and growth potential of the new company. As we get closer to the close of the transaction, and we have further clarity on all these move-in items over the next few months, we will provide an update on the overall view for 2027 and beyond. But rest assured that we remain very confident in the logic and the generational value that we see this transaction creating.

Your next question is coming from Bonnie Herzog from Goldman Sachs.

I have a question on North America, which came in a bit below our expectations. First, could you unpack the drivers of this softness, including underlying consumption trends versus retailer destocking? And ultimately, how your business in North America performed relative to your internal expectations? Then second, it sounds like you're expecting a stronger 2H. So could you talk through the drivers of this? And maybe what gives you the confidence and visibility in this expected improvement?

Why don't I -- let me unpack the quarter and the half in terms of the puts and takes and the drivers. And then Russ will chime in on why our conviction in the acceleration of the business as we go through Q3 and Q4 and our confidence in our overall North America business and the strength of our -- of our propositions for consumers and customers.

But as we chatted back in April, Bonnie, I mean, underlying consumption, we expected it to be ahead of shipments for the second quarter in line with what we saw in the first quarter. And as we think about what transcended in the quarter, a couple of things. One, shipments in North America consumer categories, in fact, lagged consumption by about 170 basis points. And to be clear, the shipments were down about 1.4% in consumer as opposed to a consumption growth, which was 0.3%. And that was mainly by 2 factors. The first one, as we chatted back in April, the L.A. distribution center fire would represent a headwind of around 80 basis points to top line in the quarter for North America, and that largely came in as expected, right around $22 million to be exact.

And then in addition, we had the retailer inventory movements, which in total year-on-year, impacted shipments growth by roughly 100 basis points versus last year. And of this, we had about half of that was not something we anticipated when we gave you our outlook back in April. And this had to do with a particular channel and largely the adult category.

Taken together, these 2 factors largely explain the gap between shipments and consumption. If you look at the first half, 3 factors would have caused shipments to lag consumption by right around 200 basis points for the North American consumer business. And these are, one, the L.A. distribution fire, which was around 40 basis points of a headwind in the half. Then the retailer inventory movements, which, for the half, represented again about 100 basis points year-on-year. And then lastly, as we chatted back in April, we had a heightened activation programming across several channels, particularly club, which started early in Q1. And for these, we have made the shipments largely in the end of 2025.

But to add some color on why we see the second half gaining steam. I'll try to throw over to Russ.

Bonnie, yes, I think overall, look, we are very confident in the health of our North America business. And while Nelson unpacked the drivers of the quarter, which was below expectations. If you kind of look at the bigger picture, we've gained -- we've driven volume plus mix-led growth in 8 of the last 10 quarters. The trailing 12-month share, we've gained share in 70% of our sales base in North America. And if you look at the share in the quarter, the majority of the weighted average share decline was driven by that club distribution loss, which we talked about previously in the last couple of calls.

And we do have a very strong innovation pipeline as well as brand investments coming. Our tissue business is performing extremely well. Our e-commerce business continues to perform really well. And in the second half, we'll be scaling those innovations and we've got some very good activation planning as well as some revenue growth management actions coming. So we do feel confident in the second half that the outlook really is to grow in line with our categories, but we'll be able to achieve that considering all the elements that Nelson mentioned.

And it's an easier comp as well because the other benefit remember, Q2, in North America, we had 5% volume growth in North in the prior year. the comps get easier as we go into the second half in North America.

Your next question is coming from Michael Lavery from Piper Sandler.

I just want to touch on innovation and you've laid out a robust pipeline this year, obviously, and you touched on some examples in the prepared remarks, which are great. Maybe just help us understand some of how it's running against expectations and timing. And I guess, specifically, how much wraps maybe into 2027 and maybe it's just overshadowed a bit this year by China disruptions and destocking.

But then I would also love to understand the new fiber platform, maybe how quickly that could drive new end products? And what if any upfront costs we should keep in mind about how you launch that?

Yes. Okay. Thanks, Michael. Yes, overall, on innovation, I'd say we feel great about our innovation that we're launching. And I think we said at the beginning of the year that this is probably the most commercial activation of innovation that we've had in my time here at Kimberly-Clark.

And I would tell you, I would say also that pipeline is good going forward. I think if you see kind of what we're doing this year, I think the stuff that we have coming in the next few years, I feel like we're going to be bigger and better than that. And so I'm really excited about our development. And I think that reflects the discipline that we've had in our organization, and this is kind of an artifact of this kind of fast agile matrix that kind of pulls the markets and the functions together, Michael, I think we started looking further -- much further out. And one of our core metrics is future pipeline development, and we're feeling like -- we're feeling pretty good about the trajectory.

But maybe, Russ, you may want to comment about some of the [indiscernible].

Yes. I'll just double click a little bit, Mike, on that and talk a little bit more. You may have recalled our Chief R&D Officer, Craig Slavtcheff talking about the pipeline development and that's one of the reasons why we're very confident as we can see into the future in the next 3 years and the quality of our consumer insights has gotten better and then the Powering Care matrix has really enabled us to scale innovations around the world much more quickly. And so we've done that in femcare. You're seeing the impact of that in IPC, for example, where we've seen our organic growth accelerating our share gains coming through in categories like diapers and that really is significantly driven by innovation.

And I think that's what's been powering the North America business, especially in personal care, and now you're seeing it come through in tissue. So it really is a broad-based set rather than any one particular innovation. I think we feel very good about the portfolio we're building and have continued visibility that that's going to take shape and gain traction time through that 3-year funnel process that we've been diligently building with the teams around the world. So I don't know if you want to talk about the fiber one or...

Yes. Yes, Michael, hopefully, you can tell we're very excited about our alternative natural fiber program. And through that, we really believe we're going to positively impact the category, the planet and the economics of the business. I think material invention has been a core of Kimberly-Clark.

2 weeks ago, I was up in Neenah, and I was meeting with the family of the company's second CEO, a man named F.J. Sensenbrenner and I was reminded by them that under his watch, they launched a product called Cellucotton, and that was an invention at the time that ultimately became Kotex and Kleenex and then eventually bath tissue, but the creation of that tissue-based product. And so I would say this is similar, right? And this is the culmination of over 2 decades of material and plant science investment and development. And I really do think this has the potential to become our next great material platform. In the -- with the heritage of Cellucotton, I think we believe we invented global -- or the nonwovens platform as well. And so this would be like that. And I think it's going to be great on the 3 dimensions that I mentioned earlier.

Number one, better for consumers. This fiber has unique properties, and it pushes the frontiers of the softness versus strength kind of frontier, right? And so for a given amount of strength, it adds superior softness. And so that will enable us to make a superior tissue. So number two, obviously, we believe it's better for the planet, Michael. It's a farm crop. So that's going to replace natural forest fiber in our production mix. And so because of that, it's also super land efficient. If you think about our requirements for pulp, that's harvested for millions of acres annually, right? And so -- and this product would be very dense, very land efficient and it's grown on a fraction of the acreage to source an equivalent amount of volume. So that's part 2.

And then part 3, it's uniquely -- it grows only in arid conditions and because of that, it's a water miser, and so it does not consume very much water. And in fact, being a farm crop, then it would take on a fraction of some of the crops that are currently produced in the region. So we're excited about the impact on the planet that we have the potential to have. And then, obviously, we wouldn't be pursuing this if it didn't have good economics. And so it has the potential for us to enhance margins and then, obviously, Michael, further reduce volatility. So that's an update on that.

And Michael, on investments, just so you're on the loop, I mean we -- this has been factored into our investment profile for the last years. And we -- anything we've invested and anything we've expensed is been part of the results we've been reporting, and we've included in our outlook for the next few years in our strategic plans the capital requirements to continue to drive this initiative of some of the other ones we're doing.

Yes. And maybe the -- and I'm sure you may have a follow-up question, Michael. But I mean, one of the reasons we're talking about it now is because out there and we're breaking ground on a pilot facility. We've already acquired thousands of acres of land to grow this on, right? And so that -- we prefer not to acquire more land. We prefer to turn it into a cash crop for the farm community. And so again, having the larger community to understand kind of what we're trying to do here will also help us be a little more capital efficient.

Your next question is coming from Steve Powers from Deutsche Bank.

Mike, I was hoping we could go back to North America and really the competitive and promotional environment. I just love a little bit more perspective on how you've seen those conditions evolve over the past 6 months. To what extent it's sort of exacerbated that choppiness and maybe the lower category growth that you spoke to? And most importantly, how do you think it plays out over the balance of the year?

Yes. Let me start and Russ to kind of -- Russ all over this. But I would say, I think if you look at the facts, clearly, the promotion kind of environment is increasing slightly, right? And we're seeing that both from the other big branded competitors, but also some of the smaller brands, right? And so that -- I would say that, that comes and goes in this category, and I've been -- I think it was my 14th year here. And so we're seeing -- and I remember like periods of high promotion intensity and then I would say the last several have been a little bit more moderated post COVID.

And I think the reality is despite that, those swings, the reality is these are kind of very stable consumption categories where consumption doesn't change because of promotion, right? And so for us, I think having a business that is a little bit more stable allows you to run it more efficiently and allows you to bring the innovation that can help expand the category over time. And so for us, that's why we're not the proponents of driving excessive promotion in our categories.

But maybe Russ, you can give them a little more color on that.

Absolutely, Mike, and you said it well. I think, Steve, we're focused on developing compelling value propositions at every tier every day while maintaining pricing and PNOC discipline over time.

And in fact, in '25, our promo activity was below both pre-COVID levels and the category. And through the first half of '26, our promotional levels were down versus the prior year and the category and the majority of our categories. We did see, and this is perhaps what you're referring to tick up in competitive activity across multiple categories as well as we did increase promotional support in some categories, especially diapers. And that was specifically done for a purpose that's consistent with what Mike was outlining in terms of the philosophy to drive trial on key innovation launches, and we did also put some promotional activity into the marketplace to help us transition from that club distribution change that we had been talking about for a while.

And we'd expect that to normalize for us, and we're going to remain consistently focused on delivering the compelling value propositions every day and PNOC discipline. And so you look for that promo activity for us to normalize over the balance of the year. and we're going to continue focusing on winning with innovation and brand building. And as Mike said, I think we're confident that over time, the wisdom of the fact that promotion doesn't grow the category will, we'll find its way back into the market.

Great. And then I guess, Russ, this is maybe for you as well. But when you guys collectively talk about the Kenvue synergy planning running ahead of expectations. I guess for those of us on the outside, should we interpret that as greater confidence, maybe faster realization of the existing $1.9 billion cost synergy target? Or are you beginning to identify incremental synergy opportunities of Bio's original assumptions?

Yes. I think what it reflects is greater confidence in the path to achieve that we've outlined at this stage. It's still relatively early, but the bottom-up pipeline that we're building is based on specific initiatives in specific areas that are based on bottoms-up analytics. And now as you probably noticed, we've got kind of 50 teams and 600 people working on this. So I would call them being execution shovel-ready actions that we feel very confident in converting into a plan that we can confidently forecast delivery of.

And so that's exciting to us to have that visibility. It's probably a little early to see how that shakes out over 3 years, but we're working very quickly to fill that in and feel very confident that we're moving in the right direction at pace. I don't know.

And just to add, Steve, I mean, we're not getting into unpacking what the cadence will be at this stage because, obviously, things are happening that you guys have seen in Kenvue. I mean they've already announced some actions that we are in the process of factoring in to our plans, which, obviously, to the extent that that's delivering savings that we would have contemplated all the better.

But again, a lot of moving pieces that we're working through. The overall confidence really goes back to your -- what you said first. Our confidence in the total number of synergies and we'll be back when we get to the closing of the transaction to give an update on what is that cadence, what are those numbers exactly factoring in the actions that Kenvue is taking this year such that you can do the updates, and we can have that all cleared out.

Yes. And Steve, maybe I'll just add a little pop on the thing, which is I think I said when I was at you over the summer, hey, the closer we look at this thing, the better it gets. And part of it is, certainly, I think right now, we're focused -- and Russ is on point for helping us line up the synergy commitment, right? And so -- but I would tell you, -- so we're not signing up for more than that at this point. But I would say we're feeling very good about the operationalization of that.

We did have our leadership teams, the future leadership team together for a week last month. And then we've had these detailed assessments done of the entire management teams on both companies kind of brought in and just to evaluate as we're selecting talent. And the thing that the lead facilitator from that organization pointed out was the extraordinary unique kind of attribute of the combined team was a deep focus on execution. And we love that because we -- hopefully, you guys are seeing that one of our calling cards is excellent execution. And so as kind of Russ helps us and the integration team leads us through the process, we're gaining confidence in that. That said, and so we're not signing up for more synergies, but I will tell you part of my, the closer you look, the better it gets, is there's more growth in these categories than we originally thought when we did this deal.

And I would say these categories are -- especially when we look on the Kenvue side, right? They tend to be a little bit more underdeveloped mostly because there's a pretty significant gap between the incidence of a health issue and treatment. And that's a little bit different for us, right? If you think about it, if you're if you are going to the bathroom, you're probably in the bath tissue category or if you have a baby, you're probably in the diaper category. So this gap to incidents isn't really common in our categories. But I think it's very common in the consumer health categories. And so we're really excited about that because that's something that can be expanded through the right category building programming.

Your next question is coming from Lauren Lieberman from Barclays.

Just wanted to go back again to pricing and promotional environment in the U.S. I know Russ and Mike, you just kind of covered off on us. But just getting a little bit more specific, I think when we look at Nielsen data, which I know is not the end all be all for what's actually happening in the marketplace. But it's like some of the was promotion has now been in the -- from you guys has now been in the market so long and it's actually showing up as lower price not being captured as promotions.

So as we think going forward, and with your comments on PNOC and I think what implies some price increases from here, I wanted to try to understand how much of that is less promotional activity versus real list price increases as you manage through cost inflation.

Lauren, I'll take that one. It's Russ. Yes, I think you're right to point that out. And our focus has been growing volume and mix, and you hit the word on the PNOC discipline.

And in fact, what you're seeing on the headwinds, I think, have been a few temporary dynamics, and you called out a couple. We have had some temporary promotions in the marketplace but also have made some targeted revenue growth management actions to address specific consumer-driven opportunities and sharpened value surgically. And also, you're also going to see a channel mix element as the consumer looks for more value, both in terms of what channels they're shopping in online and club and pack sizes, that has an impact on our pricing.

And so that's part of what you saw in the first half of this year of seeing total company pricing down 50 bps. And over time, innovation and brand activation are going to continue to drive that, but we will be taking pricing actions. So to cover inflation in the second half of this year, and the magnitude of that, if you think about that in the overall portfolio will be kind of low single digits overall. Those are in the marketplace now, and you'll be seeing those come through. And that's part of the balance of the cycle of trying to balance out PNOC discipline over time using all the levers in the toolkit. And again, we've done that in some cases with innovation attached to it. And in other cases, targeted our revenue growth management actions based on just commodity movements that we had to hit.

So the main point is, I think, as part of the cycle, we're looking at innovation and brand building is the thing that will carry price mix over the long run, but we will be taking action in some areas to address some of those issues in the marketplace.

Great. And Russ, just to clarify, if I can, the low single-digit pricing statement. Is that a North America number or a global number?

Yes, it's primarily in North America. That number, I think, globally is going to vary a lot based on the geography. So we have taken actions around the world as well.

So we've taken actions across many countries, as you might imagine, Lauren. So -- and the overall is following the principle of pricing net of cost neutral over time. But it's not just revenue growth management. Remember, we're also delivering the highest productivity we've ever delivered. We're also managing a negotiations and contracts with our vendors and our suppliers. So it's the full toolkit and not just that, that's one number.

And let me underscore -- I'm sorry, Mike, just to underscore that. The innovation is the key element to that, that helps create premiumization and positive mix and also helps drive growth that really, to me, is the core of that engine.

Yes. And maybe related to what Russ was just talking about, Lauren, the guiding thing for us is, especially in this environment, we have to have a superior value proposition. And so -- and that's kind of the company's focus. And so even though with inflation, there are some PNOC actions we have to take, we're always going to be cognizant of making sure we're offering a great value. And I think if you look at the past couple of years, we've paid particular attention to the value consumer or the middle-income consumer, I think they've been under more stress. And we think our approach to sharpen that offering, both in terms of product quality, primarily through product quality, I think, has worked really hard for us.

Your next question is coming from Robert Moskow from TD Cowen.

It may be too early to ask this about 2027. But with all of the noise this year from a lot of incidents that certainly could be considered transitory, would you consider 2027 to have an easy comparison at this point? Or is it that these are volatile times? There's not a lot of visibility to that. And so don't get your hopes up. So maybe you could -- I could start with there.

Yes. Well, one, I'm going to let Nelson kind of weigh in here. But Rob, I think the volatility is out there. And so I think that, that answer can vary a little bit depending on what the facts are kind of in the day. And so we're very focused on running the business for the long term. But I think the thing that you point out in your question is there is a lot of volatility in the marketplace, and we're trying to make sense of it.

Yes. And Rob, to Mike's point, I mean, we've been around for 154 years in counting we've gone through a lot of these cycles in prior lives. And obviously, this has gotten a little bit more the norm in the last few years.

However, the underlying strength of the business, the power of our innovation pipelines, the executional prowess of our teams is second to none. And that, I think, is what carries the day. I mean where we land in 2027, it's early to tell. As I was sharing with Chris earlier, the thing is the speed of the recovery in China is going to be one, and we factored in a significant amount for the balance of the second half, even though we're going to get back to growth in first, second quarter because we're seeing the strength of the innovation pipeline and the executional plans that we've got in place.

We're also managing through the inflationary impacts in the Middle East. And as you heard, as we were chatting with Lauren, we are taking very clear actions to address in a thoughtful manner because we want to make sure that we're addressing our consumer needs, and we meet them where they need us to be. So that's all being factored in. We'll come back towards the end of the year, beginning of next year with what is the view for 2027, factoring that in. But I would also like to highlight that the strength of our categories, the resiliency of our categories is there. I mean we continue to grow trailing 12 months, about 2%. So that is solid, that is very solid. And we've been putting up their growth vol/mix in the last 9, 10 quarters consecutively. So the strength of the business is solid. We're very confident in our plans, and we'll just need to keep navigating the choppy waters we're in, as Mike referred to.

Okay. A quick follow-up. Is it going to be very easy for you to tell whether competition is following you on these price increases, particularly in North America. And you say that you expect the promotional environment to normalize eventually or at least your promotions to normalize, is it possible that if they don't follow, you might have to promote some of this back?

Yes. I'd say, Rob, it's always possible, but that's just not -- that we're going to run our play. Our play is really bringing great innovation, helping consumers understand how our innovation uniquely solves their problems in a different better way. We're going to drive productivity on our costs, and we want to be affordable. And so I think those are all the things. And I think that's the play.

Are we paying close attention to the promotion environment? For sure, right? And we recognize we're not going to put our head in the sand. But I think we're also trying to manage our approach because we've seen the other approach, and it doesn't work.

Right. And the other one, Rob, is no one is immune in the mid, long term to the inflationary environment. The key is that you got to manage the entirety of the tool kit. And that's why we've been so focused on the productivity bid. And as we've been sharing, we still have in North America, a lot of room to go because we were still undertaking the $2 billion investment in the supply chain restructuring in North America that's coming on over the next few months and it will carry through in '27 and '28. So there's a lot of firepower on that end to manage. But again, we need to see how things play out over the next few quarters.

Rob, you may remember, I think I talked to you back when I used to work in the snack category and their promotions do drive incremental consumption. And by the way, so if your promotions are profitable, but then that's a viable strategy, but this is not the case in these categories. It's the opposite.

Your next question is coming from Peter Grom from UBS.

I was hoping to just get some perspective on the input cost environment. So you noted in the prepared remarks, $150 million of inflation in the back half of the year, consistent with the range you provided back in April. Obviously, it's a volatile external environment. So maybe can you help unpack what's embedded in that assumption? And as we think about the back half, is the headwind evenly weighted or more pronounced in the third quarter.

Yes. So let me unpack a little bit what we've got for the second half and then also an update versus what we shared back in April because as you recall, we have not included the back half as part of the cost impact. So a few things. One, I do want to give a shout out to our teams. I mean they've been working very diligently to manage through the volatility that we've got, first and foremost, to ensure that we have product availability so we can serve our consumers and our customers.

And then also to be able to manage through the higher costs such that we can deliver and our commitments. And a few things there. As we look at what we said back in April, we said that for the second quarter, we expected inflationary headwinds to be around $50 million for the quarter, primarily related to the higher oil-linked input costs as well as some of the impacts from the L.A. distribution center. Those impacts came through pretty much as expected and are reflected in our first half results.

As we look into the second half, what we said back then was, and that's in April, that if oil prices were to remain at around $100 per barrel, we could potentially face gross incremental input cost headwinds in the back half of the year of around $150 million to $170 million and that we have not included that nor any mitigating actions in our back half outlook. Currently, based on where oil prices are and the actions that we've started to undertake, our estimate for the second half is to be right around $150 million of gross input cost headwind. And these impacts are now fully incorporated into our outlook. Through a combination of mitigating actions already underway and the tariff refund benefit that we got in the second quarter, we now pretty much expect fully offset these incremental costs and maintain pricing net of cost inflation at roughly neutral levels for the full year.

Great. And then just one of the housekeeping on kind of what's going on in China. I think it was it was a 50 basis point headwind in 2Q, the guidance assumed a 100 basis point headwind for the year. So just trying to understand how we should be thinking about the phasing in the back half? Is it just more pronounced in 3Q and then you're assuming some improvement in 4Q? And then, Russ, I think you mentioned you haven't seen any sequential deterioration, but it hasn't yet inflected. So just help us understand what you're kind of assuming in that 100 basis point headwind as well.

Yes. So basically, the 100 basis points that you would do is we for the second half, that becomes about 200 basis points. And that's more or less evenly distributed in Q3 and Q4. That's kind of the way to look at it. And then from a profit standpoint, operating profit, also, we expect roughly $70 million of headwind in the back half, again, in operating profit, roughly half and half. That translates to about $0.16 of EPS and that would be evenly split Q3, Q4. But I think, you want to add anything else for, Russ, or...

No, I think you said it well, I think we've assumed a modest improvement in the trend, but nothing -- no inflections at this stage because we do feel like it's prudent to be conservative given that sometimes these things can take a long time. And we've got to see a lot more unfold before we're confident in changing an outlook on that.

If we could take one more question and then wrap it up.

Absolutely. And our last question comes from Javier Escalante from Evercore.

I have a question for Russ and one for Mike. Hopefully, the one on Russ is not an overkill, but if you can give us an update on diapers, it feels as if that these imports -- and this is U.S. diapers, imports, the ones backed by the retailers seem to be kind of peaking. So whether that is true. And also, there is any commentary on the overlap with the relaunch from -- by your main competitor in the U.S., any core order that would be great. And in tissue, we do see an improvement in July, and there is this powerful shift to club and online. So if you can comment what's driving that? And I have a question for Mike.

Javier, on the diaper question, I think you're right, you probably have your followed the category, and I have to know that there's been a long history of new players coming in. And then sometimes, the peak and then abate. Certainly, there's a lot of those entering the marketplace right now, and that's a dynamic we're contending with. And so our focus in terms of how we deal with that is to just stay focused on executing our strategy, which I think has been very successful around the world, and that's to continue bringing innovation and focus on strong value propositions at every tier good, better, best.

And I think that has been working in North America prior to the club distribution change we've talked about. We've gained share 2 years in a row despite that competition. And we do have a good innovation agenda. I think we're now #1 in social engagement in '26. We've got a lot of good actions happening on premiumization. So we're going to stay focused on that in terms of how the other things play out, I think the consumers will decide. And we're confident that if we stay focused on our play, it's been very successful around the world, and that will continue to be true in North America. On the tissue, if I understood your question correctly, I think it was really just understanding a little bit more about what's maybe driving the improvement in our business. Is that right?

Correct.

Yes, yes. Well, I think it's -- again, it's -- I hate to be a boring and repetitive, but it's the same thing. We really took the thinking of what are our value propositions buy value tier in the marketplace. and really focused on sharpening the strength of our offerings and then improving our innovations. And so you've seen that in Viva, which we highlighted, I think, in the call were that's really been working for us. That's an example where we already have a great product. We just needed to activate it and do a better job in packaging it, communicating and building the brand, and that has been very successful. I think we gained 80 basis points of share in the second quarter on that.

We've got great innovation on Kleenex, which has been really performing very, very well in gaining share consistently over the last several years, and we have some new innovations on format that have insights around them with respect to consumer usage occasions. And then on the dry bath side, we've done a great job, I think, sharpening our value, which is very, very important to a large swath of consumers and have done extremely well in the good tier this year to date. And so it's all those things together, Javier with brand building activation and innovation. And we actually have some very good things coming as well next year and the year following on tissue that we're excited about, in addition to the fiber thing. So there's a lot of good things happening there. So I'll turn it to Mike on the second part.

Yes. I mean just a tag on. I know you got a question for me separately. But just -- I just want to emphasize, like the environment we understand. I mean the fact that there's more competitors entering categories in North America, I mean it's something that we're very well aware of. And I think you know we've been dealing with this for the past 10 years in China. There's 200 brands that we compete in diapers with in China. And we're very confident we have the best product in that market, which is why we became #1.

And so the thing that maybe I'll just emphasize, it's -- and the playbook is right, but superior value proposition, I will tell you the anchor for our superior value proposition that K-C is differentiated product technologies. And so we feel fantastic about the innovations we've brought in personal care. I promise you the innovation that you'll see in the next 3 years on personal care would be better than the ones we've launched over the last 10 years. It's also why we're doing things in tissue like alternative natural fibers, it's going to in my mind, change the category forever. And so again, that's kind of our bet, which is like -- and this is kind of the calling card to K-C, which is we are technologists first engineers, and we invent stuff, and we're good at it.

And Mike -- thank you for that, Mike. With the completion of the Suzano deal, right? Talk about a little bit, I guess, better or expand on what does it mean for you operating without the international tissue business right? What does it mean in terms of your capacity and resources to invest in international personal care and also reading the interaction of Kenvue.

Yes, for sure. We're really excited about the additional focus it brings, although that notwithstanding in a few months, there'll be a broader slot of categories, we'll have to focus on as well, but we feel very good about it. I think -- and maybe one of the best things, Javier, is I think, in setting up Arbex, it wasn't like we were trying to move on from a problem or a challenge. I think the whole fundamental premise of our joint venture with Suzano to create Arbex is we're going to create a world-class global competitor in the hygiene and tissue business. And I think when you combine the scale and capabilities of what Suzano brings with our commercial capability and knowledge of tissue making, I think that's a powerful combination.

And so I think there's no team within our company that was more excited than the Arbex team kind of getting started off about their future. And so we're really excited for them. Obviously, we all knew that we had this other thing, this alternative natural fiber up our sleeve as well. But again, I think part of it is we wanted to create an advantaged business on that side. And then certainly, within our house, the clear focus within personal care globally, I think, really helps us kind of drive the execution on that side.

Javier, just done last one, Russ again. Just on the diapers point that you made. Yes, I just wanted to underscore that we have great respect for our competitors and for the things that are happening in the marketplace. But what gives us confidence as well even beyond the United States is just how things are unfolding around the world. And that really -- and Mike just mentioned the China product performance as we've rolled the playbook out to other markets in IPC, you can see the results coming through, notwithstanding the recent China issue we've had we've been performing very strong in sequential improvements and double-digit gains in markets like India, Southeast Asia, Indonesia, and we're really strongly making progress kind of around the world, especially when you look at things like market share and diapers, 390 basis points up in Indonesia as well as 70 basis points up in Brazil. That playbook is working.

So that gives us confidence that it's not just regional battle, but the global playbook is translating across geographies, and that is no different in North America. And so that's really what we're focused on activating against and we believe in the long run that we'll be successful with that.

We'll end it there for today. And for analysts who have follow-up questions, the IR team will be around to take them throughout the day. So thanks very much, and have a great day.

Thank you. Everyone, this concludes today's event. You may disconnect at this time, and have a wonderful day. Thank you for your participation.

Hello. This is Christopher Jakubik, Head of Investor Relations at Kimberly-Clark. Welcome to our second quarter 2026 business update. Today, our Chairman and CEO, Mike Hsu, will provide an update on our overall business performance. Russ Torres, our Chief Operating Officer, will provide an overview of segment results and key market highlights; and Nelson Urdaneta, our Chief Financial Officer, will review our second quarter consolidated results and update our full year outlook.

We've also scheduled a separate live question-and-answer session with analysts. You can access our earnings release, supplemental materials and audio of our Q&A session at investor.kimberly-clark.com. A replay of the Q&A session will be available following the event through the same website. During our review, we will make some forward-looking statements that are based on how we see things today.

Actual results may differ due to risks and uncertainties, and these are discussed in our earnings release and our filings with the SEC. We will discuss some non-GAAP financial measures during these remarks. These non-GAAP financial measures should not be considered a replacement for and should be read together with the GAAP results. And you can find the GAAP to non-GAAP reconciliations within our earnings release and the supplemental materials posted at investor.kimberly-clark.com.

With that, I will turn it over to Mike.

Thank you, Chris, and thanks to everyone for joining us. Our second quarter results reflect the durability of the growth engine we've built through Powering Care. This quarter was characterized by a pressurized consumer environment, moderating category growth and a few discrete but significant one-off impacts. In the face of those headwinds, our teams around the world executed with speed and agility to manage the business with discipline and navigate externalities. We delivered our 10th consecutive quarter of volume plus mix-led performance, held global weighted share, posted another quarter of industry-leading gross productivity and continue to invest for impact. We also completed a major step forward in our transformation with the successful close of our strategic partnership with Suzano.

We unveiled our proprietary alternative natural fiber innovation program that has the potential to shape the future of our industry and further advance integration plans for our pending acquisition of Kenvue. We will be ready to hit the ground running at close. We're excited, and we're ready for what's next. We have a generational opportunity to create a new kind of health and wellness company to reimagine care for billions of consumers around the world and to create lasting value for shareholders.

With that, let's turn to the quarter. The second quarter reinforced that the operating model we've implemented can build our brands and businesses in almost any environment. With new challenges continually emerging, our teams have demonstrated the ability to adapt and execute. Despite discrete headwinds, which we'll discuss, the fundamentals of our business remain strong, driven by our disciplined approach. First, we innovate, out market and out activate to deliver superior value propositions across the good, better, best ladder. This enabled us to hold global weighted share on a trailing 12-month basis against a strong baseline.

Second, our cost discipline is a source of resilience that compounds over time. We delivered another strong quarter of productivity, advancing supply chain and AI capabilities to help us deliver the best product at the lowest cost around the world.

Third, our fast and agile operating model is fueling our ability to navigate new discrete headwinds while continuing to move the business forward. In the second quarter, we experienced a significant onetime external impact in China that has had a meaningful effect on the diaper business. As a result, we're adjusting our full year outlook primarily to reflect our anticipated recovery time line. Russ and Nelson will provide further details.

We're disappointed, but remain confident in the underlying quality of our global innovation and commercial plans. We're working hard to correct the situation in China and expect to drive continued momentum on our brands around the world. Last quarter, we told you that 2026 would feature one of our most active new product innovation agendas in recent history. We're delivering on that commitment with an onslaught of growth initiatives that are well underway.

In North America, we're delivering superior value propositions across our categories. New skin health innovation and upgrades are moving through the Huggies portfolio, reinforcing our commitment to delivering meaningful performance improvements that consumers value. Viva is the #1 cloth-like talent in the U.S., and it's a standout example of how out-innovate and outmarket strategies come together to drive household penetration and share gains. As a purpose-driven company, we're working hard to reduce the stigma associated with some of our categories and take pride in helping consumers live better lives.

Ahead of the world's biggest soccer tournament, Goodnights partnered with U.S. men's professional team captain, Tim Ream, to help destigmatize bed wedding among children. In international personal care focused markets, we have innovation-powered momentum. In Australia, our adult care innovation focused on delivering better fit, comfort and discretion, resulting in meaningful share gains.

In IPC enterprise markets, Vietnam and India continue to grow double digits and exemplify how we scale and tailor our proven playbook at speed. We're delivering winning innovation and reaching consumers with the right solutions in the right channels where social commerce is driving premium growth. The results we're generating in these markets are evidence of the durability of our Powering Care growth engine.

Our focus on productivity is deeply embedded in our culture. For us, productivity is an operating muscle that's only getting stronger. It funds our investments in innovation, brand building and activation while helping us navigate volatility from a position of strength. We remain on pace for another year of industry-leading gross productivity of 5% to 6% of adjusted cost of goods sold across our 3 productivity pillars, value stream simplification, network optimization and scalable automation.

We continue to build a robust pipeline of digital and AI-enabled initiatives. Together, these efforts support our commitment to delivering the best products at the lowest cost to consumers around the world. Three key initiatives are unlocking structural enhancements and cost efficiency. Having launched Coupa across our enterprise, we're leveraging a single global AI-powered solution that makes procurement smarter, faster and more connected, while providing enhanced visibility into global spend.

We deployed an AI-powered manufacturing agent that puts more than 15 years of institutional knowledge at employees' fingertips. We're rapidly scaling this solution across our manufacturing network. Pilot results show the agent is making our workforce approximately 40% to 50% more productive on knowledge search tasks. It's also accelerating decision-making and training and driving more consistent execution of manufacturing best practices globally. As we continue our digital transformation, we're also equipping our technologists with the capabilities needed to run the supply chain of the future. We launched an academy-based learning program spanning 17 critical skill areas, including agile, artificial intelligence and data visualization.

To date, the program has increased skill growth by 60% for more than 650 participants, and we're just getting started. We remain focused on performing while transforming. We're navigating a choppy external environment while driving disciplined performance on our base business. Through all this, we're making excellent progress executing 3 major strategic transformation initiatives. On July 1, we successfully launched Arbex, our joint venture with Suzano as an independent operating company.

Comprising substantially all assets of our former international Family Care and Professional business, Arbex launches as a global tissue and hygiene leader with strong capabilities to grow and expand margins over time. The launch of the joint venture sharpens our focus on our highest value opportunities in personal care, meaningfully enhances our financial profile and will further reduce future earnings volatility. We're also making excellent progress toward closing our acquisition of Kenvue.

The regulatory process is on track and integration planning is progressing well across all work streams. The closer we look, the better it gets. Having announced the future leadership team, we're finding the culture and capability fit is stronger than we had hoped. As we've engaged deeper in the planning process, we're gaining more clarity and conviction in our ability to capture this generational value creation opportunity. Third, we unveiled a proprietary alternative natural fiber innovation platform.

This exciting moonshot is brought to life by our Powering Care growth engine after decades of research. This initiative is the result of Kimberly-Clark's commitment to make bold, disciplined bets on category-transforming innovation that could reshape the future of care, our business and our industry over the long term. Through this program, we're positioning Kimberly-Clark to sharpen our focus on proprietary right to win spaces that improve our growth trajectory, reduce exposure to natural forest fiber cost volatility, make meaningful progress against our company's natural forest fiber-free ambition and build on our strong track record of U.S. manufacturing investment.

Our pilot plant in Yuma, Arizona marks our first facility in the region. We're honored to be part of the community as we become a new kind of global health and wellness leader. Now I'll hand it over to Russ to discuss the progress of our transformation in greater detail.

Thank you, Mike. Despite what remains a challenging operating environment, we continue to make meaningful progress. Importantly, across our key priority sales, we're holding or gaining share across approximately 70% of our net sales base on a trailing 12-month basis and 62% in the second quarter. However, we did experience several discrete one-off factors that impacted our second quarter and some that will likely impact our full year. Our teams have proven time and time again that they're very resilient and agile, and they remain focused on better innovation, stronger value propositions and sharper execution. We remain energized and focused on executing our repeatable playbook and positioning the business for long-term success.

In North America, our science-backed innovation and insight-driven marketing continue to resonate with consumers, strengthening our value propositions across the good, better, best ladder. While consumers remain under pressure and month-to-month consumption patterns are choppy, demand across our categories has remained relatively stable. And on the top line, organic growth declined 0.7% in the quarter, impacted by several temporary factors.

These include about 100 basis point impact year-on-year from changes in retailer inventories and an additional 80 basis point impact from the distribution center fire. As a reminder, this was set against a difficult comparison in the prior year when North America volume growth was approximately 5% in Q2 2025. Our tissue business is performing well. We saw strong volume plus mix-led growth in consumer tissue and our seventh consecutive quarter of volume growth in North America Professional. In fact, our consumer tissue business gained 10 basis points of weighted value share versus the prior year and improved our volume share by 70 basis points sequentially.

And we've got the best slate of innovation and marketing we've had in my tenure. And in our personal care business, we've been coming off 6 consecutive quarters of volume plus mix-led organic growth and 2 consecutive years of share growth. In Q2, we saw the full impact of the club distribution loss we noted in the last 2 calls in our diapers and training pants business, largely as planned. This was approximately a 240 basis point drag on our diaper share and a 290 basis point drag on our share in training pants in the current quarter.

We saw increased competitive activity in some segments of personal care as well. So as a result, share momentum was muted during the quarter with a weighted share down 40 basis points versus the prior year. The club distribution loss in diapers and training pants accounted for substantially all of the weighted share decline. Overall, we held or gained share in 4 of the 8 categories. And on a trailing 12-month basis, we continued to hold or gain share in approximately 70% of net sales across our key sales in North America.

And importantly, we remain on track for another strong year. Through the first 6 months of the year, volume plus mix is up 0.8% versus the prior year, and we delivered positive volume plus mix growth in 8 of the 10 last quarters with relatively flat pricing. On the bottom line, we continue to create fuel for growth through productivity and disciplined cost management.

Operating profit increased approximately 11% in Q2 and approximately 1% in the first half. This was driven by strong productivity savings, targeted revenue growth management actions as well as a onetime refund benefit that more than offset the headwinds from business exits and increased brand investments. So as a result, North America operating profit margin increased 50 basis points in the first half despite a volatile operating environment and up against our most difficult comparisons for the year. Looking ahead, we remain confident in our momentum entering the second half and into 2027.

Our innovation pipeline remains robust with some exciting new launches expected to provide an incremental tailwind to growth. Combined with continued brand investment and strong commercial execution, we expect to build on the progress we've made. Let me share a few highlights from the quarter that underscore our confidence. We've continued to strengthen our position across the good, better, best ladder by cascading innovation across our U.S. diaper portfolio. And in the second quarter, we launched the next-generation Skin Essentials diaper, the first and only zinc oxide enriched liner available in the U.S.

This premium innovation for sensitive skin is clinically proven to help reduce irritation and is receiving strong early ratings from reviews and from parents. We're also energized by the launch of our upgraded Little Snugglers line, leveraging new fast absorbed system and the luxury softness of our snug and dry diaper. This product has now some of the most innovative features, including all around blowout blocking, leak protection and gentle protection for the most delicate skin.

We've also been building brand love by authentically engaging in timely cultural moments. Before the championship match of the world's biggest soccer tournament, a 2007 photo resurfaced, featuring one of the sports greatest players bathing a baby who would grow up to become one of today's brightest young stars. And nearly 20 years later, these 2 athletes were set to face off in the much anticipated final match of the tournament.

As this story gained traction on social media, our Huggies marketing team identified the connection to a universal parenting truth. They grow up so fast. And in under an hour, we created and published a simple Huggies social post inviting consumers into the moment, and they responded immediately right before the big game. It garnered nearly 1.5 million views without paid spending and is the most engaged with Huggies U.S. organic post of all time and our second most shared. That's the speed, creativity and cultural fluency we've developed across our marketing organization.

It's part of the same creative strength that earned Kimberly-Clark 8 Cannes Lions in June. Our social acumen paired with winning products will become a key asset for us in creating authentic brand connections with new parents that result in driving volume and mix-led growth. Let me give you another example of the power of unifying our out innovate and outmarket strategies. In family care, Viva is a hidden gem in our portfolio with a differentiated cloth-like feel.

When consumers try it, they love it. So in the third quarter of 2025, we launched the Bold Mess Makers campaign, which celebrates Viva as the go-to solution for the biggest messes. With a superior product and compelling creative storytelling, we've grown market share for 5 consecutive quarters, up 80 basis points year-over-year for Viva Signature cloth in Q2 alone. The same consumer-first mindset shows up in our recent campaign for Goodnites. The youth pants category is an area where the functional need is clear, but the stigma is real. We launched an extension of our successful never stop dreaming campaign with U.S. pro soccer captain, Tim Ream, who shares his childhood experience of bed wedding. It's an inspiring and authentic story. With his strong partnership, we're reminding kids that nighttime accidents do not define who they are or what they can achieve.

Our approach to storytelling is driving growth and expanding the category. Year-to-date, Goodnites share is up over 200 basis points versus a year ago. In international personal care, we continue to see strong evidence that the Powering Care playbook is working and is highly repeatable, particularly across our focus markets. We're focusing on delivering strong volume plus mix growth and consistent margin expansion by scaling that winning playbook across markets.

Our second quarter and year-to-date results remain consistent with this strategy. Across focus markets, our top line momentum continued, fueled by innovation, strong end market execution and differentiated social commerce capabilities. These strengths continue to drive meaningful share gains across the portfolio, particularly in diapers and pants. And we're also seeing momentum build across several enterprise markets, including Vietnam and India as they adapt our playbook. Mike referenced the unfortunate issue we faced in China in June.

Just before the critical 618 shopping festival, one of the 2 notable annual consumer events in that market, false and misleading allegations regarding the quality of multiple diaper brands in the China market emerged and quickly went viral across social media channels. There is no scientific evidence backing the claims and multiple independent tests conducted by certified third-party labs confirmed the safety of our products.

We continue to cooperate with the Chinese authorities in managing this issue. This incident impacted our Q2 results and will impact our full year potential. The China team continues to do an excellent job navigating this unfortunate situation and remains focused on serving customers and executing its very successful business strategy. On the top line, while we delivered solid organic growth of 1.0%, this was held back approximately 140 basis points from the China social media disruption.

Excluding this impact, solid volume plus mix gains were driven by innovation, brand investment and disciplined execution with share gains across several countries and categories. Within diaper and pants, we continue to see strong momentum in our focus markets with share gains of 390 basis points in Indonesia, 80 basis points in China, 70 basis points in Brazil. We also delivered share gains of 240 basis points in Indonesia fem care and 260 basis points in Australia adult care.

At operating profit, we delivered more than 2 points of growth despite a roughly 440 basis point headwind from the China social media disruption. And year-to-date growth was double digits, driven by strong gross productivity savings and favorable volume plus mix. Our productivity savings continue to fund investments in our brands, strengthen our consumer value proposition and build brand equity across our markets. For the full year, the China social media impact has the potential to temper our IPC segment's organic growth by 3 to 4 percentage points and hold back operating profit growth by 10 to 12 percentage points as we invest aggressively to defend our franchise.

Our IPC team continues to focus on building sustainable top and bottom line momentum by adhering to our proven playbook of bold and scalable innovation, creative that strengthens brand love and excellent marketing and activation across markets. This will sustain our momentum and set us up for further gains consistent with our long-term algorithm in 2027.

As an example, in Australia's adult care category, we're tapping into an unmet need and driving share gains among women. Poise intimates is designed to look and feel even more like regular underwear while delivering leak and odor protection. Purchase intent among new users is over 80% significantly higher than the category benchmark, and Poise market share in Australia is up 210 basis points versus prior year in the last 3 months.

Vietnam and India are 2 of our strongest growth stories with strong potential. Both are tangible examples of how we're taking the best of what we've learned in one market and injecting that into important emerging high-potential enterprise markets to rapidly deliver results. Our team in Vietnam is leveraging a highly sophisticated dynamic social commerce model that is winning in China and adapting it to the Vietnam market with speed and agility to make it even more powerful.

We're winning by bringing the right portfolio to the right strategic channels, deploying the right message at the right time. As a result, organic growth is up high double digits year-to-date. In e-commerce, Huggies growth doubled year-over-year with market share up 430 basis points. And on TikTok, where we know discovery is a powerful driver of purchase decisions, our market share has nearly doubled in 2025 versus 2024.

In India, we're proving that when we solve real consumer needs, people are willing to pay for superior products. And this is particularly true within the Huggies portfolio. The key has been bringing the right innovations to the right consumer need states and building brand love. Organic growth is also up high double digits over the first half of the year. Our focus on e-commerce has emerged as a powerful growth engine, increasing more than 50% year-to-date versus last year. Premium segments are growing significantly faster than the category, up 67% over the same period.

So together, these gains underscore the strength of our premiumization strategy and have contributed to 80 basis points of market share growth year-to-date. What's playing out in these markets is that this is not one launch or one campaign. It's scaling our model across geographies. We're getting down the curve, powered by our rewired organization. With Kenvue, we see an enormous opportunity to supercharge our performance with the same playbook broadly.

We're especially excited about markets like India, where Kenvue has the potential to quadruple our distribution or Vietnam, where we have a proven model for digital engagement, social commerce and premiumization that we believe can travel across a broader combined portfolio. Our pending acquisition of Kenvue and the integration planning we've been carrying out is on track, and we're building greater visibility to the tremendous potential of this combination. We plan to close immediately after regulatory clearance, and we're currently tracking to Q4 of this year. We now have roughly 50 teams and 600 people involved in building our integration plans from the ground up.

Our employees are excited about the future together as we're gaining greater visibility into what we can accomplish as a combined company. In fact, employee engagement scores are rising at both companies. On the Kenvue side, an April pulse survey showed improvement versus the Q4 2025 baseline across all 6 categories they measured and with significant improvement in key segments and markets.

And for Kimberly-Clark, our June employee engagement scores remained above benchmark with a further uptick versus October and a big jump in our prospect score that speaks to employee excitement about our future. On the cost synergy front, we're tracking ahead of our expectations on the 3-year pipeline of specific actions that will deliver our $1.9 billion goal. I want to take a moment to highlight our approach as it's a bit different from some other integrations you might have seen. For several months, our operating teams and best-in-class advisers use detailed cost analysis, benchmarking and an assessment of the operations of both companies to identify sources of inefficiency and opportunities to create value in the future combined company.

From this work, we asked our 50 integration teams to identify and quantify the specific discrete initiatives required to deliver the full $1.9 billion in cost reduction. Then we asked them to build integrated well-resourced plans to execute those initiatives over time. So it's a rigorous process designed to gain a high degree of visibility and confidence in delivery by year.

The integration management office and key future leaders review the pipeline in major initiatives every 30 days, and the pipelines we just saw in July are very strong and well ahead of expectations at this stage, giving us high confidence and line of sight to achieving the $1.9 billion. The biggest contributor will be straight integration activity, eliminating duplication, leveraging scale and consolidating our activities. This will come in years 1 and 2, and we have very clear plans forming in these areas.

In fact, some of the actions that Kenvue has taken on its own this year give us a running start to achieving the overhead and SG&A efficiency levels we envisioned as part of our acquisition model. Beyond the actions Kenvue is taking on their own, we've identified more than $600 million of savings with half of this coming in year 1 from implementing our operating model, leveraging our combined scale and procurement as well as optimizing overlapping non-people spend in areas like service providers, media, IT, data and many other big-ticket areas.

The second biggest contributor will be the integration of our supply chains and commercial operations. We'll be able to leverage our combined scale, along with the best assets and capabilities from both companies to create new value. We expect to see these savings unfold primarily in years 2 and 3. For example, we'll be able to build much more efficient and effective distribution and logistics platforms through integration in markets like the U.S., Canada, Australia, Brazil, China and India. This will reduce costs, reduce inefficiencies and improve our ability to serve customers better.

We'll be able to integrate sales and merchandising organizations to expand coverage, increase sales and drive more efficiencies. In IT, which is a major expense for both companies, we will consolidate and simplify our systems and IT infrastructure to gain scale and lower our costs. For instance, between the 2 companies, we're currently operating 6,000 different applications and greater than 15 ERP instances.

Standardizing, simplifying and consolidating this onto one platform will be a huge driver of efficiency in terms of people hours, run costs and license fees over time. In supply chain, we will leverage the combined company infrastructure and proven playbooks in value stream, planning, procurement, distribution and logistics and digital technology to drive costs out and improve execution. We have many exciting opportunity areas teed up to implement.

The third piece will come from continuing to transform both businesses, involving process simplification, application of new technology and strengthening capabilities, and we will see the bulk of the benefits from these actions contributing more to year 3 and beyond.

The opportunity is tremendous, and we're taking the opportunity to reimagine how work will be done in the future and apply state-of-the-art tools in areas like global business services and artificial intelligence to our core activities to increase speed, reduce costs and improve effectiveness. So in each of these areas, we're taking a balanced approach with a strong focus on risk mitigation in the near term while targeting world-class capabilities and costs over time.

We're equally excited about the opportunities to accelerate growth. Only a few months after naming them, our future segment leaders are now organizing efforts across roughly 20 future accountable business unit teams around the world to identify, validate and prioritize the best ideas ready to action post close. It's already resulted in a 4-year revenue opportunity pipeline of specific initiatives that's more than $1 billion versus our $1.4 billion goal, and it's ramping fast.

We expect to flesh out further actions in the months prior to close, and we will then overlay our global strategies to determine how we can better accelerate the most promising plans even further. To summarize, we're building a highly motivated team that continues to build greater visibility to the tremendous opportunities we have ahead. So with that, I'll hand it to Nelson to discuss our consolidated financial results and outlook for the balance of the year.

Thank you, Russ. Together with Mike and Russ, I would like to start by recognizing the responsiveness and agility of our teams, delivering strong operating performance, quickly and effectively addressing multiple headwinds as they have materialized and advancing our strategic initiatives to truly transform our company in ways that promise to deliver sustained value to all our stakeholders. The risk mitigating actions we've taken in the past through integrated margin management are enabling us to maneuver more effectively through a complex operating environment, and we're positioning ourselves to hit the ground running on both the newly formed Arbex joint venture and the Kenvue acquisition.

Q2 organic net sales were broadly flat, including a roughly 50 basis point negative impact from the China social media disruption Russ highlighted and reflecting the more challenging consumer environment, retailer inventory reductions versus the prior year and the impact of the L.A. distribution center fire in North America. For the first half, organic net sales grew 1.2%, driven by continued momentum in several international markets, including South Korea, Indonesia, Vietnam, India and Brazil.

Adjusted operating profit increased 6.2% in the second quarter and 4.9% in the first half. Results benefited from onetime tariff refunds and strong productivity savings, partially offset by discrete headwinds related to business exits and disruptions in our China diaper business. Underlying operating performance remained healthy. Continued productivity gains were partially offset by unfavorable pricing net of input costs, driven by higher inflation stemming from the Middle East conflict as well as targeted investments to strengthen our value propositions in key markets.

As noted, we generated gross productivity at more than 6% of adjusted cost of goods sold in the second quarter, building on our strong first quarter performance. These savings continue to fund strategic investments behind our innovation-led growth model and support efforts to enhance our value proposition for consumers.

Second quarter adjusted earnings per share from continuing operations and adjusted earnings per share both increased 10.4% versus the prior year, driven by adjusted operating profit growth as well as benefits from lower net interest expense and higher income from equity companies. Finally, we delivered adjusted free cash flow of approximately $1.1 billion through the first 6 months, putting us on pace to deliver approximately $2 billion for the full year. Turning to our outlook. For 2026, our focus remains on delivering sustainable growth and strategic progress as we navigate an increasingly dynamic and challenging operating environment.

On the top line, weighted average category growth is now pacing at 2% versus 2.5% previously. This reflects a more cautious consumer environment, particularly in North America compared to our outlook in April. In addition, we expect disruptions in our China diapers business to represent an approximately 100 basis point headwind to full year growth. As a result, we now expect full year organic growth to be roughly 100 basis points below weighted average category growth for the year.

At adjusted operating profit, given the significant disruption in our China diaper business and our intention to invest aggressively to defend our franchise, we now expect mid-single-digit growth on a constant currency basis compared to our outlook in April of mid- to high single-digit growth. As a reminder, when we provided our April outlook, we included approximately $50 million of expected second quarter cost headwinds, primarily related to higher energy and other operating costs. Those impacts materialized largely as expected and are reflected in our first half results. Looking ahead and considering where energy prices are now, we anticipate incremental second half gross input cost headwinds of approximately $150 million, consistent with the range of risk we outlined in April.

We have incorporated these costs into our current outlook through mitigating actions already largely underway, Together with the benefit of the tariff refund, we expect to offset these impacts and maintain pricing net of cost inflation at roughly neutral levels as it relates to previously mentioned gross input cost headwinds. While some risk remains, we are approximately 90% covered across our total input cost basket for the year and are diligently working to manage through the remaining exposure. For adjusted EPS growth from continuing operations, we are similarly lowering our outlook to high single-digit growth on a constant currency basis, down from our prior expectation for double-digit growth.

Included in this outlook is an approximately 30% increase in income from equity companies, reflecting the addition of equity income from the International Family Care and Professional transaction in the second half. Our outlook continues to assume an adjusted effective tax rate of approximately 23% and relatively flat net interest expense and shares outstanding versus the prior year as we expect to hold the proceeds from the International Family Care and Professional transaction in cash to help fund the cash portion of the Kenvue acquisition.

For adjusted EPS attributable to Kimberly-Clark, we now expect a low single-digit decline on a constant currency basis compared with our prior outlook for results to be in line with 2025 levels, reflecting the impact of recent disruptions in our China diaper business. As a reminder, with the formation of the joint venture with Suzano on July 1, the contribution from discontinued operations will now be 0 and adjusted EPS from continuing operations and adjusted EPS attributable to Kimberly-Clark should be the same in the second half of the year.

On free cash flow, we remain well positioned to deliver approximately $2 billion of adjusted free cash flow consistent with 2025 levels, even as we accelerate capital investments in our growth and transformation plans to approximately $1.3 billion, up from $1.1 billion last year. Finally, please note that our outlook excludes anything related to the closure of the Kenvue acquisition prior to December 31. With that, I'll turn it back to Mike.

Thank you, Nelson. Our durable Powering Care growth engine is driving our performance around the world. Even as the environment remains dynamic, we're effectively navigating several discrete impacts. We remain rooted in our purpose. We're executing our proven repeatable playbook, and we're managing the business with discipline. Every day, we're building on our track record of resilience and fueling our underlying business momentum. We are in the early innings of creating a new kind of global health and wellness company. I'm proud of our teams, not only for the results they deliver, but also for how they deliver them with dedication, integrity and great care. Thank you for your time and interest in Kimberly-Clark.

All right, everybody. Welcome back. Thank you. For our next session, we have Kimberly-Clark Corporation back at the conference. There's a lot of...

Thank you for having us, Steve.

Thank you, Steve.

With us, we have Chairman and Chief Executive Officer, Michael Hsu.

He told me right before this, this is like #21.

We're getting there. We're getting there. And Chief Financial Officer, Nelson Urdaneta. So thanks, guys, for being back.

Thanks for having us.

There's a lot going on. So Mike, I'm going to start with you just to frame what you've talked about as a generational moment for Kimberly-Clark, both in terms of business momentum and the Kenvue transaction. So maybe we just start there and maybe expound on what you mean by that.

Yes. Well, Stephen, thanks for having us. We're really excited about our base business performance and probably even more excited about having the opportunity to build a -- what we're saying is a preeminent health and wellness leader. I think embedded within that, what's driving our base performance and what we think we have, is a powerful value creation engine with our Powering Care strategy, right? And I think that's driving consistent volume and mix growth, consistent share growth. And I think you've seen that through the first quarter and probably for the last 9 quarters from us. And so we feel great about that.

And then, in terms of building a preeminent health and wellness leader, together with these companies combined, we think we can really elevate the standard of care for all consumers. We tend to play in the same life stages. So if you take our portfolio, Baby, Kenvue have -- obviously has a portfolio that lines up against Baby, Women, Family and Seniors. And so I think it's a powerful portfolio where we can really serve all these life stages more effectively. So again, we're really excited about the opportunity.

Great. And you have -- I mean, we focus on the base business for a bit, I mean you focused -- you've delivered multiple quarters now of volume-led growth in categories that historically have been volume-challenged. So I think what do you think has structurally changed the most in the model, whether around innovation or brand investment execution? Just what's driving that? And what gives you confidence that that's durable?

Yes. The -- Steve, the idea is superior product equals superior value and that drives volume mix. And that's kind of how we approach it, which is we're a company of engineers. We invented most of the categories we operate in. We believe there are real differences in performance that exist. And I think that's different than maybe what outsiders perceived back when I joined the company. I think many viewed these categories as commodities. And I said, well, gosh, mom and dads entrust their most important thing in their life to us. There are real things that we can do to take care of baby better, right?

And if you extend that through our portfolio, I think we've demonstrated that. And so I think going back over the years, the opportunity that we saw was an opportunity to really elevate the category or premiumize the category by adding better features and benefits that maybe consumers hadn't envisioned that would be valuable, but turned out to be very valuable. So we've really, Steve, premiumized the business, and that's really driven a lot of our growth over the last 5 years.

The example I'll give you is when I joined the company back in 2012, maybe 65% of our Huggies business in the U.S. was in the value tier. Today, we're 80% premium, right? So that's a big move. But I think what's also driving our growth in the last couple of years is that we said, hey, we're not going to be just a niche premium player. If we want to lead our categories, we need to serve all consumers. And so we've really sharpened our offering, particularly with the value consumer. And I think that in China in the last 2 years, in the U.S. last year and this year, I think that play is really working hard for us. And we really made some significant improvements to our Snug & Dry line, which is the value tier Huggies in the U.S., and you could see that impact on the volume.

Yes. Okay. Great. Let's stay on the U.S. for a second. Nelson, there's been volatility between consumption trends and your reported shipments. So maybe just walk us through some of those disconnects and how that's going to map out. But also just what -- and Mike, you can jump in on this as well, but just what you're seeing in the North American consumer in general? How that's impacting your balance of year expectations?

Sure. Let me unpack a little bit what we saw in the first quarter. But we've seen, Steve, over the last 2 years, and even in the first quarter of this year, sustained momentum in both our global business and our North America business with consistent volume plus mix-led growth from very strong pipelines of innovation and activations across all of our categories and across all of our value tiers.

As it pertains to the first quarter of the year, we saw shipments lag consumption by around 200 basis points. In fact, consumption grew by 3.7% in our consumer categories in North America versus shipments, which grew 1.4%. And there were a lot of moving pieces in the quarter, but one to highlight is the fact that we have strong programming in the club channel at the beginning of the quarter for which shipments actually took place in the latter part of Q4 of 2025.

As a reminder, in our April update of earnings -- Q1 earnings, we highlighted that we still expect the second quarter to see a similar trend. And there's 2 factors at play in the second quarter. In the case of North America, we are foreseeing headwinds of around 70 to 80 basis points on our shipments related to the recent L.A. distribution center fire. And also, for the second quarter, we're going to be lapping the strongest comp versus 2025. Because as you'd recall, last year in this quarter, our North America business grew volumes north of 5% from a very strong pipeline of new products that we were putting out, particularly in our Baby and Child Care business.

For the second half, we expect shipments to accelerate, firstly, because our innovation pipeline remains strong. And then secondly, we will be lapping a lot of the stronger comps from the first half.

And then lastly, for the full year, and I'll let Mike chime in on the state of the consumer, for the full year, we stated that we still expect to have growth that's at or above our categories, weighted average growth of the categories, which trailing 12 months as of the end of March was right around the 2.5% range.

Yes. And maybe just to tack on, on the state of consumer, my view would be that consumer in North America, particularly, which I think you're asking about, resilient, resilient. And I think maybe my lens is may be colored, Steve, by the categories we operate in. And as you guys are familiar with our categories, like diapers and bath tissue, Kotex, like they're pretty stable categories, daily use categories, and consumption doesn't change much based on pricing, right? So I think -- so that's kind of maybe one aspect of it. And it's reflected in our Q1, where I think our volume mix was up about 3%. Organic overall was up 2.5%. We grew share in, I think, 90-plus percent of our business.

And so I think we feel good about that. But we're also cognizant since the start of the war that the elevated fuel and fuel prices have an impact, especially on the consumers at $100,000 income and below, which is 90% of the U.S. households. And so that really kind of plays into the strategy that we've been on, which is we pivoted to strengthening value within the value tiers in addition to premium, and I think that's working hard for us.

Great. So if we pivot overseas, international personal care, IPC, just standout performance, both in terms of growth and margin expansion. I guess, talk first about your confidence of that and the sustainability of that because I think you are confident in that. But then, also any watchouts given the same macro context?

Yes. Great momentum. I'll remind everybody that in our categories, D&E, or developing/emerging, markets are still very early in the stages of development. And, however, in the quarter, you may have caught like -- Steve, like I think double-digit growth in Brazil. I think our Indonesia business was up 30%. It's a business that had been challenged for a few years. Vietnam was up 40%. Even Korea, the diaper category in Korea, Steve, was up over 20%. There's a baby boom because as you know, the births have been declining in Korea for like 15 years. And last year, the births were up 6.5%, which is driving a bit of a boom in some of our categories. So we feel good about that.

What's driving it? I do -- I would say the Powering Care strategy. And the core elements are we kind of mixed -- made up our minds. We have to have product superiority. We really invested to create differentiated product offerings. I think we've really improved, and we think we have some of the best digital and social marketing methodologies out there. We're excellent at managing data and mining data and then marketing consumers directly through social channels. So that's driving it. And then the last thing that makes it all work is we said we're going to have best product at the lowest cost. You can see the productivity flowing through, and that gets us on this virtuous cycle of growth.

Yes. Yes. Great. In many markets, I think this is true in Brazil. It's true in North America. So I'm going to focus the question there. And you mentioned this like the Snug & Dry, you've been pushing essentially premium features into value tiers, which is enhancing the product offering. You've also been promoting to drive trial against those innovations. And that's created some concern among investors as to is this -- is it trial-driving activity only? Or is it going to be a structural pricing stance? And does it risk creating a competitive situation that is not productive for the category? How do you think through that?

Well, one, our strategy is consistent, which is we're growing by driving innovation and innovative features. We're advertising to support those features and to grow the category. We're activating in store with great execution, but promotion is really only to support trial of the innovation. And so -- and I know like some analysts or other companies, U.S. is promoting more. But if you look at the math, we haven't even returned to 2019 levels of promotion, and we promote less than all the other branded competitors in the category. So -- and part of that is because I don't like to promote from a trade promotion perspective. I think it's at best dilutive. At worst, it's unprofitable. And I think it gets you into this doom cycle where you invest too much to promote and then you end up cutting the product quality, which drives the category into a downward spiral. So I'm -- we'll never go that way. And so despite the rhetoric, I would urge you to look at the facts.

Okay. And Nelson, I think that, that dovetails into what you've been consistent about for a while in terms of the positive PNOC, price net of commodity costs, and that being a core principle for you. Just given what we're seeing in the cost backdrop, how are you thinking about the balance of pricing, productivity, investment to maintain that PNOC as we go forward?

Sure. So Steve, the environment promises to stay quite volatile, and we will remain very agile and disciplined throughout it. In the past few years, we've gained a lot of experience in how to manage through this type of volatility and disruption as shown in the super inflationary cycle that we just went through in 2021, 2022, when, as you know, we faced about $3.4 billion of incremental cost headwinds in the course of 2 years. And because of our discipline, our agility and our focus on our playbook, we were able to quickly recover our margins to pre-pandemic levels. And in the past 3 years, we've actually been expanding them.

Our teams are very clear that we expect them to manage the pricing net of costs of at least neutral over time. And they need to leverage all their tools within our integrated management framework -- margin management framework to ensure that we recover those costs over time. Right now, we don't have any update versus what we provided back in Q1. Our teams are diligently working through identifying what the exact impacts are going to be. And more importantly, what are the actions that we're going to take, leveraging all the tools at our disposal.

The one thing that I will reassure you is we're not going to cut back investments behind the innovation and behind the brands. We have a very solid pipeline of products we're going to put into the marketplace and solutions, and we will be balanced in our approach, but we will ensure that our teams remain fairly disciplined.

Okay. We were talking a little bit about this before we got on stage. But back at your Investor Day, you targeted $3 billion of stand-alone Kimberly-Clark cost savings over time, which is a big number. And so, I guess, maybe where are you in that journey? How much left us to go, especially in the areas we're talking about in terms of network optimization, value stream simplification and some of the manufacturing platforming that you're doing across facilities?

Sure. We're actually tracking ahead of plan on the $3 billion 5-year productivity program, and we have line of sight to continue to deliver strong productivity over the next few years. Through the first quarter of this year, we've actually delivered 56% of the target, and every segment has contributed its fair share. If we look at our continuing operations made up of North America and our International Personal Care business, the average delivery program to date has been 6% of gross productivity.

Now, peeling the onion into the 3 components of our supply chain strategy, the sources of the productivity, the value stream simplification has delivered roughly 50% of that number program to date, whereas the network optimization and the digital scalable automation have each delivered around 25% of that target. And we expect those to ramp up, particularly the network optimization over the next few years, as we stepped up the capital investments in 2026, and that will remain very near that level for 2027.

We're very confident about the size of the productivity pipeline looking forward. And one thing to keep in mind is that you're aware of the $2 billion investment that we're making in the North America network. That productivity -- in fact, we were at Beech Island last year visiting the facility. That's one of the places where we're making a very big investment in distribution on top of our greenfield facility. We -- that productivity is going to kick in starting 2027, hence, our confidence in our ability to continue to deliver on strong productivity over the next few years.

Yes. Steve was commenting before we got on stage that he was reflecting on his visit to the Beech Island, which is our largest facility in the world, and we make almost every product that we offer in that facility. And so it's a big complex operation. And so I think you're commenting, well, it may be hard to kind of drive the productivity because there's so much to kind of get your arms around. But I think the thing that I said is a couple of things happened, which is, one, bringing on some very good outside perspective, starting with Tamera Fenske, our Global Chief Supply Officer, joined us after a long career at 3M, just got a different lens on how manufacturing should be done. And then, she's brought in some other people from the outside.

So I think they could take an objective look, Steve, at like how K-C did things and really kind of found a lot of good opportunities for us to simplify. So that, I think, is a good starting point. And then, the other side of it is we are a company of engineers. We're kind of nerdy. And so because of that, people like to get stuff done, and they execute really well. And so, even though it looked very complex, I think there is structuring kind of how people are organized.

Yes. The other thing -- I mean, there's the raw cost-out efficiencies, but also a lot of what you're doing is going to enable faster speed to market and more commonality in terms of what you bring to market, which I think we're already seeing the early signs of in this wave of innovation.

Yes. Actually, we kind of refreshed some of our manufacturing assets over the last year. We did this restructuring back in 2017, if you recall. And part of that was to update the fleet of assets. And part of what we're doing is, one, commonizing them so that like all of our diaper assets are the same around the world now. But the other thing that we were doing was increasing the flexibility of each, right, so that we could run value tier and premium tier on the same asset and make feature adjustments without increasing capital costs.

Yes.

Okay.

Kenvue.

Yes. It was all about that. Right.

Yes. He was talking about Kenvue.

So -- I mean, you've been clear that this is about creating a broader health and wellness platform. And so let's just kind of start there. And I guess, as you've gotten further into this process, updated thoughts on why you think this is -- this combination is going to be uniquely positioned to win. And I guess, how you've been viewing recent progress at Kenvue?

Yes. We had a global town hall with the Kenvue organization 2 weeks ago up in New Jersey, and Kirk had me out there. And so that was kind of their question, like you're 6 months in, what are your thoughts? And I said, like the headline is, the closer you look, the better it gets. Like -- and on our side, the K-C side, and I think increasingly on the Kenvue side, we couldn't be more excited. And so what are some of the things about why is it better? Number one, I would say -- and I didn't realize this as closely, even though we do a lot of due diligence, but we've been doing these category deep dives in each of the Kenvue categories. And I will tell you, the state of development of these categories, they're very early in the journey.

And even though a lot of these categories have been around, like [indiscernible], I think, launched in 1954. So it's been around for 70-plus years. But I would say -- the reason I would say that categories are early in the stage of development is I think there's a huge gap between incidence of a health issue and treatment. And this is in almost every category that Kenvue operates in. The example I'll give you is allergy. When we're doing our deep dive on allergy, and when we do these deep dives, we kind of assess the structure of the category and all the subcategory components. We interview consumers, and we understand kind of what the big unmet needs are and how they think about the category.

On allergy alone, Nelson, I think the number is 100 million allergy sufferers in the U.S. alone that don't treat, right? They're not even aware they have an allergy, right? And so I think that for us as there's a big opportunity for, I would say, a company and our approach with a more traditional CPG mindset is to come at these categories and say, how do we systematically develop them. And so I think that's part one, which is we see, one, these are the biggest categories in CPG among the fastest growing, and they're underdeveloped, right? And so I think that's one big thing.

The second area where I say, "Oh, the closer you look better it gets". And I think you wouldn't see this in what's available publicly. But since we're doing our monthly trading updates with Kenvue, and we do the business reviews, I would say there's a lot of good performance in that business that you all cannot see. And why can't you see it? It's because they tend to report by category, Steve, right? And so you just see the overall. But there's a lot of markets and a lot of -- particularly in international, where I've seen very good performance across many brands. And that's reflected in the appointments that we made. We announced our senior leadership team for the future company post-close back in April. And people were surprised that there's a pretty good mix, balanced mix between K-C and Kenvue.

Well, when I was interviewing some of the Kenvue executives, let's say, Carlton Lawson, who runs EMEA, and Leo, who runs Latin America, I said, "Hey, your performance is as good over the last 5 years as anything that we've got on our side, right"? And so -- and I was super-encouraged by that because international has more of the complexity than North America, right? And the Kenvue portfolio overall is a little more complex than ours, right? And so, however, they've been managing that pretty well. So I think there -- so that's the encouraging thing.

And then, as we get further into it, and as we meet with the Kenvue management side and so forth and do our category dives, everything that we're doing in powering care, right, which is like, hey, make the innovation better, differentiate the product through value-added innovation, Kenvue is spectacular on the science front. The big thing that we did at K-C that they told me to go through is when we did our market structure, we understood where the biggest consumer unmet needs were going to be. And then, we just said, we're going to pour all of our R&D resources into those things. And that was a little bit different than how K-C used to do, which is kind of like self -- you guys self-determine what you want to work on, right? And so when you concentrate your firepower, that's where you get the breakthroughs. So that's one area.

The second big area is the marketing and where we have made a ton of progress, and that's evidenced by our surge to market leadership in China is. I think we're one of the best companies, and our customers would tell us that we're among the best at digital marketing and social media marketing and e-commerce marketing and all those things. And so we've really invested in a lot of capability in that. We're very good at it.

We tend to index higher on e-commerce. I think we're, on average, 700 basis points higher share on e-commerce than offline. Kenvue is the other way, right? So that's going to be a great opportunity for us. So I think there's going to be a lot of -- we're really excited to apply kind of our value creation model to the Kenvue portfolio.

Is there -- I don't know if you're prepared to do this, but is there a way to take us underneath the covers a bit and talk about how the integration office is being structured in terms of just the work streams that you're kind of putting on papers? Because I think there's a big concern that once the deal gets regulatory approval and closes, then the complexity really kind of hits home. So how are you getting ahead of that?

Yes. So the integration management office is up and running since we announced the deal. It's being headed by our Chief Operating Officer, Russ. And we've got over 40 work streams underway with over 400 people involved. Obviously, no gun jumping and following all the regulatory requirements, but we're not wasting time in getting ready, Steve. I mean, these work streams are allocated to each or organized to each of the functions, organized within the segments and with the new segment leaders that have been announced because we've got to focus on multiple elements of the integration.

One is obviously a work stream around people and culture. That's plowing ahead and moving forward. And you've seen that Mike already named the leadership team, and we will keep progressing on that element of the integration. Secondly is on the cost side. We have very ambitious cost synergies that we feel very confident in our path to deliver them as committed. And we have been working very diligently on that. I mean, we started on this as we were doing the due diligence, but obviously, we wasted no time in ensuring that everyone within every function is clear on what the plans are and what the cadence is going to be between year 1 and year 3 to accomplish the task.

And then, the most important and exciting aspect of the entire integration is the revenue side, the growth, because this transaction, above anything else, is about growth, about really leveraging the potential that the categories have and the potential to serve consumers across all life stages. So that's up and running, up and going and more to come, and it's not going to be a day 1, wake up, see what you're going to do.

Good. As a follow-up on that, so the cost synergy target, nearly $2 billion, $1.9 billion. Are there areas where you're gaining conviction or seeing potential upside? And then, I guess the other side of that coin is as we've seen Kenvue make margin progress. And one of the concerns or one of the questions I've raised, investors are thinking the same, is Kenvue -- it's good, but is Kenvue kind of getting ahead of the synergies? Is it change -- so how do you respond to that?

Yes. So a few things. First, as I mentioned just now, we continue to gain clarity and confidence on our path to delivering and/or beating the synergy and earnings levels objectives that we have for the transaction. The sources of the cost synergies are areas in which we, Kimberly-Clark, have been building significant execution capabilities over the last few years. Our results in the last 2 years and even in Q1 are proof points that we can drive sustainable volume-led mix growth, that we can drive record levels of consistent productivity level, that we can drive overhead efficiency all at the same time.

There's 3 sources of productivity that we shared on November 3 when we announced the transaction. And we continue to gain more confidence in each of the 3. On the overheads, it goes beyond duplications. The approach of plug-and-play, as we call it, is going to allow us to rapidly leverage capabilities like revenue growth management, global shared services, areas in which we've been investing over the last few years. That will drive over 1/3 of the productivities. We're confirming that over the last 6 months.

Secondly, it's on costs. Mike talked about transportation just a few minutes ago. We're seeing those opportunities, particularly in a market like North America, which will be $18 billion out of the $32 billion in revenue, give or take. We tend to cube out a truck at about 50%. Kenvue tends to weigh out at about 50%. And we tend to deliver at almost the same drop-off points. So that's a key source of productivity. But it goes beyond that. If you look at procurement, we're going to be having a much bigger scale and many materials that are shared. And on top of that, we'll be able to drive efficiencies through standardization, leveraging the tools that we've been deploying, which, by the way, has been one of the sources of the productivity we were just talking about a few minutes ago.

And then lastly, sales and marketing, again, beyond duplications, we see opportunities on agency consolidations, things we've done at Kimberly-Clark 2 years ago. We see opportunities on driving efficiencies on nonworking media, on trade spend. Again, things we've been doing. In terms of the recent actions that Kenvue announced and their organizational structure, we're encouraged by that. We feel that that's a great move. And frankly, if that drives acceleration in earnings and efficiencies sooner than what we planned for, all the better.

Yes. And maybe just -- right, we're focused on for both companies, I mean, what Kirk is on his side and we're doing on our side. We're trying to expand the earnings capacity of both companies. And so the last restructuring, they did reorganization. I would tell you, we were excited because it moves their operating model closer to how we operate. And so we think we'll link up at some point as we close, and it will be a very smooth transition.

Good. What about on the growth side? Because in addition to those cost synergies, there are revenue opportunities, too, Mike. Just I guess, your increasing understanding and optimism around that potentially.

Yes. I'm a bull on the revenue synergies, but, Steve, I was told that investors don't care about revenue synergies until they make it into the algorithm. So I'll temper, but I'll just tell you why I'm excited, right, which is there's a lot of stuff near term that's very obvious. And what's obvious is like distribution opportunities, where one company has either channel or market strength and the other doesn't, right? And so I talked about e-commerce. So on e-commerce in North America, we're 700 basis points higher share than offline. They're the reverse. They're under-shared on e-commerce and below what the category development is for some of their categories. And so we've developed outstanding relationships with the big e-commerce retailers in this market here in the U.S., and we're confident our capability can help accelerate that. So that's kind of one near-term one.

If you get into like markets where Kenvue has scale and we do not, right here in Europe, they are over $3 billion in Europe. After our IFP transaction, we'll be about $100 million, right? And so -- and we used to have an over $1 billion Personal Care business in Europe. And certainly, that may be an opportunity for Carlton and the team to consider going forward. And they have great strengths across retailers in Europe, but also healthcare provider networks and other channels that we wish we had back when we were a stand-alone company or before this.

The other area where they have strength is India. And I think they have about distribution in about 3 million points of distribution in India. We're primarily an online player, and we struggled with physical distribution. And so we think Huggies will be a good opportunity for the Indian market. If you go to the flip side, where K-C has strength, Mexico, a $3 billion business for K-C to Mexico, where Kenvue is very relatively small in Mexico. We're well over $1 billion in Korea, where they have a small business. And so again, I think just through sheer distribution growth, that provides significant near-term opportunity.

And then longer term, I think the combination of our engineers and their scientists to put together some of these products. The examples I'll give you that are obvious are they're great at skin care. Our diaper products, whether it's the Depend or Huggies are in contact with skin 24/7. And so there's certainly some things that I think both teams can bring together to really improve the condition for consumers in that space. So we think there's great opportunity.

And then probably the biggest one goes back to this underdevelopment of categories. And again, it may be an artifact of kind of maybe the pharma approach to -- which is more product-centric, I think, and we tend to be more category growth centric. And so the example I'll give you is with 50 shares in Kleenex across most markets, it's our responsibility to grow the category. And we hadn't done a good job with that for a while. But over the last 5 years, we've put dedicated effort. And so household penetration has been growing, especially in our biggest market, the U.S., for the past 3 years because we put effort into that. It's also why in the U.S., if you're familiar, you'll see Deion Sanders on Depend and Katherine Heigl on Poise, it's because we're trying to help consumers understand that these categories -- these products can help serve needs that they weren't thinking about.

Yes. Great. And maybe lastly on this, just confidence in the path back to 2x net debt-to-EBITDA leverage post-close, Nelson. That's a big focus for investors.

Yes, sure. So firstly, Steve, we remain committed to having strong cash returns to our shareholders, as we manage through the 2 transactions, forming the JV with IFP middle of this year as well as closing the Kenvue transaction.

As we've shared, we -- as we go through it, our commitment is to remain or to keep a strong balance sheet as well as flexibility. And firstly, when we close the transaction, our expectation is to be at around 2.9x of leverage, 2.9x of EBITDA. And we expect this to reduce to around 2x EBITDA within 24 months through a combination of growing earnings as well as reducing our debt.

Importantly, I'd also like to highlight that we made the decision when we announced the transaction that we're going to deploy the cash proceeds from the JV formation to fund part of the cash consideration for the Kenvue acquisition. Beyond that, our capital allocation priorities remain unchanged. First, we have tremendous confidence in our science-based proprietary technologies, and we will continue to invest behind our business to drive profitable, sustainable growth over time.

Secondly, it's our dividend. We are committed to our dividend to growing it over time. This year marks the 54th consecutive year of growing our dividend, and we intend to continue doing that. We will preserve the Kimberly-Clark dividend policy as we merge the 2 companies.

And then lastly, we will deploy any excess cash to purchase -- to the share repurchases on an opportunistic basis.

Perfect. Perfect. In the couple of minutes we have left, Mike, maybe paint for us a picture of your end-state vision for the combined company and maybe -- highlight maybe the 1 or 2 things that investors should be focused on over the next year as we approach close.

Yes. Yes. I mean, I'll finish where we started, Steve, which is our focus is on building the preeminent health and wellness leader. And we're really excited about that opportunity. And first of all, there is a multi-decade demographic tailwind for health and wellness. The aging population isn't just a trend in developed markets, it's a trend in every market. And as the population ages, there's going to be more need for health products, right? And so we're excited about the built-in tailwind there.

And then, when you click on and understand that these categories still have a huge opportunity to be further developed, right, through communications and marketing and partnership with retailers, we're further excited about that. And we feel like we have the capability to kind of accelerate the Kenvue portfolio on that journey.

And then, the last thing I'd say is with respect to the synergies or efficiencies, we're very proud that we're able to deliver world-class productivity and a couple of years consecutively of 6%, which is probably the highest in the industry right now. And to be able to apply that to the Kenvue portfolio, we're very confident in the synergies. And so I think in the near term, we're focused on improving the base execution of our business. We're watching closely with Kenvue, not managing, but we're encouraged by the progress that I think Kirk and the Kenvue team are making on parts of their portfolio. And I think our integration team is working very well together to bring this to hopefully a very boring close.

And I'd just add to Mike's point, when we complete the integration and we're through with the process, we should expect to be in a position to consistently deliver leading organic growth in the industry with top-tier gross margin and EBIT margin, all resulting in double-digit returns to shareholders through a combination of earnings growth, a healthy dividend as well as share repurchases.

Perfect. Well, we welcome you back here next year to talk about how we're going to realize that vision. Thank you so much.

All right. Thank you.

Hello, and welcome to the Annual Meeting of Stockholders of Kimberly-Clark Corporation. Please note that today's meeting is being recorded. [Operator Instructions] It is now my pleasure to turn today's meeting over to Mike Hsu, Chairman and CEO of Kimberly-Clark. Mr. Hsu, the floor is yours.

Good morning, everyone, and welcome to Kimberly-Clark's Annual Meeting. This meeting is called to order. Before we get started with the business of the meeting, I will comment briefly on our recent performance and strategic transformation. Over the past 2 years, our Powering Care strategy has put us on a virtuous cycle of value creation. Through our team's excellent execution of our strategy, we have created a durable growth engine that is enabling Kimberly-Clark to win with consumers around the world. In 2025, we accelerated our momentum across the board, delivering strong results while navigating a dynamic external environment. We took several decisive actions to pivot our portfolio to higher growth, higher-margin personal care categories. We announced our pending acquisition of Kenvue, a powerful next step in our transformation to create a new kind of health and wellness leader and serve billions of consumers across every stage of life. This transaction is a generational opportunity to reimagine care and create lasting value for shareholders. We remain on track to close the acquisition in the second half of 2026.

To lay important groundwork for our acquisition of Kenvue, we announced a strategic joint venture with Suzano to create a preeminent international tissue and professional products company with substantially all the assets of our IFP business in which we'll own a 49% stake. This joint venture positions Kimberly-Clark and IFP to move forward with clarity and seize the tremendous opportunities ahead. We remain on track to close this transaction in mid-2026. Additionally, in 2025, we took a decisive step to optimize our supply chain network in North America with a $2 billion investment focused on building a new advanced manufacturing facility in Warren, Ohio, and an automated distribution center at our Beech Island, South Carolina plant. These investments will accelerate our innovation plans, support our growth ambitions and enable us to serve consumers even better.

Our 2025 results reflect the enhanced strength and resilience of our business. Our teams around the world continue to perform while transforming, and I want to thank them for their passion and dedication. The investments we made in innovation and marketing are differentiating our products across the good, better, best ladder and strengthening brand love with consumers. This has driven our strong shift to delivering broad-based volume plus mix-led growth even while volume growth has been somewhat challenging to achieve across the broader CPG landscape. At the same time, through Powering Care, we have transformed our organization and processes to maximize returns on those investments. We've wired Kimberly-Clark for speed and consistency with a lean and agile operating model. We have improved enterprise-wide visibility and discipline with a focus on delivering the best products at the lowest cost across all price value tiers and in every category market where we compete.

Critically, we've embedded a growth and accountability mindset across the organization. These fundamentals help us deliver financial performance that gives us the flexibility to reinvest and sustain the virtuous cycle. Our growth engine is innovation-led and amplified by emotionally resonant advertising and superior commercial activation. As we deliver volume and mix growth and industry-leading productivity, we use the savings to invest for impact and fuel the cycle. I want to thank our Board of Directors who are with us on today's call. They have played a key role in overseeing our transformation and are committed to serving our global consumers and driving balanced sustainable growth that enhances shareholder value.

We're building for the future and working to create a company unlike any other in our industry today through our acquisition of Kenvue. We've hit the ground running in 2026, and we are excited to seamlessly plug Kenvue's brands and businesses into our proven durable operating model. Together, we will unlock a new phase of growth and capitalize on the opportunity to provide extraordinary everyday care to billions of people around the world and deliver generational value for shareholders. I now invite Courtney Roane, our Vice President and Corporate Secretary, to inform us of housekeeping matters and open the polls.

Thank you, Mike. I will first go over a few housekeeping matters. Today's virtual-only meeting is a live webcast. Through the meeting portal, you will find our agenda and rules of conduct. The portal also has links to our annual report and our proxy materials for the meeting. A representative from our Inspector of Election is in attendance and has confirmed that a quorum is present. If you have not voted or wish to change your vote, you may do so during the meeting through the virtual meeting portal by clicking on the vote icon located in the upper right-hand corner. However, any stockholder who has already voted and does not want to change his or her vote need not take any further action. The polls are now open. We will accept votes until the polls close later in the meeting.

[Voting]

Feel free to ask a question at any time during the meeting by clicking the message icon in the upper right-hand corner of the screen. We will respond to questions and comments later in the meeting after we close the polls. We have 4 proposals for this meeting: first, the election of 13 directors; second, ratification of the selection of our independent auditors; third, approval of the compensation of our named executive officers; and fourth, a stockholder proposal to require an independent Board Chair. Each proposal is described in our 2026 proxy statement.

I would like to introduce our director nominees who are all in attendance on today's call: Sylvia Burwell; John Culver; Mike Hsu, who is our Board Chair; Mae Jemison, Deeptha Khanna, Todd Maclin, Deirdre Mahlan, Sherilyn McCoy, Christa Quarles, Jaime Ramirez, Joe Romanelli, Dunia Shive, Mark Smucker. Also joining this meeting are representatives of Deloitte & Touche, our independent auditors. Melissa Cloniger, who is the partner in charge of our 2026 audit, is in attendance today. The proponent of Proposal 4 is Mr. Matt Prescott, acting on behalf of the Accountability Board, which owns greater than $25,000 of the company's common stock. Operator, could you please play Mr. Prescott's prerecorded statement in support of this proposal?

Hi, everybody. I can keep our remarks brief today for the sake of everybody's time and just say that we think the proposal speaks for itself and would refer anybody with questions about it to the proxy statement. Only want to add that Institutional Shareholder Services and Glass Lewis are both recommending a vote in favor of the proposal. And obviously, we also encourage shareholders to vote for it. Thank you very much.

Mike, I will now ask for a motion that the 4 proposals listed on the agenda be introduced for a vote by the stockholders.

Moved.

I second the motion. For the reasons stated in the proxy statement, the Board of Directors unanimously recommends that you vote against Proposal 4. We'll now have a brief pause to allow any stockholders desiring to submit or change their vote now to do so.

[Voting]

I now declare that the polls are closed. The inspectors have advised me based on preliminary results that all 13 nominees have been elected to the Board. Our stockholders have approved the proposal to ratify our independent auditors and approve our executive compensation. The stockholders did not approve the proposal to require an Independent Board Chair. We will announce the final voting results in a current report on Form 8-K to be filed with the SEC within 4 business days of today's meeting. We will now consider questions you may have about Kimberly-Clark. It is possible that our responses will include forward-looking statements or certain financial measures that have not been calculated in accordance with generally accepted accounting principles. Please see the meeting rules of conduct for more information on these matters.

Great. Mike, we have one question already from Phil Brown, a long-time shareholder, he notes he's enjoyed our dividend over holding our stock. However, is concerned that the payout ratio, his math has now reached a higher level. Could you please comment on that?

Yes. Mr. Brown, thank you so much for the question, and thank you for being a long-time Kimberly-Clark shareholder. Hey, we're really proud of our 54-year history of increasing the dividend, but also recognize that we do that with, I would say, discipline and rigor, right? And so I think your question is appropriate. In 2025, as we looked at the payout ratio, I think your number -- your math is correct. However, there were some restructuring charges that were noncash that affected kind of the stated earnings. And so we feel great from a cash flow perspective that the dividend is an appropriate ratio for what the company can afford. And so we're going to continue to work hard to continue to increase I would say, the growth and the profitability of the company over time, and we'll continue to strive to drive for an increased dividend to satisfy long-term shareholders like you.

Mike, we have not received any additional questions via the virtual meeting portal. And with that, I will ask you to please adjourn the meeting.

Okay. We thank you all for your continued support of Kimberly-Clark. This meeting is now adjourned.

The meeting has now concluded. You may now disconnect.

Good afternoon, everyone, and thank you for joining us. I'm pleased to welcome you to a fireside chat with Kimberly-Clark today. The company is in the midst of a strategic evolution, a significant one, reorienting the portfolio by reducing its international consumer tissue exposure through a joint venture with Suzano while expanding into consumer health with the proposed acquisition of Kenvue, which will create a broader platform across personal care and consumer health. To discuss the strategy, the rationale behind these moves and how management is thinking about execution and value creation from here, I'm joined by Mike Hsu, the company's Chairman and Chief Executive Officer; Nelson Urdaneta, the company's Chief Financial Officer; and Chris Jakubik, Head of Investor Relations. So thank you all for being here. Thanks so much for making the trip to London.

Great to be here, Lauren.

Thank you.

So we'll get started. So first thought was that given many investors here today have a somewhat outdated perspective of the company, I wanted to start off at a high level. So over 2 years -- just about over 2 years ago, you announced the Powering Care strategy. Mike, could you start by giving an overview of that strategy and perhaps where it suggests the greatest change from how the company was operating previously.

Okay. Yes. Thank you, Lauren. Yes, I think the core idea of Powering Care is the concept of getting the company on a virtuous cycle of growth. And most companies talk about that, Lauren, and that's something I think most companies aspire to. The thing about it within CPG, as you well know, there's a lot of factors conspiring to kind of knock companies off of staying on that virtuous cycle. So it's notoriously hard to do, right? But the core elements of what we're trying to do is really make products better that the consumers want to drive volume, drive great marketing to get consumers interested in our products, great execution in stores, and that will drive the volume.

At the same time, we're working to get much more efficient on cost and then reinvest that savings back into product quality or marketing or advertising or anything else. And so hopefully, if you get that cycle right, it starts that virtuous cycle of growth. I think -- so that was kind of the goal. I think the key elements of the strategy, I mean, there's really 3 big components. One, we call accelerate pioneering innovation, right? But the real thing about that is at the time, and you've seen us for a long time. I think at the time I joined K-C, there was a question about whether superior performance was possible in these categories, right?

A lot of people externally and even some within the company said, aren't these categories commodities? And how are you really going to differentiate a diaper or bath tissue or whatever product you want to think about. And I would say, so for us, step one is that, hey, superior performance is possible, and it's not only possible, but it's necessary. And I think over time, and I think you've seen what's driving our volume is that we've really found a way to make our products superior and desirable, right? And so that's part one.

Part 2 is what -- another thing that's really changed is our cost structure. And I think we've been driving industry-leading productivity gains over the last few years. I think the big change in K-C over the last maybe 10 years or so is it turns out there is one best way, right? And I think we were kind of a decentralized confederation of companies that operate in local markets. Products were different in markets. Our manufacturing process could be different. Our assets or our manufacturing assets could be different. And I think what we've learned over time is that now consumers are more similar. It doesn't mean all products are identical between the U.S. and China or Brazil, but they're more similar than they are different. And so it does turn out there tends to be one best way to make stuff efficiently.

And so -- and that's kind of what's behind the margin improvement that you're seeing with us. And then the last thing is a change in our operating model. Again, I think a calling card of K-C and what makes us special is we're very attuned to local market competitions. We run our business through the markets. And so that's something we'll always want. But I think what we've done is overlaid that local agility with a little more considered global scale to help the markets go faster. And so I think those are the big changes that are driving the performance that you're seeing.

Okay. Great. So with that as context, let's talk about top line trends over the past 2 years for North America and then the International Personal Care business. Organic sales have performed well. And more notably, volume mix has been positive, which is not what we can say for most of U.S. staples. Just to specify for people here who don't know, the company had 1% volume mix growth in 2024. That accelerated to 2.5% in '25, and they grew 3% in the first quarter of '26. So how is it that you've been able to drive this in categories that I think many think of as sleepy and really just linked to population growth at best?

Yes. I think the main thing I'll say, Lauren, and we'll see if you think this is interesting, but superior product performance equals superior value. A lot of time when you say value, people think you're going to pull price down, right? And price matters. But actually, we believe since you -- people experience our products and if you're wearing a diaper, whether you're a baby or a senior adult or a Kotex pad, you're wearing it 24/7, right? So it's on you.

So people really notice differences in performance. And so I'd say we've made a conscious effort to differentiate our products. We think they are superior than anything that's in the category. And it's been that way for a few years now. And I think that's what's driving the volume. The how did we get there? If you reround 12 years when people thought these were commodities, I think what we ended up doing was going through a process of like, "hey, we're going to get pickier about how consumers use these products." And they're not just looking for absorption, right? Things about like comfort, fit, breathability, skin health, all these things matter. And so we're going to spend a lot of time trying to understand how needs will evolve. I will tell you, Lauren, our big exposure and big business in China really helped us because I think that's where we saw both in Korea and China, the Asian markets, the sophistication of the consumer over the last 20 years has really accelerated.

There's a lot of manufacturers, a lot of brands. In diapers alone, there's 200 brands in China. So the competition is very aggressive, and that competition forces companies to get better and forces companies to innovate. And so I think what we did was really kind of develop multiple angles of product differentiation, whether that's on comfort, fit, absorption. And I will tell you, we have a big pipeline. We are very proud of big ideas that we have in the pipeline that's coming. We have this -- a lot of the growth that you're seeing is on what we call a Gen 3 diaper core. We have Gen 4 and 5 in the works that's going to be better than Gen 3. And so we're really excited about that.

The other thing that's happened this year, and maybe it started happening in '24 was our emphasis on the value tiers. It turns out consumers in a market like North America are really under stress. And while our premium business continues to grow, and we're driving the premium business very hard with innovation, 90% of the population has incomes at $100,000 or below, right? And so as category leaders, we don't really want to ignore, right, the bulk of the population. And so we decided to innovate as aggressively in our value tiers.

And in fact, in the U.S. on Snug & Dry, I think you understand that we brought our best innovation and most advanced technology and launched it in our value tier first before we've launched it into our premium tiers. And that's what's behind a lot of the volume momentum that we're seeing right now.

It's really interesting you brought that up because one of the things that I have very casually said when asked by investors, like why do I think there's no volume growth? Or what's the big challenge in the industry overall. And I always come back to 80% of U.S. consumers are under a lot of pressure and the staples companies have to sell to all 100% of U.S. consumers, right, not just the top 20. And so we care about it -- our industry cares about everyone.

And we decided we're not going to be a niche premium company, right? We're going to serve everyone or try to.

Yes, that's great. Okay. I wanted to touch quickly on the impact you've seen from the conflict in the Middle East. Back at earnings just last week, you noted the potential incremental inflation should oil remain elevated, but you stopped sort of including that in the formal guidance. Can you just walk through that decision, why not to bake it in. And just kind of what mitigation might look like as you think through the rest of the year?

Yes. Let me just make a quick comment and then Nelson will -- I would say it's an unfortunate circumstance that the company and our management has become very accustomed to dealing with these situations, right? And so this is I think the third military conflict -- the first one in Ukraine and Russia was the first one kind of on our watch for a multinational deal with in quite a long time. And so then you had Israel and now this one. And so I think operating in a volatile environment is something that we're becoming accustomed to. Our underlying principle, which I think Nelson will want to talk more about is, right, PNOC or price net of commodity cost discipline, right? And so generally, we expect our PNOC to be neutral to positive, right? And so adhering to those principles is pretty core to how we think about our business.

Yes. And Lauren, just to provide a little more color on the situation. So 2 things. One, from a capability standpoint, as we went through the whole COVID situation, all these learnings have been built into our toolkit. And as you remember, we overcame $3.4 billion of costs between 2021 and 2022. And we emerged out of that fairly successfully. We recovered our margins and actually started expanding our margins beyond pre-pandemic levels at the end of 2023, and we've been on that trajectory.

Now as it relates to the outlook in particular, for the second quarter, we did include and we advised that we expected about $50 million of gross input cost inflation, largely related to the volatility we're seeing in the oil markets. As a reminder, we have about 80% of our input costs already covered either through contractual structures or programmatic hedging programs.

As it relates to oil-linked commodities or costs, about 25% of our basket is exposed on one extent or the other. And if you add distribution, it's a little bit higher than that. So the $50 million that we included for the second quarter, we expect to be able to fully mitigate it as the year progresses. That also includes a slight impact from the California distribution center fire that we experienced a few weeks back. Now what we don't know is going to happen in the second half of the year because prices have remained fairly volatile in terms of oil as well as some of the surcharges and force majeure that's being declared by some of our suppliers.

So we did some estimates around a scenario of what if oil were to stay at around $100 a barrel. And that's what yields a scenario of around $150 million to $170 million of gross input costs that we would face in the second half of the year. That's not built into the outlook, neither any mitigating actions that we would take to tackle them. As Mike pointed out, our teams know that we expect them to manage to at least neutral pricing net of cost over time. And they need to leverage all the toolkits within the integrated margin management approach that we've developed over the last few years. That includes revenue growth management, productivity where we've delivered 6% gross productivity in '24 and '25 in Q1, and we're projecting that for the full year as well as the always-on overhead savings that we've been delivering over the last few years.

Our plan is we should have much more clarity in terms of what that will be, gross impacts as we close the second quarter. So when we give the update on performance for the second quarter in August, we'll be able to provide a more clear view of what that will look like from a growth standpoint, how much of that can we mitigate and what, if any, net impact we foresee to the bottom line in the balance of the year.

Okay. Great. Before we get into talking about Kenvue, I wanted to just talk about the joint venture with Suzano a little bit. So for those in the audience who might not be aware, when Kimberly announced Powering Care, there was a third segment as well called International Family and Professional. In June of 2025, they announced a deal to sell 51% of that to Suzano forming this joint venture we're going to talk about. So could you just talk a bit about the strategic rationale for that transaction, why -- and also why Suzano is the right partner?

Yes. They're a great partner. I think that this transaction is really about building a better tissue business. And I think we realized, Lauren, that wholly controlled by ourselves, I think we had structural challenges to enable us to do that. And what were the structural challenges. Our International Family and Professional business or the tissue business, maybe the biggest component is here in Western Europe, right? And so Andrex here in the U.K. and then we're in most markets on the European continent.

But given the share positions in Europe, I would say the margins in Western Europe are structurally lower, right? And because of that, our earnings were highly volatile. And why were they highly volatile? The only thing that fluctuated was pulp costs, right? And so it made it difficult within our control, we had to cope with the volatility of the input costs while the margins were kind of at a fixed amount. And so really, the magic of this transaction is in partnership with Suzano, which is our second partnership, we did a similar transaction with our Brazilian tissue business, and we sold that 100% of them a few years back. But their cost structure on fiber is inherently stable, right?

So the only thing that fluctuates is the price, right? And so what you're marrying and creating a business that has stable prices, stable costs and they can operate more effectively in this environment. On top of that, I would say both companies have operating strengths. Ours is papermaking or tissue production. Theirs tends to be more industrial, pulp production, agriculture. Ours is also commercial execution, right, selling, marketing, all those things that they don't do as well. And so the reason why it's a joint venture is we both bring strengths to the party that we both value, right? And so we think there's a great structure, and this is going to build a business that's going to be a very good tissue business.

Okay. In Brazil, though, you sold it 100%. So just did they have a different capability set in that market with regard to the commercial aspects or the paper making that made Europe a different decision.

Not because of that. I would say they're doing a great job with it. And so I forecast this will go very well here as well. I think maybe the reason why it wasn't a full exit is I think we will evolve over time. That's part one. But part 2 is there's more behind what we're doing on either side, right? They have more capability they're developing. We're having more capability we're developing on the tissue business, and we both want to be able to participate in sharing that. So there is a reason why it's kind of a measure. But I think over time, could they increase their ownership stake? It's possible.

Okay. And just to add, I mean, 3 things where we see also benefits from how we structured the transaction, Lauren. So the first one, with a 49% stake once the transaction closes, we expect our shareholders to participate in the value creation that we foresee in the following years. Secondly, there's an important cash amount that will be received by Kimberly-Clark at the moment of the close, which we will deploy for the Kenvue acquisition as part of the cash consideration, which again will allow us to maintain a strong balance sheet post the close of Kenvue. And then lastly, adding on what Mike said, there is a fixed mechanism for us to be able to exit at a time when Suzano offers to purchase our remaining stake.

Okay. Great. Perfect lead into Kenvue. So that was June. So then in November, you announced plans to acquire Kenvue.

It was a busy year.

Busy year. Yes. Thanks, guys. So while I'm sure most of them are well aware of the deal, maybe you could just talk a little bit about the strategic attractiveness of this business combination or just plainly like why are Kimberly and Kenvue better together?

Yes. Okay. I know for some outsiders that may not be the most intuitive, we're excited. And we're excited about, in our minds, creating the preeminent health and wellness leader globally, right? And that's kind of what we're doing. And so -- and what do we mean by that? One, there's a couple of things. And you know covering our categories. I think we've done a great job growing our categories.

I would say our categories this year are growing about 50% -- 2.5%. And that's kind of the historical range of kind of where we are. I would say the Kenvue categories grow at a higher rate to start with, and they have built-in multi-decade tailwinds. And so that was both in health and wellness, driven by the logic of a globally aging population, right? And so -- and as the population ages, demand for the Kenvue portfolio, along with ours, like our adult care businesses will continue to grow. So there's some strong built-in tailwinds.

But really, what we're trying to do is similar to what we talked about with diapers, serve 100% of the population, what we really want to do and believe we can do is raise the standard of care for all. So our goal is to provide extraordinary care for all. What does that mean? I would say our view is a lot of these health and wellness categories, particularly within self-care, we view are lower penetration and relatively underdeveloped, even though they're great solutions and have been around for a long time. And so we believe working together and understanding kind of markets and need spaces more structurally that we can help expand the categories over time in a more disciplined manner.

I think, obviously, there's tremendous geographic complementarity between our portfolios. If you're not as familiar, they're very big in Europe. They're about a $3 billion business in Europe. After our IFP or our Suzano transaction, we'll be about $100 billion in Europe. And so there's an opportunity for us to grow our business here. Similarly, they're very big in India, which is a market that we've struggled in with our Huggies brand. And so we think there's great opportunities there.

If you flip it around the other way, we're about a $3 billion business in Mexico, and they're just a few hundred million there. And so I think we see from a geographic perspective, Lauren, an opportunity to kind of grow both businesses through distribution, right? So that's kind of one set of areas. The other is, if you think about the consumers that we're serving, we're covering basically the same life stages through different ends of the category. So we're in baby. Obviously, they started their business or their company within baby care. And so -- and we're obviously in baby, but then you keep going serving women, whether that's through feminine care products or skin care or beauty or whatnot.

All family, we do it primarily through tissue, but they have a lot of products like Listerine and Band-Aid that cover all family. And then finally, the active aging, which we primarily do through Poise and Depend. And so we think there's a lot of complementarity in terms of serving life stages. And maybe the opportunity for us, Lauren, is we've been working in a lot of markets, primarily in Asia and the U.S., but increasingly across our other focus markets to develop an advantaged consumer engagement model powered by digital. And we've made a lot of progress, I would say, over the last 10 years. And I think that's an opportunity that we feel like we can really expand with the Kenvue portfolio as well.

Okay. Great. So one pushback that we've heard pretty often is that Kenvue's categories are fundamentally different from yours. Things mentioned are like channel mix, seasonality, competitive concentration barriers to entry. I'll skip the geographic exposure. You just commented on that and just even expertise. So how would you respond to that, the fundamental differences between the businesses.

All right. Here's my argument, Lauren. I want to tell you that when you asked about Powering Care, I'll say the tenets of Powering Care apply to Kenvue's categories, too, right? And if you just click through what are those? I would say how we've been able to manufacture growth in what you would characterize are slower growth categories, I would say it's a deep understanding of need states and really being, I would say, very specific about what sophisticated consumers are looking for.

And even when -- and consumers -- it's very hard for consumers to say, this is what I want for the future, right? And so you have to kind of -- you have to piece it together, right, through insights and research and understanding. And then -- but I think we've been able to do that, right? And I'll just -- like one example, right? This whole thing around our current product on Kotex that's selling great globally has this liner that pulls the menses or the liquid away from the surface of the pad and then channels it into other parts of the pad, right, to spread it out and disperse it, right? That's -- no consumer can ever tell you that's what they want, right?

But what they said was we want to feel dry, right? And that's kind of how we deliver it. And so I think the core idea is we've got to understand what the need states are and what they're trying to solve. And then what we do well is we declared like this is what we're going to win on. And we declared that like 10 years ago. And then we kind of plowed all of our financial R&D researches into solving those problems, right? And so I'd say need state and then aligning the tech pipeline to support those need states.

Second, this consumer relationship model. I think interestingly, I told you we've been investing a lot in digital. Our e-commerce shares, and I think you probably know this fact, our e-commerce shares are 700 basis points higher in North America than our off-line shares, right? And so we think we have an advantaged model. We have an advantaged model in China, in Korea. Increasingly, I think we're feeling great about Indonesia and Brazil and what we're doing online there. And so we do think there is a different engagement model that's going to be much more efficient than the traditional marketing model that also applies to the Kenvue brands.

The third area I talked about margin management. And I think it's early, but we're excited about the integration planning. I think even though they're high margin, and I think their average is close to 60%, right, our average is approaching 40%. So they're much higher margin, but we also think there's much more opportunity to improve the margins on the Kenvue side through cost discipline. And our calling card given that our margin structure is lower is cost discipline, execution discipline, and I think a lot of that applies to Kenvue.

So I think while the categories look and feel different, I think as you may be familiar with, in the world of CPG, I think the basic principles apply. I mean, honestly, the 3 of us that are sitting in the front of the room, you know we all came from Kraft, and we didn't even know how to spell diaper if you spotted us to D 12 years ago, right?

I'm sure your...

Sorry, I didn't mean it to sound that way.

Okay. A few weeks back, you announced a leadership team for the combined entity. Not surprisingly, many come from K-C, but there's a few that come from Kenvue. So can you just give an overview of the new organization structure for the combined company, the leadership team and through that decision calculus when bringing over talent from Kenvue.

Yes. Okay. Interesting, world-class team. I'm excited. We had a -- so anyways, the process -- I'll just give you a little on the process. So obviously, I met with all the leaders on both sides. And we put everybody through this rigorous process with a third-party assessment, right? And so -- and that way team evaluated them and then I had my own individual discussions with every leader.

So a rigorous assessment and -- but we wanted to set the principle of we're just going to take the best of both. Like we don't really care which side they're from. It's -- we're just going to pick the best, right? And that's part one. I will say number one, I would -- exceptional market and operating expertise. And if you look at our business leaders, a couple of them, John, who runs North America for us; Katie, who runs focus markets and you met her. I mean everything is growing. I think you saw in the quarter, I think, John, 95% of his sales were growing share. Katie, 84% of hers.

And by the way, for Katie, all of her markets when I gave her those markets were declining when she got them. So I think -- so 18 months later, they're all growing and growing share. So I think we've got exceptional leaders on the K-C side. John is going to lead North America. Katie will have 5 markets primarily in Asia, which includes China and Indonesia and things like that.

I think on the Kenvue side, Carlton, who runs their EMEA business, Leo, who runs Latin America. I think if you look at those 2 businesses, this is what happened when we started doing our internal business reviews just to get to know the categories. I said, "Wow, I don't think we have any markets that performed as well as you guys did," and we're pretty proud of our performance. But I think what got lost, Lauren, is there's some pretty outstanding performance that they've had on their side that kind of got swamped by a few big problems out there. And we know those markets, and they're very difficult to operate within. And I think they've done a really nice job.

So I'd say with those leaders, Carlton, Leo, Andy in Asia Pacific, Andy is going to lead enterprise markets, which is part of Asia and Latin America, together with Leo, I'd say they've got exceptional market expertise. I think they've done a great job with the Kenvue brands. Andy is newer, but has engineered quite a turn in performance in some of the businesses in Asia. So we're excited about, I would say, the market operational capability of the team. And then functionally, again, we picked the best of both. But I'd say primarily with a focus on the capabilities that we think we need to grow the business now.

And I would say on R&D, and you've met Craig, Craig has experience in some of the Kenvue categories. He spent a long career starting at Procter and Unilever before going to Campbell's and then coming to us. So I think he's a real R&D pro. I think Tamara, she's helping us deliver multiyear industry-leading productivity, and she's going to be great at that. And then interestingly, on the growth side, we tapped Carlos from Kenvue and Jon Halvorson from the Kenvue side. Why? I think we were really excited with Carlos' experience, having been an operator and coming from Procter, right, in this past, but detailed operator for a long time and having a disciplined operating mindset to think about category growth. We really love that idea.

And then together with Carlos and Jon and Mike Wondrasch, who is going to be our digital leader, I'm going all in on digital, right? This whole thing around the consumer engagement model, that thing is going to be a competitive advantage for us, and we're investing a lot to build it.

It's interesting, too, because, obviously, Kenvue and Hyzight didn't stand still, right? When Kirk came in, they made some really fantastic hires that you're now bringing over.

Yes.

Okay. Looking at time. Okay. So cost synergies that you've discussed are on the high end as far as CPG deals go. So $1.9 billion or 13% of Kenvue's 2025 sales. You've given us good detail on the breakdown. So just for anyone here, it's 30% in sales and marketing, 30% in COGS and 40% in G&A and time line largely realized by year 3. But we still get pushback that the number is just too high, just it's too high. So how would you respond to that?

Yes. So a few things, Lauren. So we've continued over the last months since November 3 of the announcement to build our clarity and confidence on the path to delivering and/or exceeding the synergies. I mean, Russ last week at our earnings update was providing some updates around all the hundreds of work streams that are underway, getting ready for that day 1. .

When you look at the benchmark in deals, yes, in traditional consumer staples deals, the average is more around the 8% level. But when you look at consumer health, that average is actually 13%. So our 12% which is kind of the number, is very reasonable when you look at it from that end. The other element that's important to note is that the 3 sources that you've quoted as it relates to how we drive and attain those synergies are things that we have been executing over the last 4 years at Kimberly-Clark. That's what's allowed us to drive in the last 2.5 years, increasing better performance on the top line, driven by volume/mix gains consecutively quarter-by-quarter, expanding margins, increasing our investments behind innovation and brands, driving better cash flow. And at the end of the day, all of this happening simultaneously.

If you look at the 3 buckets on overheads, it's not just the duplicate structures that we will tackle. It's the fact that by us leveraging our plug-and-play approach that we've been talking about, we'll be able to accelerate things like revenue growth management or global business services. If you look at cost of goods sold, it's the same thing. We've chatted about the benefits we'll derive on the transportation side because there are synergies, they weigh out, we cube out on procurement. There's a lot we've done over the last 3 years in terms of driving digital capabilities in procurement that's driving the productivity.

And then in sales and marketing execution, we've done a lot in that space. Think of all the agency consolidations that we've done, look at how we've optimized then our working media spend. Look at how we've optimized trade spend. That's what's been allowing us to grow over the last few quarters, and that's what's going to bring all these synergies to life as we go into the deal closing. We're very excited about what they've announced earlier this year in terms of their organizational structure changes because that's basically just setting it up for a way that for day 1, we'll be much ready to execute.

Okay. Talk about revenue synergies. Actually, no, I'm skipping revenues. We might run out of time. I'm going to come back to -- I'm going to skip it because -- we may come back if we have time. I wanted to talk about the scale and then the long tail within Kenvue's portfolio. So they've shared finally that they have 115 brands and 74% or less than 25% of sales -- sorry, 74 brands. So -- and a significant portion of SKUs are just 1% of sales. So we haven't seen any divestitures yet from them. I thought that, that would have happened by now prior to Kimberly's involvement. So just sort of what's your approach going to be. Do you think -- should we think about divestitures? Because there's a lot to be cleaned up there, it would always seem to me.

Yes, I'll say -- and I think Nelson will have some comments, too. But I would say, hey, the portfolio can always get better, right? I think portfolios are never fixed. I would say a couple of things. One, we're seeing it. I think one of the reasons they're pausing it is with the deal and everything happening, there's a lot going on. And so I think we're waiting to kind of make sure that we can close properly and get all the work done.

But the thing that I also say is it is not as complex as it appears. Because what happens is because of regulatory requirements on a country basis and some brand choices they made, they -- again, they probably -- at some point in time, they operated very decentralized, right? And so there's a lot of brands and formulations for the same category, right? And so if you add it up by category, let's say, pain care, there's dozens of brands and different formulations, but it's all serving the same kind of need, right?

And so on the surface, it looks very complex, but from an operating perspective, a little less. Part 2 is while there is a tail, and Nelson and I have some experience from our Kraft days, we also ran a portfolio that was incredibly complex at Kraft, but has also delivered all the profit of the -- or most of the profit of the company. And so I would tell you that the tail is profitable in general, right? And so it's not as easy as striking the tail.

And then the third thing that I will say is a lot of the tails in international, and I think I had just mentioned, international, particularly in Latin American and EMEA is where the performance has been good. And so I think they've developed a way or a path to manage that complexity effectively. It doesn't mean that it's going to stay fixed this way because I think over time, there will be some things that would say, hey, not a great fit long term for what we want to do. There may be some things that we may want to come into the portfolio at some point, depending on how we think about need states and everything else. And so I would say there's always going to be an opportunity to get better. But Nelson is going to say we're going to stay disciplined on capital allocation.

Yes. And I'll -- just to add to Mike's point, we've demonstrated, Lauren, over the last 3, 4 years, our discipline around portfolio management, where we identify that there is no clear path for a right to win, be it for a brand, be it for a country, be it for a category, we will make determinations on the portfolio. Back in 2023, we sold our Brazilian tissue and professional business. Back in 2024, we sold our personal protective equipment business. We exited private label largely. And we -- right now, we will be probably less than 1% of our revenue exposed to private label.

And we are executing the transaction in the International Family and Professional Care business middle of this year. We'll be disciplined. We always want to make sure that we are creating and protecting shareholder value. It's an always on. And of course, it will apply to the new portfolio once we've closed the transaction with Kenvue, but in a disciplined manner.

Okay. Great. I need to talk about Tylenol and also Talc, particularly since we're here. So big concern from investors still that we definitely get questions about. From the S-4, we know that your bid for Kenvue came down pretty substantially throughout the process, given all of this, the elevated risk. So just maybe you could share with the audience how you grew comfortable with the potential liability that's, again, potentially unknown size?

Yes. One, I'll start with the science supporting the safety and efficacy of acetaminophen continues to grow. And there's a report that came out at the beginning of this year that kind of further support of the safety. And in fact, it's -- I think even today, by almost every governmental health agency, including the U.S. FDA, still recommends Tylenol is the only safe pain and fever reliever for pregnant women, right?

And so we stand behind with Kenvue on the science, and we're confident in that. In addition, and as we went through our due diligence process and recognize that we have directors like Sheri McCoy, who ran this business for a long time, and Joe Romanelli, who was at Merck. The Board -- Sylvia Burwell, who was the Head of the Health and Human Services department for the U.S. So the Board requested that we really get thorough. And so we did bring in some of the best advisers. Kenvue has hired excellent counsel who's been defending the case very well, and they're from Kirkland & Ellis. We brought in Gibson Dunn, Ted Boutrous, who I think is generally regarded a top litigator within the U.S.

We brought in King & Spalding, who's been arguing and defending successfully some of the Zantac cases. And so I think we brought in a really accomplished advisory team. And so we went through with an econometric firm to estimate what the liabilities are and everything else. And I would say, number one, we feel very good about the science and the defenses of Tylenol itself. And then I think I've said this publicly a few times, and we've gone through different scenarios of litigation. And I would say all scenarios end up being significant or I would say, generational value creation even if you assume some number for the litigation side. So we feel very good about both the science and then the economics of the deal.

Okay. So to round this out, I want to maybe take a step back. So you're -- the company is in the midst of a transformation that is finally taking hold optically stand-alone, Kimberly, I think, from a fundamental standpoint. Clearly, really excited about the opportunities in front of you. But M&A of this scale often proves more disruptive than initially expected. So I guess, why acquire Kenvue and introduce more complexity to now to a story that was really beginning to take off? And what do you think Kimberly looks like in 5 years?

Yes. So that's exactly the -- I will say, Lauren, because I think you're channeling some -- a subset of investors, Chris, that are a little frustrated with me because they saw the play happening, Powering Care working, it's going to move in the right direction, right, finally, all that kind of stuff.

But I guess my retort is, okay, we definitely believe, we believe our organic play is going great, and Powering Care is going to continue to go great. We're very confident. I think the thing is, though, we're building a company for the next 50 years, not for the next 5. And so if you look at the portfolio combined, I think there's going to be built-in tailwinds that are going to be tremendous for multi-decades. And I think not in 50 years, but in like, I would say, in 5 years, you're going to say, "Well, I can't believe you didn't think about this earlier." And so -- and we're going to do it the right way, right, by generating a virtuous cycle.

And we're really excited about the potential. We're really excited about the Kenvue team, the organization. Our cultures end up being surprisingly similar, Lauren, in the fact that care is kind of at the core, like what motivates K-C'ers and what motivates Kenvue'ers is taking care of their consumers and help them live healthier lives. And so I think we'll be able to do that together better.

Okay. Great. We have to wrap there. But thank you so much. I learned new things today despite how much I already know about your company. So thank you for coming you.

Thank you.

Thank you.

Good morning, everyone. This is Chris Jakubik, Head of Investor Relations at Kimberly-Clark, and thank you for joining us.

I'd like to remind everyone that during our comments today, we will make some forward-looking statements that are based on how we see things today. Actual results may differ due to risks and uncertainties and these are discussed in our earnings release and our filings with the SEC.

We will also discuss some non-GAAP financial measures during these remarks. These non-GAAP financial measures should not be considered a replacement for and should be read together with GAAP results. And you can find the GAAP to non-GAAP reconciliations within our earnings release and the supplemental materials posted at investor.Kimberly-clark.com.

With that, I will turn it over to Mike for a few opening comments.

Okay. Thank you, Chris, and thanks to everyone for joining us this morning. Our first quarter results underscore the strong progress we're making towards creating a company unlike any other in our industry today. Our Powering Care growth engine is enabling Kimberly-Clark to continue building industry-leading base business momentum. We are delivering differentiated science-backed innovation in all rungs of the Good, Better, Best ladder.

In the first quarter, innovation helped fuel our delivery of solid organic sales growth with volume plus mix growth increasing to 3%. This builds on 2 consecutive years of broad-based volume plus mix growth. We're building market share across our key focus areas of Baby Care, Women's Health and active aging and with a second quarter launch late that's 1 of our most active ever across the categories and markets where we compete.

Our supply chain team continues advancing our commitment to deliver the best product at the lowest cost. We generated another quarter of industry-leading productivity, enabling us to continue investing for impact.

Our fast lean operating model is making us more agile, navigating external turbulence. It's also helping us continue to bring the best of Kimberly-Clark to the world with speed and efficiency. We're still in the early innings of our potential, and we're well positioned and continue accelerating our virtuous cycle of value creation. We look forward to seamlessly plugging Kenvue?brands and businesses into our proven durable operating model.

We're ready to raise the standard of care for billions of people around the world and deliver generational value for shareholders. I'm very proud of our teams for their passion and dedication as we work to make our bold ambition a reality.

And with that, I'd like to open the line for questions, operator.

[Operator Instructions]Our first question is coming from Dara Mohsenian of Morgan Stanley.

First, maybe just a clarification on the full year guidance, obviously, we're seeing commodity pressure today, oil stays with now above $100 a barrel, that's not officially in guidance nor is the mitigating actions. But Nelson I was just hoping you can walk us through the range of potential actions you would take to help offset any pressure on full year earnings if oil stays up here, maybe rank order how you think about pricing versus productivity versus flex on ad spend?

And just conceptually, do you think it's realistic, you can offset most of that if oil stays up here, understanding it's very volatile. And then Mike, if we can drill down a bit I did want to delve more into the pricing side in North America. We've obviously seen a pretty promotional industry environment the last couple of quarters. At the same time, you're generating very healthy volume growth on your portfolio within that environment and now we have this unexpected cost ramp up externally. So just a lot of moving pieces, and I was hoping you could help us understand strategically how you plan to manage pricing in North America given all those factors.

Okay. Thanks for the question, Dara's a lot to unpack that. Let me kind of give you kind of the overall framework of how we think about it, and then I'll ask maybe Nelson can give you some of the details about how we'll process it and also -- and maybe ask [ Russ ] to click in on some of your questions about pricing. But I'd say, overall, that I feel like we're making great progress creating a new kind of health and wellness leader. And we're really encouraged by the strong base business momentum we're seeing. 3% volume mix in the quarter builds on I think sorry, ninth or tenth quarter of solid volume mix growth. And so we feel great about that.

And the important thing, I think, as you kind of embedded in your question is that, that volume mix growth is being driven by innovation, right? And we're not renting that through promotion. The promotion is supporting the innovation. And so that's kind of the big deal for us. On top of that, we feel like our supply chain is in full swing and generating industry-leading productivity, which we feel great about. And that enables us to reinvest back in the quality and the marketing of our brands.

So I think we're feeling good about our underlying base business momentum. I'd say the environment promises to remain turbulent, but we're going to remain agile and disciplined. We've been through a number of these things over the last -- well, in my tenure in this role, right, if you go through COVID and a few other wars, unfortunately, and other commodity or input cost situations. So we've had a lot of experience navigating a lot of different disruptions, including this quarter.

And I'd say, overall, our process is to remain very disciplined. And 1 concept that we've felt very important is PNOC or pricing not a commodity input cost discipline. And we expect that to be at least neutral over time, and we're going to leverage all the tools that we have to make sure that we continue to do that. And so I think the key thing for us is we have a lot of levers to pull in terms of how we're managing our cost profile, which Nelson is going to talk more about right now. But I also say having that discipline on pricing net of cost is an important concept for us.

Yes. Picking up where Mike left Dara, a few things. As we look at the overall input cost inflation for the year and what we have factored into the outlook, and I think it's important to bring up the last 2 years. So for 2024, 2025, we faced right around $200 million of input cost inflation. As we got into this year in January, that was really flattish all in. So we were staring at about a flat input cost inflation outlook. And with the latest data and information that we've got, let me unpack what's in the outlook and what we've yet to build into the outlook, including the mitigation actions, as you stated.

So for the second quarter, a couple of things. As we stated in the prepared remarks, we're going to be facing around a $20 million top line impact from the California DC fire, which for North America would be in the 70 to 80 basis points of headwind in the quarter. Then in the bottom line, we expect to have in the second quarter around $50 million, stemming from the inflationary impacts that we're seeing as a result of the Middle East war. And some of the impacts related to the LA DC fire, which as you stated, we expect to recover that in the second half of the year.

If we look into the back half of the year, and we assume that oil prices remain at around $100 per barrel on average, we will be facing potentially gross incremental input costs of around $150 million to $170 million. We've not built this into the outlook because there's a lot of moving pieces as we speak, but we have also not built in any potential mitigations, which our teams are currently working through as we roll through the different scenarios.

It's important to highlight that we, as Mike said, have instituted this philosophy of pricing net of costs, over time, neutral. And this is really embedded in our integrated margin management process, which ensures that over time, we expand margins, and keep on track with our plan stated our Powering Care plan rollout back in March of 2024. As such, we have several levers in there.

First one, revenue growth management. Second one, a very strong pipeline of productivity initiatives. We've delivered 2 years of 6% gross productivity back to back. And this first quarter of the year, we're already at 6%, and our plans are to deliver for the full year 6%. The pipeline is very rich. We're making significant investments in the North America supply chain with the $2 billion announced a few quarters back, and that's progressing as planned.

And then lastly is the whole strategic relationships with our suppliers in terms of pricing contracts as well as hedging programmatic elements that we've put in place. I'd also remind everyone that we've got a solid track record over the last 4 years of recovering any input cost inflation and actually expanding margins. If you look at 2023 through 2025, we expanded both gross margins and operating profit margins beyond the levels prepandemic. So we're confident in our ability to cover all these input costs over time. And again, we will be back with more news in our next earnings call.

Sorry, I'm keeping track for you. So sorry, if our answers are a little full, but I'm going to ask Russ to comment on the promotional environment.

Yes, sure. Thanks. Dara. So I would say, just underscoring what Mike said that growing volume and mix profitably while maintaining PNOC discipline really is the key focus for us. And innovation is really the key to that. And specifically within North America, if I were to just double-click on that, you were asking about the promo environment. I would say that our overall pricing was in line in the first quarter, as you saw. And in fact, our overall weighted average promo intensity in North America is down versus pre-Covid versus category levels.

And that's because we're focused on driving innovation. You will see innovation tick up when -- sorry, promotion tick up when we have an innovation agenda that's really strong because we're trying to drive trial, and that's exactly what you're seeing in diapers right now. We are using more promotion to drive trial. And we talked about that in the fourth quarter. We promoted Snug & Dry. We have a great innovation there that drives softness in our new absorbent core and we're pleased with the results there. We've seen household penetration and velocities up on that post promotion.

And we've also shifted some investments across channels with surgical programming to ensure -- our loyal huggies buyers can find us after the recent distribution change, as we talked about in the last call in the club channel. But I'd expect that to normalize as we go through '26. And the bottom line is in North America diapers, our '25 promo was below category for the year, and it's below 2019 levels. So just to give you some context.

Our next question is coming from Peter Grom of UBS.

Great. Thank you, operator, and good morning, everyone. So you updated your outlook for category growth to 2.5% versus 2% previously. Can you maybe just unpack that a bit more what regions or categories are you seeing a stronger performance, and then I think in the prepared remarks, you noted stronger category growth in North America, call it, I think it was 3.3% though, do you think that's a realistic run rate moving forward? Or do you think we could see a bit of a step back just given more uncertain operating backdrop.

Okay. Peter, I'll start, and I'll ask Russ to weigh in here. I would say we're very encouraged by the resilience of our categories and the impact of our commercial programming. I'd say, notably, North America categories rebounded strongly in Q1. That was driven by some shifts in timing of competitive promotion activity, particularly and I think in the paper categories, but also -- you may recall in Q4, I think the categories had slowed down to just under 1 point. And that was really related to, I think, some things that happened in the year ago, port strikes and all this other stuff that happened. And so we're cycling that. But as we got into the end of the year, we're still a little unclear whether the slowdown was going to be endemic to the category or it's a one-off? And it turns out -- it looks like having cleared the quarter with a strong kind of increase in the category and in our organic, I think we feel like that was a one-off. And so I think our outlook for the year on a rolling 12 months, it's like 2.5% across our categories globally is what we have, and that's kind of the way we're looking at it. And so we feel good about the progress.

Yes. And I'd just add, I think Mike, you said it well. I'd just add, we aren't really seeing any large-scale shifts in consumer buying behavior. And we are still seeing consumers under pressure, but that's not a new dynamic. And so we're -- I think our trailing 12-month weighted average category growth is around 2.5%, and we don't see a reason for that that to evolve too much. And there are some puts and takes, as Mike mentioned, with respect to specific dynamics, but hopefully, that helps.

Our next question is coming from Javier Escalante of Evercore.

Thank you, operator. My question is on the merged entity. Mike, you laid out a new organizational structure. If you can help us understand it better. So how will it help restore growth Kenvue?while preserving the competitiveness of the core stand-alone Kimberly-Clark. What are the biggest changes that you made? And if you can explain how you see those working. And also finally, on the combination, if you can give us updates on the completion of the joint venture with [indiscernible], you may have some of it in the prepared remarks, as you can expand on that? And also, what is the status of the approval for the merger.

Okay. All right. There's a lot to unpack there. I'll try. You can remind me, [ Ravi ] if I'm missing something -- let me start with -- after working on this since November, I would tell you for me and our team, and I think the team on both sides, the Kenvue?view side and the KC side, I would say, for all of us, even more conviction in the growth potential of the company that we're about to create.

Kenvue?is going to report their first quarter results in early May, and that's consistent with their typical timing. So I'm not going to -- I'm not going to have your prejump that. But I will say, we've been working through kind of in our preparation for integration planning, some category reviews, Nelson, Russ and I with the Kenvue?teams. And I would say our view is that the recent challenges, although widely reported have been largely executional, and we don't see them as being structural.

And in fact, there are pockets or more than pockets of strong profitable growth throughout the company. I would say a lot of that's been overshadowed by a few notable large challenges. I would say, primarily North America skincare, North America Oral Care has been a challenge and some of their business in China. So I think those are notable. But I would say, if you look at kind of how we've structured the management team, I think the management team and the combination of both KC and Kenvue?players reflects, I would say, the strong performance that I observed in the businesses on both sides.

The other thing I'll say is Kirk and that management team at Kenvue? have taken some strong positive steps. And we're confident that Kenvue?will improve this year. And 1 of the moves they did make was adopt their operating model, and they announced that change back in February. And I would say it's very consistent with our kind of market-centric balanced matrix approach to operating. So I think we're very encouraged with kind of the progress on their side and also in the integration planning.

And then as you kind of raised, I'm very pleased with that we've been able to assemble what I would view as a world-class team to create the preeminent health and wellness leader. And I think roughly, the bench from both sides is about 50-50. So the leadership team composition reflects strong talent that reflect -- that exist within both organizations.

I think there's a great blend of market experiences, functional capability and technical expertise. And we felt like it was important to retain kind of the knowledge and leadership of what's working and also retain the strong institutional knowledge that exists in both companies. And like I said, I think if you look at the composition of the leadership team, it also reflects the strong performance in some of the Kenvue international markets.

And so I'm pretty bullish on kind of what this team is going to do together. I will tell you, the operating model is going to be very market-centric but also leverage global scale. The culture, I think, will be ownership, speed and competitiveness. And I think that dovetails well, as I mentioned earlier, with what Kenvue has been doing. So maybe I'll -- I know I said a lot there. And Javier, I think Russ has got some comments as well.

Yes, I was just going to pick up on what Mike was talking about around execution. I think that really has been something we've been building and strengthening at KC for many years as those who followed us know both in terms of how to drive growth, but how to drive productivity and SG&A efficiency. And by the way, doing all those at the same time. So we've been basically taking that approach and applying it to the synergy process. We now have over 40 integration teams that are working on planning the combined company post close to build the future of the company to drive the synergies and ensure we can operate effectively together. And that process, I would say, is going very well. I've been very impressed with the actions that Kenvue?has been taking recently, Mike talked about in their base business and what they're bringing to the table for how we're looking at the future together. And we are seeing very good line of sight to synergies in all areas, COGS, I'll just give 1 quick example, their product is pretty small and dense. And so therefore, they tend to weigh out their trucks and ours is bulky and light, and we tend to cube out trucks. And so we're shipping to the same places, let's put them on the same truck. And there's actually quite a lot of value there.

And SG&A, lots of examples we could highlight beyond just duplication we're really looking at it as an opportunity to leverage the combined scale to work differently, and that's simplification of the systems environment, SAP in, application rationalization consolidating processes, accelerating global business services using AI, lots of things there. And on the revenue side, we're really excited. I think there's tons of opportunities in distribution and leveraging commercial capabilities like e-com, all of which require getting the execution fundamentals in place, and that's really what we're emphasizing. And we're not waiting for the close. We are working on those things, as Mike mentioned, I know Kenvue?is working on them in their base business hard, and so is KC. So we feel like we're pretty well positioned to hit the ground running.

Go ahead, Mike, just like a high-level thought. Do you think that part of these execution issues on the Kenvue?side had to do with the fact that the demerger from J&J at a time of a great deal of retail changes both in the U.S. and China? Do you think that, that's what led to underperformance.

I don't think I can -- I know enough to comment on that, Javier, right? But all I'll say is running these kinds of businesses is hard. There's a lot of things that add up to being, what feels like small decisions end up having big impacts. And so that's why as I met with some large investors, and that's the question I asked, which is why does quality of management matter so much? It's because these are arcane businesses that have a lot of operating and running rules and they can be very difficult and things that feel small, like small inconsequential decisions end up having at times a big impact. And Nelson, and Chris and I saw plenty of those are craft back when we were at that company back in those days. And so -- so I wasn't there for that, and so I won't comment however here, but I would just say doing this is hard and making sure that you're kind of lined up correctly across all fronts of operating a business is really, really important.

Our next question is coming from Lauren Lieberman of Barclays. .

I was hoping you could just talk a little bit about the shipment timing that you mentioned in the prepared remarks on North America because it's category growth has accelerated. I don't recall if you guys use Nielsen or Sarcoma, but the Nielsen trends, including Costco, your business grew 5% and you reported in sub-Q. So just if you could discuss kind of in what categories, in particular, you're seeing those headwinds. Is it an inventory kind of correction? Or is it something that is timing related and kind of picks up in 2Q?

Yes. Sure, Lauren. So a few things. As you say, scanner data consumption data very strong. And as we've seen in many years, many quarters, there's always going to be some noise within the quarter between shipments and consumption. The key is really consumption. And looking into North America consumer specifically, as you point out, consumption was ahead of shipments by around 200 basis points, and trying to piece through the entire noise, I'd say, trade stocks inventory is not really the big thing there. It's more having to do with the fact that we had very strong activation programming in the first quarter, which started in January. So we had some shipments that came through in December, and that kind of anticipated what we went through. And that had to do a little bit with what you're seeing there and the difference.

I think it's also important to highlight that as we think of the second quarter, we do expect organic sales growth to be slightly below Q1. And 2 things to keep in mind on that end. The first 1 we're going to have the strongest comp versus 2025, in which for total enterprise last year, we grew about 4%, and in North America, volume was actually 5%. And again, that goes back to the quarter-on-quarter can be a little noisy. And in last year's situation had to do with the fact that we had a series of product launches, particularly in baby and child care, which drove strong shipments in the second quarter.

And then the other bid for the second quarter is we're going to be having a little bit of a headwind from the distribution center fire in California, as Russ had mentioned in his prepared remarks, that will be around $20 million or 70 to 80 basis points for the North America segment. But as we go into the second half, we expect that organic growth to actually accelerate because some of these noise elements we don't project.

Okay. Is my line still open?

Yes, yes.

Oh, cool. Okay. Awesome. So for her asking myself a question. Okay. So the operating profit headwind that you talked about for 2Q, which largely reflects the incremental inflation and also some of the pressure from the DC fire. So you've included that, let's call it, roughly $50 million for 2Q, you've held the guidance for the year. So what are the mitigating impact for the inflation you'll feel in Q2 specifically? And then if you're handling it that way for 2Q, why not, let's just call it, like complete the plan for the full year to talk about whether or not how you're going to be offsetting because the 6% productivity rate, while super impressive, you're already at that level. So I don't feel like -- it doesn't strike me as an easy task to up that rate of productivity to deal with this incremental $150 million to $170 million of potential pressure in the back half.

Laura, maybe I'll just say 1 thing. Nelson is ready to pounce. But the 1 thing I will say is that the underlying assumption we're making is that we know what the cost impact is going to be. And we don't really feel like we know that yet. It's early. It's -- we know what it is today. We don't know what it's going to be tomorrow or through the balance of the year. And so that's kind of why we're kind of keeping the cards a little close to the best.

But building on that, Lauren, I mean, 2 things. As you say, the $50 million for the second quarter, we feel pretty confident we can maneuver through that. So that's not something that, again, we're bringing up as a major, major situation because it's not. As a reminder, we're about 80% covered in the entire cost basket between contractual arrangements, programmatic hedging and other items we're doing. .

We've got the full set of toolkits within our integrated margin management approach. And it starts with the philosophy of pricing net of costs. And if you think about that toolkit, it includes revenue growth management. It includes the productivity. And yes, 6%. We're already at that level, but we've had quarters that have been ahead of 6%. We have a very strong pipeline of initiatives and our team is not sitting still as we're going through this. The reason why we didn't get into what would the specific mitigating actions be for the second half is that the teams are actually working through them today.

We are having sit-downs with all of our suppliers, where force majeure or surcharges are being enacted. We're sitting down and renegotiating and opening up contracts as need be. We're looking at price pack architecture. And we're looking at all other elements of the toolkit. As I said, in the last 2 years, we faced about $200 million of incremental costs. And if you add up what we sort of estimate right now, and it's a point in time, plus the 50, you're right around that level. So again, as Mike said, we want to take the time to do this right. We want to see where things kind of settle because it's moving by the day. And we'll do what's right. We'll continue to invest behind the innovation and to do revenue growth management, it takes a little bit of time, but it's something that we know how to do. We've done it in the past, and it's going to be part of the toolkit.

Our next question is coming from [ Anna Lizzul ] of Bank of America.

I was wondering if I could build on Lauren's question, Nelson, if you could comment, I guess, on the pacing of the top and bottom line as we move through the year, with both the impact from the distribution center fire in Q2? And then as you were mentioning, the other impacts down the line of oil and raising input costs. On the margin side, if you could talk about maybe the impact between Q3 and Q4, that would be really helpful.

Sure. A lot to unpack there, Anna. But let me kind of give you a little -- start with the top line. So as we mentioned, strong start to the year at the 2.5% organic growth as we go into the second half, we do -- the second quarter -- pardon me, -- we expect to be slightly below that for the reasons I explained in the prior question, largely with lapping the strongest quarter of last year at around 4% organic growth. North America volume 5% and obviously, the $20 million headwind that we'll face because of the distribution fire in California. But heading into the second half, we've got an acceleration in top line, and that's what's embedded in our outlook for the full year at this stage.

As we look at the bottom line, a few things to unpack. First, we expect overall margins to actually pick up as the year progresses. We had in the first quarter, an expansion of gross margin sequentially versus Q4, and gross margin versus the prior year was slightly down 60 basis points, but that was largely expected because we are at the last full quarter of an impact from our exit of the private label contract in North America.

Heading into the second quarter, third quarter, fourth quarter, we're largely going to lap that, plus -- and we expect gross margins to actually be expanding on a continuous basis for the balance of the year based on the outlook of what we have today.

On operating profit margin, we expanded operating profit margins again this quarter by about 20 basis points, partly driven by the 90 basis point improvement year-on-year, from overheads, overhead of 13%, 90 basis points lower than the prior year. And we're getting good traction on delivering the full $200 million or exceeding it in savings as part of our Powering Care program. And we expect for the balance of the year to continue to see expansion in operating profit margins.

For the full year, we expect gross margin, operating profit margin to expand both in the vicinity of 70 to 80 basis points. So that's largely a construct of what we see between the following quarters and the first quarter for both top line and margins.

And our next question is coming from Robert Moskow of TD Cowen.

I just wanted to test the overall theme of the call here that the business is truly resilient to all of these unexpected cost headwinds because when I look back to 2025, you had the tariffs was the big unexpected factor. And even though tariffs were mitigated for the full year, you still had to lower your profit guide for 2025. So when I'm looking at the 2026 number, the $150 million, $170 million is actually higher than what the tariff headwind ended up being. So I'm just trying to figure out how nervous to be about the ability to offset that much cost.

Yes. I mean I think, Rob, I'll give you a little bit of historical background, and maybe I'll ask Nelson to comment. I would say, again, -- if you look at our recent history, back in 2022 and 2023, the business took on, I think, $1.6 billion of additional costs and $1.7 billion consecutive years. And so I'd say what we're looking at here is a fraction of that, right? And so I think what happens -- those were like all-time high I would say, inflation super cycle for us. And while the costs haven't receded, we've been able to manage through that cycle with discipline on this pricing that net of cost impact, right, or commodity impact. And so -- so I'd say at the level we're talking about, we feel like the business should be able to operate and manage through things, we'll let you know. And certainly, I think 1 of the reasons why we're hedging a little bit here is because we don't know what the costs are going to be. We know what they're going to be as of today or what the outlook is as of today, but it's still kind of a moving target. But I think our thing is I think since the 2022, 2023 period, I think we've developed much stronger cost management capability, which is why we're delivering industry-leading productivity. We've been really enhanced our RGM or revenue growth management, discipline. And so we feel good about our capability.

And then the other thing I will tell you is we feel very bullish about the base business, right? Our organic growth being driven by a rebounding category, but also, hopefully, you saw in that presentation, the fact that we were up in 95% of sales weighted markets on share in North America and 84% in international. I think we feel great about that. And just to give you a comparison on the old metric that we use, which is just a pure count of cohorts, we're up in about 80% -- a little over 80% of cohorts, right? And so I think we feel good about the momentum of the business.

Our next question is coming from Edward Lewis from Rothschild & Co Redburn.

Just a couple of questions from me. Just be interested to hear how -- if we think about the good, better, best, how you're performing on those is good doing better than better or is better doing better than best? Just interesting to hear some commentary around that. And then I look at the international business, you called out good share gains in some of the markets. Just wanted to sort of get a sense check for how you're feeling about those markets given what's going on in the straight and the concerns people have about the impact and particularly in sort of the Southeast Asia region from the slowdown in shipping or in, I guess, in tankers coming out of the strait. Any update, any commentary there would be appreciated.

I'll ask Russ to comment on the good, better, best. But I will say, unfortunate situation that we're operating in yet another region with another conflict. And so number one, Ed, I'll tell you thankfully, all of our people and employees have been safe and operating through this. And so -- and they been really kind of working overtime to make sure that we continue to kind of operate the business while keeping everybody safe.

I will say business and performance has continued to be robust, especially in international markets. I think in multiple markets, strong double-digit growth. Interestingly, especially in Southeast Asia, our [indiscernible] business was strong double-digit growth, share up significantly. Russ, you may want to comment -- but the thing I'll also hit is in developed Asian markets like Korea, we're seeing a baby boom. So I think births were up 6.5% last year in 2025. And so the category was up 20% in Korea, where we have over a 60% share. So that's pretty meaningful for us, Ed.

And so I think we're feeling very good internationally. And Russ you may want to comment a little further and then the good better best.

Yes, I agree. We've seen a lot of strength, especially in Southeast Asia, as Mike talked about, also India, Australia, kind of across the board. So we haven't yet seen a significant impact on the strait impacts yet. It's not to say that it wouldn't happen, but we're feeling pretty good right now. In terms of the Good, Better, Best question, I would say the premium side of the business remains healthy and it's continuing to grow, and it's the key to category growth. The consumers with higher incomes have remained resilient.

And then on the good and the better, we're not seeing any specific patterns. I think what it comes down to is the strength of the value proposition to the tiers. And that really is what's winning. I think consumers are getting more choiceful for their money. I would note that, for example, in personal care, the penetration of private label continues to fall overall. And what's winning is the branded value propositions that are offering compelling value for money and those aren't necessarily in the lower price tiers. They're more of the mid-priced tiers. They're just providing a great proposition in consumers, especially in our categories are willing to pay. So that's our focus is to have the winning value propositions in all the tiers and let the consumer choose what's most appropriate for them. So we haven't seen very significant shifts into the good tier if that's kind of where you were going. It really depends on the specifics.

Yes. I think Ed, interestingly, I think what's driven our growth over multiple years is the premiumization or kind of improving the product quality at the premium tiers and driving positive mix. And that's been consistent for the past, I would say, 7 years for us. I think what's changed is that it's not a pivot. It's just that we're applying the same approach to the value tiers. And so interestingly, we did in North America was bringing some of our best product technology from China and implemented it first in the value tier. And it will eventually go to all our products here in the U.S. But again, I think the fact that I think, as Russ says, we're bringing our best product at every run of the good, better, best ladder is kind of the real core strategy for us.

Great. If we could take 1 more question?

Our next question is coming from Chris Carey of Wells Fargo Securities.

So I just kind of tend to wrap up a couple of key concepts explored on the call. Just number one, just -- I've gotten a decent amount of questions on the commodity outlook and mitigation as could be expected. But I thought I would just ask it this way, right? Like at the Investor Day, you had talked about changing your ability to confront different commodity cycles. Can you just give us a sense of how you feel differently right now, whether that's the time lag when commodities hit your P&L, that's the mix changes from portfolio adjustments. How are we different today versus, let's say, the last commodity cycle?

And then secondly, just on the conversation around PNOC. I think embedded in some of your comments is the prospects of potentially looking at pricing? Or I think, Nelson, you said that RGM takes time. So maybe RGM is a potential lever here do you think that incremental pricing or incremental RGM could disrupt some of the volume improvement that you've been seeing, which is partly helped by some of the demand building activity that you're doing? Or do you think that you can continue to deliver volume if you were to kind of lean in a bit more on price or RGM, if you want to control PNOC if inflation stays higher, so appreciate those 2.

Okay. Chris, let me start. Nelson is going to want to weigh in here on the commodity kind of management, but let me just start with the -- I would tell you, in my tenure, everything has changed about commodity management since we've been here. And I think I think in the past, I think we used to let things flow quite a bit. I think -- and I think I may have mentioned this, Chris, as we kind of looked at what was like holding the stock back, it was kind of the earnings volatility, and when you look at what's driving earnings volatility, it was input cost volatility, right? And so we -- with Nelson coming in, we made a very conscious effort to kind of reduce the volatility of input costs by using all available techniques to do that. And you can see that in terms of how we buy and how we contract, but also in some of the partnerships that we've developed over time. And so we feel very good about the progress we've made. And hopefully, I think the facts are that the beta on the input cost volatility has reduced significantly in the last 5 or 10 years. And so -- but Nelson, you may want to comment on.

Yes. And just building on that, Mike. And Mike mentioned it before, -- when I joined, we were going -- we were getting into the second year of the heightened inflation related to COVID. That's the second year in which we faced $1.7 billion of costs. And as I've said in some of the calls and in some of our investor meetings, we learned from that. We developed a lot of muscle around risk management over the last few years. We've instituted not just programmatic hedging but also strategic relationships with suppliers that allow us to have more visibility into costs and allow us to have flex to manage through the whole process. Before four years back, we would probably been talking about a different number today. But given what we've instituted on that end, this allows us to be able to manage any shocks much better.

The other bid, and it's not the commodity itself, but it's how proactive are we on the rest of the toolkit. And that's why we refer to the pricing at a cost philosophy and the integrated margin management approach which is a philosophy that we've been embedding in the organization. It's very different. We're managing end-to-end. We're measuring the team's end-to-end, and that leads to different outcomes. And that's why our level of confidence in being able to manage through these cycles is much better at this stage, Chris.

Yes. And then I'll mind you, we're not in previous cost shocks, but I think we're in much better position than we were, let's say, 5 or 10 years ago. .

Great Okay. All right. Well, thanks, everybody, for joining us. For analysts that have further questions, Investor Relations will be around all day. So thanks very much, and have a great day.

Thank you very much. This does conclude today's conference call. You may disconnect your phone lines at this time, and have a wonderful day. We thank you for your participation.

Hi, everyone. Our next presenter is Kimberly-Clark, which is currently in the midst of one of the largest transactions and biggest corporate transformations in CPG history. The team is led by Chairman and CEO, Michael Hsu. Since taking the helm in 2019, Mike could do reach within the company, building a veteran leadership team with extensive experience in key areas and reshaping the portfolio to become a leader, a global leader in branded personal care. Under its power and strategy, Kimberly-Clark has been one of the few in the industry to inflect positive volume-driven organic growth while [indiscernible] profit margins from strong productivity.

Today we look forward to hearing how the company will continue the momentum it's built and how we can bring that to [ continue ] when the transaction is expected to close in the second half of 2026. Following the presentation, members of the management will be available for Q&A. Please ensure to make your way outside during lunch to their signature island. And a big thank you to Kimberly-Clark for sponsoring today's lunch.

So just a reminder, the breakout will be at lunch. With that, it's my pleasure to hand it over to the company. Please welcome, Mike Hsu, Chairman and CEO of Kimberly-Clark, who will be joined today by Russ Torres, President and COO; Craig Slavtcheff, Chief R&D Officer; Patricia Corsi, Chief Growth Officer; and Nelson Urdaneta, Chief Financial Officer. Thanks, Mike.

[Presentation]

Okay. That was a little bit about us. For K-Cers, it's a powerful reminder of our mission. This is why we do what we do. We provide the best, most innovative to deliver better care to our consumers every day. This is what makes a K-C-ers tick and precisely what makes Kimberly-Clark a very special company. For more than 150 years, Kimberly-Clark has been there for people at their most important moments. People place their trust in us. From the beginning of life to the very end, consumers invites us into their lives, and we're proud to be with them every step along the way. With innovative products that solve their most intimate challenges.

Babies with Huggies and Pull-Ups, young women experiencing their first period with Kotex, adults with incontinence living fully with Poise in the pen. Every day essential like Kleenex and Cottonelle are iconic brands deliver for our consumers when they need us most. So by caring for people throughout the journey of life, Kimberly-Clark is there for moments of connection. We form deep connections with consumers that establish brand preference for years and decades. We reinforce that brand love with powerful consumer-inspired innovation in storytelling that resonates emotionally. Moments of connection are how we drive brand love and lifetime bonds that translate to superior lifetime value.

Now our presentation today is about the operating model we've built, the momentum we've established and how it positions us to capture the generational value creation opportunity we have as we prepare to integrate Kenvue. Our products are everyday essentials that serve 1 in 4 people every day in categories for the most part, we invented. We have $6 billion global brands and leading positions in over 80% of our key markets. We're pivoting the portfolio towards personal care categories with attractive long-term growth potential and where we're executing at a high level.

Powering Care has established industry-leading momentum. We're performing well transforming in a difficult environment by accelerating pioneering innovation, optimizing our margin structure and wiring our organization for growth. Our momentum is reflected in our financial performance. We've delivered 2 consecutive years of broad-based volume plus mix growth and accelerated our rate of growth in 2025. We're delivering that level of growth in categories growing on average about 2%. And we're excited about the opportunity to accelerate growth in Kenvue categories, many of which are currently growing faster than [indiscernible].

We're on a sustainable path towards the margin milestones we established 2 years ago. Industry-leading productivity gains are funding investments to improve our brand proposition, drive brand love and enhance our commercial capability. We've also made significant investment in our capabilities and our infrastructure. Those investments set us up for where we are today, ready to capture a generational opportunity with the acquisition of Kenvue.

Powering Care is our proven and sustainable value creation engine. This approach is designed to generate a virtuous cycle of growth. The components of Powering Care are mutually reinforcing and designed to drive durable, sustainable and profitable growth, even when the environment delivers the unexpected. Powering Care is enabling us to make the best most innovative products for the lowest cost, build brand love and drive robust volume plus mix growth. Today, we're going to double-click on out innovate and out market and will illustrate how we pull all together to create lasting impact for our consumers.

Science is our competitive advantage. Our innovation approach uniquely pairs our scientific expertise and our obsession with solving the consumers' most important problems. This approach has accelerated our pace and impact of innovation. We focus on the most important consumer needs in our categories, leak-free confidence, garment-like comfort, healthy skin and sleep full night. This focus provides us to deliver these benefits with compelling offerings and value at every run of the good, better, best ladder. Our innovation is to deliver category shaping performance. We've led the premiumization of our categories by redefining the boundaries of what performance means.

As we look ahead, we're excited about our innovation pipeline and have convictions that our next 10 years will be even stronger than our last 10 years. We build brand love by visualizing our groundbreaking benefit in the context of life's most intimate moments. We're leveraging content at scale that builds brand love to extend our category leadership. We've experienced notable successes across the Pen, Poise and Kleenex not to mention Huggies in North America. We've built a unique and advantaged digital commerce engine in China, a market that is comprised of some of the world's most discerning consumers and a leading edge demand ecosystem. This is the platform for our digital commerce engine that fuels KC globally. We've also been thinking outside the box and built differentiated in-house creative capability that is generating award-winning creative. We're breaking stigmas and building a deeper brand connection.

At retail, we're fostering better, frictionless shopper journeys online and offline and backing it with flawless end-to-end execution. We strengthened strategic customer partnerships through joint business planning over an extended financial [ driver ]. And this approach has been recognized by all our top customers. We're supporting them to help shape the future of digital commerce. Powering Care is a repeatable [indiscernible] by our acquisition of Kenvue. Like us, Kenvue's iconic brands form lifelong bonds with consumers. Together, our powerful stable will raise the standard of care for millions of people around the world. And I should note, like many of you, I was at Johnson's Baby. The earliest memory I have of my mother is of her washing my hair with Johnson's Baby shampoo. Joining forces with Kenvue presents a generational opportunity to create the preeminent personal wellness company that provides extraordinary everyday care.

Together, we'll have leadership positions in many of the industry's largest, most attractive category. These categories have favorable growth and penetration trends across Baby Care, Women's Health and [indiscernible]. We'll be uniquely positioned across these core growths to grow as they grow. We'll earn the trust of more people by helping them raise their children, care for themselves and care for their loved ones. And doing this will create durable value for our shareholders. We're ready to accelerate into our next chapter. And for today, we'll highlight those capabilities and how they set us up to hit the ground running with Kenvue.

We have a generational opportunity for us. We've established strong repeatable growth momentum that's grounded in a fast and agile operating model. It's driving a successful transformation, building differentiating capability and core financial strength. The repeatable, durable model of Kenvue will seamlessly plug into.

So next, Craig, Patricia and Russ will illustrate how we out-innovate, out-market, out-activate and deliver the best product at the lowest cost to our consumers and customers.

Thanks, Mike. Hello, everyone. I'm Craig Slavtcheff, and I lead Research and Development at Kimberly-Clark. At our core, we are a company of inventors and discovering science that serves consumers, as Mike said, is our competitive advantage. It's what energizes our 1,300 scientists and engineers around the globe, solving for the biggest consumer challenges. And we built a system that turns that into profitable growth consistently. Today, I'm going to walk you through the transformation that has put us on new path, one that out-innovates, out-markets and out-activates competition and delivers real measurable results.

So how do we do it? Well, it starts with our innovation ecosystem. We have transformed against 3 simple pillars: First, consumer intimacy that leads to insights that then frame the need [indiscernible] to solve against. Second, connecting our efforts on short, medium and long-term innovation through our matrix wiring. Then doing so allows us to aggressively scale innovations in the short term, accelerate the launch of large technology platforms in the medium term and drive our future disruptive thinking in the form of [indiscernible]. And lastly, we have embraced agile design methodology across the organization in support of pipeline [ acquisition ], allowing us to put our best minds on the biggest technical problems we see shifting our project delivery from years.

So as I said, [indiscernible] consumer insight. Now these consumer need states with the demand signals that direct all of our future innovation, marketing and activation. Now some of these are intuitive and a bit obvious at this high level, leaks-free, fresh and oder-free, et cetera. But double-clicking on each reveals the richness of category-specific insights that are the genesis of our pipelines. And broader insights allow us to innovate in nonobvious [ medicine ] areas, and therefore, premiumize the category to grow value. Globally relevant, drawn from jobs to be done, shaped by emotional and functional drivers and weighted by how dissatisfied consumers are with what's currently available in the market. Those need states don't just shape our product road map, they direct us to where we push the science. Now Kimberly-Clark has a long history of pushing the boundaries of science. That hasn't changed, but how we direct it has. Our scientific discovery is laser-focused on areas, all driven by foresight and deep consumer understanding.

Like our global need states, there are some usual suspects here on this page. For example, next-generation absorbent systems and materials, designed to bend the performance curve of our personal care products. Mothers push the boundary of the premium benefits we see to deliver to our consumers. Most notably, advancing of the human microbiome and its impact on human health and skin physiology because really, every one of our products is used on skin that is vulnerable to [ insult ] and our goal is to bring the latest science to maintain health and comfort. But breakthrough science only matters if we can get it to every market and price point where our consumers [indiscernible]. That's where our wiring comes in.

Our wiring gives us on powerful, visibility and access to the best technology and consumer insights across the globe, leveraging the latest AI tools and our matrix structure to do so. That's how we drive portfolio harmonization. Now here's what that looks like in practice. In baby and child care, across 65 countries that make up our enterprise market segment, we went from 300 individual and independent projects to 11 scalable benefit platforms, all within 12 months. Then we deploy best performance, best cost technology into each market to make sure we are delighting consumers everywhere we compete. And at the end of the 2025 after 12 months, we have moved 70% of our geographies to winning product designs with plans to close the remaining 30.

Now wiring also allows us to drive connectivity between short-, mid- and long-term technology efforts into one integrated system with commercial governance across all 3. Near term, we're scaling aggressively. Our 3-year pipeline has benefited from over $500 million in incremental net sales from scaling launches alone. Midterm, we're investing in a simple list of 10 core technology platforms that will shift performance curves across our categories in the next 3 to 5 years. And we're getting new platforms to market in as little as 18 months. Long term, 5 simple but stretching moon shots over the next 5 to 10 years, instructing not only category bending science that will direct the future of our categories, but new claims space to continue driving premiumization.

So what does it all add up to? Let me show you. Kimberly-Clark's growth in 2025 was overwhelmingly boosted by innovation. This isn't a 1-year story. Our innovation portfolio has over-indexed on contribution to organic growth for over 3 years running, and it continues to be margin accretive. The numbers tell the story. Over 75% of volume plus mix-led growth came from innovation and the innovations we launched [ posted ] average margins that were 280 bps accretive.

Looking ahead, the pipeline is extremely healthy. Our F'26 to F'28 pipeline is 160% the size of our pipeline in 2020. And the average margin of our full pipeline is 670 basis points accretive to our current base business. This system is working and we're building on it. So scaling innovation into multiple markets increases the ROI on our innovation investment. And to be candid, historically, our global scaling efforts were slow. Our generation 3 absorptive core, no wiring, 20 years, only 3 launch countries. Since then, we have flipped that entirely.

In Baby Care, our Cloud Waistband premium feature wraps a baby's waist in a plush, cushiony cloud that moves when they move. It was launched as a premium feature and top tiers diapers initially. Fast forward with global wiring, 3 years, 57 launch countries. That's what the system delivers. Now speed is one thing, but we also need to make sure innovation reaches every consumer at every price point. And a key part of out-innovate is continuously scaling premium innovation features down through the value tiers, driving towards best product, lowest cost. We take premium features and value engineer them to scale across the good, better, best ladder. Cloud Waistband is a great example.

As I said, we started with the most premium design at the top tier. Been engineered a second generation of that feature at 75% lower cost, 75% lower capital and runs on more assets, expanding our launch reach dramatically. Most notably launching in Tiers 3 through 7 across the globe. That's how we scale what we have.

Let me share a fem care example. Kotex Gravity is a breakthrough Feminine Care innovation that delivers a step change in performance. Consumer testing confirms superior cleanliness, dryness and comfort driven by a proprietary absorptive core technology that rapidly pulls fluid away from delicate [ volvo ] skin. Compared with the conventional core, Gravity delivers 120% faster absorption, 60% less surface residue, 30% improved dryness and at the same time, can absorb 20 times its weight and fluid.

Now scaling across 27 markets with strong IP protection, Gravity strengthens competitive advantage for Kotex and elevates the standard of menstrual care for women worldwide. Pretty awesome. And consistent with our playbook, we are building premium benefits on top of this scale technology. One of our newest innovations, Kotex BioCare, was built off of a key insight. Traditional period pads can disrupt intimate skin's natural barrier, trapping excess moisture increasing skin PH, leaving skin susceptible to irritation and discomfort Kotex BioCare is pH proactive proprietary technology is designed to help you protect it and support a healthy PH and help defend against odor and irritants. This is a game changer for the category. BioCare takes our winning globally scaled Gravity core and builds a premiumization benefit on top of it. And you all will have a full pack of BioCare before it's available in the U.S. in your gift bags out in the lobby.

So now recall that I talked about longer-term disruptive technology. One of our [ fine ] Moonshots is called sleep uninterrupted. And as part of that, we asked a bold question, how much can a diaper actually influence a baby's quality of sleep? And by inference, mom and dad's quality of sleep? Well, we tested it, and we prove just how much it matters. In China, the Deep Sleep Master launch is our hero with consumer tests showing significantly more total sleep a significantly more deep sleep time, delivered through faster absorption, better breathability, better leak protection. This launch has led to 210 basis points of share gain in the very competitive top tier diaper market in China. That's what happens when future-directed science meets a consumer insight, no one else has sell before.

So we're not just meeting needs. We're anticipating them the proprietary solutions no competitor can match. But breakthrough innovation is only the first step. Innovation creates the substance, creativity creates the connection. And that's where my partner, Patricia comes in with marketing.

Over to you, Patricia.

Thank you, Craig. Good morning, everyone. My name is Patricia Corsi, I'm the Chief Growth Officer at Kimberly-Clark. Out-innovating with our products is just one of the powerful tools that we have in our toolbox. And today, I want to share with you another 2 out-market and out-activate. We have a disciplined approach to leverage these 3 pillars and unlock long-term growth. We are going to focus on these 3 key areas, Holistic Blueprint for Growth, Building Brand Love, and Digital Transformation. And with those, we are going to deliver end-to-end superior experience to our consumers and deliver best-in-class performance results.

And we are well positioned with our categories to benefit from demographic and populational shifts. We are seeing healthy growth categories and in a rates that are much higher than historically. The acquisition of Kenvue will give us further relevant moment of connections with well-known and loved brands globally. And to fully benefit from these positive trends, we will apply our holistic Blueprint for Growth. This is a systematic consumer grounded and repeatable approach that focus on how to unlock the biggest opportunities. With it, we simplify it and we make it actionable in the marketplace. With more users, usage and occasions, we will continue to unlock growth. And in our categories, there is a wealth of opportunity ahead of us.

And I'm going to show you just a couple of examples, starting with this one with Baby and Child care. With innovation and non innovation-led growth opportunities in the different pillars also in different geographies and an increasing bifurcated world, this allows us to serve better and more consumers. And this is just another example from Feminine Care category, just to showcase to you that we are implementing this in all our categories and geographies. And as you can imagine, there is much more behind these boxes than you can see today.

And we are building Brand Love, and you heard Mike talking about it. Our transformation does not only rely on data. We are building Brand Love and building a generational value to moments of connection. We are grounding ourselves in consumer differentiated insights and we will continue our product superiority focus while building much, much stronger brands that consumers love and admire. And this is not marketing fluff. It is important and why it's important because building Brand Love drives loyalty, repeat, trial and increase brand equity. And all of this deliver much stronger results.

And I'm going to show you some examples, starting with the Baby and Child Care category. And by the way, for all of them, I'm going to show you the results that we are getting in the marketplace. First, video, please.

[Presentation]

This is the first example. It comes from a home country, Brazil, where product insight was translated into communication, leaving parents free of worry of diaper marks. This showcase our end-to-end approach yields superior results.

Let's start with market share gains, almost 300 basis points, and we reached over 1 billion media impressions since the launch. This was an end-to-end because we have launched new product innovation, new packaging, visual identity and also new communication campaign. And from Brazil, we move to Indonesia, and I'm going to do a little bit of [ front 2 ]. This was our previous Sweety brand packaging in Indonesia. And let me show you what we have done last year. New product, winning concept, new design, new communication and of course, the results show 34% growth in the premium segment. Not only that, the consumer response as well, 4.9 stars on TikTok, #1 premium seller on Shoppe and 5 stars in Lazada.

And let me go to the last example on the BCC category. Video, please.

[Presentation]

I'm sure you agree with me that it has nothing to do with the traditional diaper advertising, and this is how we are transforming Kimberly-Clark. Another example, this time from the U.S. end-to-end new product, new brand visual identity and new campaign, over 1.8 billion impressions and around 30% better return on investment. When I say it's not marketing fluff, it's really not marketing fluff. And share gain again. So this is how we are delivering it in BCC.

And now moving to Adult Care, showing that we can use creativity to build Brand Love but also deliver better consumer experiences. Impactful creativities, even more needed in categories that are so stigmatized. Over 1/3 of the men in here and in the world and 2/3 of the women will suffer bladder leakage in any point on their lives. And this is a topic that you can imagine nobody wants to talk about. But we are here to help this discussion to start. And in Australia, you can see that with the new packaging design that helps you clarify what the product does and how to help consumers, we are taking the stigma of being seen in front of the shelf. And in the U.S. We partner with Katherine Heigl, and we are helping women to stop whispering in fun sports and digital content. And in both cases, you can see market share gain once again.

And my last one on this pillar, very close to my heart. This has just been launched last week in the U.S. It's a new Kotex platform. And I'm going to let it speak for itself on your [ floor ].

[Presentation]

Now I think you would agree with me that this is putting this brand back or where it should be. So this is from where we were and this is where we are going to go. We are completely relaunching Kotex in the U.S., new product you have heard from Craig with Gravity technology, bamboo and BIO-CARE. We have new packaging design and an end-to-end consumer discovery on shelf and online. And this is a global platform. This is going to go to multiple countries across the globe showcasing that what we are doing is a repeatable model, and it delivers economies of scale.

So I'm going to move now to the third and last part, but before that, I'm not going to have the chance to show all the transformation that we have been doing in the past 15 months. Brands like Kleenex, Poise and Andrex have also been recognized not only externally but have been delivered with Brand Love an outstanding creativity, household penetration gains, market share gains and also sales growth. You will have the chance to see it during lunch on our screens.

Now I'm going to move to the last and third pillar of my presentation today, Digital Transformation. We continue to elevate our capabilities on digital transformation with really important strides in AI, data, social and agentic commerce. And I'm going to show you today, 3 examples on how this is already delivering results in the marketplace. I will start with China. And as Mike said, really, really important market and digital is leading in there. We are leading in social commerce with superior results with our best-in-class social first model. It includes co-creation of products and designing concepts to win in social platforms. We have placed big bets on creators, and we are doing partnerships that build content that is both journey and occasion led.

With that, again, I know that I'm sounding like a broken record, market share gains, 890 bps and 60% lower cost per view. I'm going to show you just very short videos on how does it work in digital in China.

[Presentation]

And the next one, needless to say that can be applied to any country. I think in Brazil, it's with [ Carameelo ]. And if we move to the next one, this model continue to be expanding. In Indonesia, it has delivered exactly the same outstanding results. And soon, it will scale up to Brazil.

And lastly, we are coming to e-commerce. In the U.S., our business benefits from 700 bps share in online versus offline. And because of that, one of -- this is one of the reasons why Kimberly-Clark U.S. was selected as a -- by a key e-commerce player as a beta partner for its new Gen AI capability. With this platform work that previously took 2 weeks now takes 2 days. We have piloted with Huggies and Wipes, and we are going to scale this up to our brands. This data-driven approach is really transforming category discovery and has delivered over 200 basis points of share growth in this critical channel.

And this is how we are transforming Kimberly-Clark from a company of inventors to a company that has brands and innovation that transform and improve consumer lives. With our holistic Blueprint for Growth, Building Brand Love and with Digital Transformation, this is our playbook to win with consumers and customers.

Over to you, Russ.

Okay. So I know lunch is next, so I'm going to bring us home. I'm Russ Torres, the President and Chief Operating Officer of Kimberly-Clark. And I can tell you, I've spent a lot of time with our teams and customers around the world and what is unmistakable is the incredible momentum we have here at KC. And our people are the key. They possess a sense of purpose that's not just cultural. It's a competitive advantage that powers our execution every day.

Mike outlined the Powering Care strategy. Craig talked about driving pipeline strength and product superiority. Patricia just showed you how we're unlocking Brand Love and driving growth in users and usage. And I'm going to talk about our focus on volume growth, our drive to be the lowest cost producer and accelerate investments and how our operating model brings it all together to help us win in our markets.

We are seeing the results of Powering Care in top-tier volume plus mix-led growth, 2.6% in 2025, 8 consecutive quarters of solid performance, and it's also showing up in our share. Even in a dynamic consumer environment, we have driven share gains in 2/3 of our key category country sells. And a key differentiator for us is driving to best product and the lowest cost. We want both. We're focusing on driving to the lowest cost with 3 key pillars: value stream simplification, optimizing our global network and scalable automation. And those pillars are delivering. We've had 2 years in a row of 6% productivity. We're 50% of the way towards our $3 billion productivity commitment, and that's well ahead of schedule. And we have strong visibility to our future delivery. And we've done it all while improving product performance and dramatically increasing the pace and the quality of our innovation. These capabilities are going to drive about 1/3 of the cost synergies we expect to deliver from the Kenvue acquisition.

And we're driving this approach in North America. Our new mega plant in Warren, Ohio will serve as a productivity engine capable of delivering best-in-class throughput, enhanced product performance and significantly lower unit costs. We're going to cut miles on the road by 22%, reduce the number of DCs we have, double the volume we're directly shipping to our customers and dramatically improving our automation and therefore, our converting costs. And we've got visibility here again to a consistent stream of strong productivity gains in the years to come.

Let me bring this idea of best product at lowest cost to life with an example, and that would be Vietnam, already a relatively sizable but fast-growing market for us. Our local team was faced with increased competition from Chinese OEMs, and they were targeting growth amongst value-seeking consumers with offerings at significantly lower prices than our premium Huggies products. So we assembled a cross-functional team of experts to leverage the best of KC and build a solution. And in just 5 months, we launched a high-performing diaper under the Sweety brand, and we believe we now are the lowest cost producer. In fact, we were able to create a 25% converting cost advantage versus those Chinese OEMs by leveraging our global capabilities, but also high-speed automation.

So the result, a $0.07 diaper that is preferred by 2/3 of consumers and most importantly, at attractive margins because of that cost position. And in the marketplace, Vietnam gained 50 basis points of share in the fourth quarter in part due to that activity. So we're really excited about the potential to replicate this concept of best product at the lowest cost across the world, and we can't bring -- wait to bring that mentality to Kenvue.

So that growth in cost work is enabling us to reinvest a portion of those savings and impact to drive the cycle. So for A&P, Advertising and Promotion, that means we invested $150 million more per year than just a few years ago. And we're accelerating our capital investments as well to approximately $1.3 billion in 2026 to support our growth and transformation plans. And these investments, they're paying off. They're helping us drive the results that you're seeing today.

Just as importantly, our Powering Care operating model has wired our teams together with a shared mindset of speed, accountability and collective agility. And that model also is a key driver of the momentum you're seeing. Now this matrix structure chart, you may look at it and say, this looks like everyone else's. But the key driver of its effectiveness is the market-oriented way we run it. Our markets own the business end-to-end and are empowered to be locally agile. And the role of those functions is to bring KC's best capabilities to the markets at speed to help them win. The goal is to bring global might to the local fight.

The 2 best examples of this are our 2 biggest markets, North America and China, and they strengthen each other. The real unlock with Powering Care has been creating less friction for ideas to move between the 2 at pace and then scaling them throughout the rest of the world. China's digital and content commerce playbook is now flowing into North America, while North America's retail partnership approach and premium innovation and execution capabilities are being leveraged across IPC. Over the last several years, we've transformed our North America business from a cash generator to an engine for growth.

And we did it with 4 key actions. First, we invested heavily in improving innovation. We tripled our forward-looking innovation funnel, and we strengthened our consumer value propositions in every price tier. Second, we invested in building an advantaged digital engagement capability in North America, leveraging and adapting some of those capabilities from China. And third, we built a world-class commercial execution engine, transforming our retailer partnerships and dramatically strengthening our modern marketing capabilities, especially in the areas of creative and social. And last, we improved our margins through stepped-up productivity, revenue growth management and premiumization.

So since 2021, North America has delivered a 3% organic sales CAGR with consistent volume plus mix growth, improved our operating margins by 300 basis points, all while increasing that marketing investment by 33%. We gained or held volume share in 7 of 8 categories in the year of 2025. And we're leading the industry with 3 consecutive years ranked #1 in the Advantage retailer survey, and I believe the best is yet to come.

China continues to be proof that our scalable proven model works even in the most competitive market in the world. Over the last decade, we've doubled revenue and tripled gross profit, and we have built an advantaged digital capability. Our e-commerce share today is more than 2x our brick-and-mortar business. And we've sustained incredible brand performance despite the very difficult competition. Huggies share is up more than 890 basis points and Kotex share is up roughly 260 basis points since 2019. And those gains came from a strategy with 4 key elements: a compelling consumer promise, science-powered innovation at pace, best-in-class digital engagement, and a premiumization engine that's fully integrated with the business model. And this is scalable. It's not just a China or U.S. story. We're now lifting the elements of these capabilities into other priority markets to accelerate our growth.

As you can see from the left-hand chart, across our international markets, we saw a meaningful sequential organic growth acceleration last year. And on the right-hand side, we gained weighted average share across both focus and enterprise markets with accelerating momentum across the year. And the share gains are broad-based and they're being driven by the playbook. As you can see, many, many markets are delivering strong gains despite tough competition. And these elements are somewhat plug and play and can be leveraged by Kenvue as well across the world.

Our pending acquisition of Kenvue is a really unique and exciting opportunity. Our integration machine is up and running. We have a global integration management office that's a blend of talent from both companies about 50-50 with over 30 work streams currently operating globally. The acquisition was overwhelmingly approved by shareholders of both companies with well over 96% of the Kimberly-Clark shareholders voting yes, and we've secured regulatory clearance in the U.S. and we remain on track to close in the second half of 2026. And we're using that time to drive to deliver $2.1 billion in total net synergies.

Beyond the normal G&A synergies you might expect, we see future value creation coming from 3 big buckets. First, supply chain. And this is going to include all sorts of things like consolidating distribution to better fill trucks and ship more directly to our customers. And we think there's great opportunities here as well to take the proven 3 pillars I just talked about and apply them to Kenvue. The second big bucket, SG&A. We see opportunities in commercial spending optimization and scaling our functions and optimizing our joint IT landscape to deliver even more value. And we're really, really excited about the growth opportunities.

I'll just give one example, India. Kenvue has the potential to quadruple our distribution in the traditional trade. And we see similar distribution-based opportunities in Mexico, Indonesia, Brazil, the United States, Eastern Europe and many more. And we believe we can leverage many of the capabilities we've talked about earlier today within Kenvue to accelerate growth. For example, our top-rated sales team in North America or our digital commerce capabilities. We're also being deliberate about what we're doing because we want to make sure that we stay focused on where the value is. We're being very choiceful about prioritization and sequencing to focus on the places where there's real tangible value.

So in summary, we built a company that knows how to execute with speed, discipline and accountability. And we have the will and the capabilities and the operating model to drive that into results. And you're seeing it in our performance today, and you're going to see it in the way we integrate and scale Kenvue upon closing the transaction. And I believe we're still in the early innings of what this organization delivered.

Thanks, Mike. I'll hand it back to you.

All right. Thank you. Okay, thank you, Russ. All right. For more than 150 years, we've delivered essential everyday care to improve the lives of our valued consumers. So today, we're better positioned to carry that out that mission than at any time in our company's history. Powering Care has created a virtuous cycle of value creation driven by an innovation-led volume and mixed growth model, industry-leading productivity and an organization wired for local agility, global scale and speed. Our acquisition of Kenvue builds on our successful transformation. And together, we will be a preeminent consumer health and wellness company, serving billions of consumers around the world across every stage of life. We'll be there for more moments of connection, delivering more innovation and growing Brand Love while delivering generational enhancement of shareholder value.

So thank you for your time and interest in Kimberly-Clark.

Thanks, everybody, for joining us. We invite you to join us outside for lunch where we'll have management there for you all to grow.

Greetings. Welcome to the Kimberly-Clark 4Q 2025 Earnings Call. [Operator Instructions] Please note, this conference is being recorded.

I will now turn the conference over to your host, Chris Jakubik, Vice President of Investor Relations. Chris, you may begin.

Thanks so much, and good morning, everyone. This is Chris Jakubik, Head of Investor Relations at Kimberly-Clark, and thank you for joining us. I would like to remind everyone that during our comments today, we will make some forward-looking statements that are based on how we see things today. Actual results may differ due to risks and uncertainties and these are discussed in our earnings release and our filings with the SEC.

We will also discuss some non-GAAP financial measures during the remarks and these non-GAAP financial measures should not be considered a replacement for and should be read together with GAAP results. And you can find the GAAP and non-GAAP reconciliations within our earnings release and the supplemental materials posted at investor.kimberly-cark.com.

Finally, I will apologize in advance if there are issues with the quality or delays in our audio today because we are all working remotely due to the winter storms. So with that, I'll turn it over to Mike for a few opening comments.

All right. Thank you, Chris. 2 years ago, we launched Powering Care to unlock Kimberly-Clark's next chapter of growth, building on our 150-year legacy. Now since then, we've made tremendous progress and accelerated our momentum across the board, our execution of Powering Care is driving strong results even amidst a dynamic external environment. In 2025, we continue to advance our volume plus mix growth model, delivering an eighth consecutive quarter of solid volume plus mix performance in Q4. We gained enterprise weighted share and we marked a second straight year of industry-leading productivity with our fourth quarter being the strongest of the year. .

The energy across our company is palpable. We are introducing consumer-directed science-based innovation and breakthrough marketing across brands and markets faster than ever before. We're exercising cost discipline in deploying our greatest capabilities across the enterprise to optimize our margin structure and we've rewired our organization for growth, including strengthening our bench of exceptional leaders and pivoting our portfolio to higher growth, higher-margin personal care categories. We've hit the ground running in 2026 and are energized by the opportunity ahead. We've built a robust achievable plan focused on further differentiating our trusted brands, and ensuring we have healthy levels of investment across our value chain.

We expect pressure on the consumer and a focus on value to persist. We're confident in our strategy and committed to giving our brands the fuel to thrive. Powering Care has put Kimberly-Clark on a virtuous cycle of growth and positioned this great American company for a better future. We have the right foundation and a proven playbook to capitalize on our pending acquisition of Kenview, acquiring Kenview a powerful next step in our transformation that will compound our momentum. It will advance our trajectory toward higher growth, higher-margin spaces and create a global health and wellness leader positioned to serve consumers at every stage of life. We're excited to see the vast opportunity ahead and confident we will create significant value for our consumers, our partners and our shareholders.

So with that, let's open the line for questions.

[Operator Instructions] And the first question today is coming from Bonnie Herzog from Goldman Sachs.

All right. So I guess I was hoping to hear some color on the state of the consumer and what you're doing different in this environment Mike, I asked because you're growing volumes, whereas this really has been challenging for others? And then how are you thinking about this going forward? And you guided organic sales growth to be aligned to ahead of the category in '26. So hoping you could share what your expectations are for category growth this year and whether it will accelerate from the 2% growth currently. I guess, essentially, do you need end market growth to improve to hit your mid-single to high single-digit EBIT growth guidance.

Okay. Bonnie, great question. Thanks for that. I'll open and I think Russ has a lot more texture that he's rearing to inform you all of. And then I might even ask Nelson to cover a little bit about how it affects the outlook. But one, -- and I think you raised the point that we are growing, and it's a tough environment out there. However, I think the big thing is that maybe 2, 2.5 years ago, Bonnie, we did see that pressure in almost all markets was going to increase on the consumer and especially in North America, kind of given the state of the middle-class consumer. And so we started to focus on was delivering superior propositions at what we said is every rung of the Good, Better, Best ladder, right? And so we've worked really hard to do that, and we continue to see ample opportunity to do that and do that better and also continue to elevate and expand our categories globally.

I have a couple of additional comments. We feel consumers remain interested in better performing products, and that's at all price tiers. In this environment, as I think you're pointing out, Bonnie, strong value proposition is the paramount thing. And so we're growing because what we're doing is strengthening our offerings at every run, and that means -- we're continuing to bring great innovation at the top end, and then we are rushing that innovation through into our value tiers. And I think our consumers are really noticing that. We've really worked hard to deliver superiority at a very, very competitive cost. So we see further opportunity to expand our categories, expand penetration and premiumize over time. And so we've developed a robust pipeline of innovation that the world hasn't seen yet.

I will tell you, parenthetically, I'm more excited about our next 3 years innovation than what we've done in our past 3. And so we're really excited about what the company has been working on. So with that, maybe I'll kick it to Russ and maybe you can provide a little texture.

Yes. Thanks, Mike. Bonnie, yes, you're right. I don't think we are expecting, as Mike noted, the consumer focus on value to change anytime soon. And as Mike noted, I really think our mantra has been to meet consumers where they need us. And that's where the combination of innovation, marketing and activation. And like other categories, we are seeing consumers demand shift across channels. They're looking for different pack sizes, purchase frequency in some parts of the world, especially internationally and in developing markets is being impacted a little bit, and that's clearly led to kind of more choppy month-to-month consumption data.

So in terms of your question, I think Mike nailed it. I would just add a little bit more texture on it is that we're really focused on serving consumers on every run with a compelling value proposition. I think that's the reason why we're growing volumes right now. We have made a number of targeted price pack adjustments as well as paying extra special attention to channel participation and ensuring we have really compelling offerings at the good tier as well as the better and the best here. And we put an extraordinary effort into driving elevated benefits on the trade-up side to maintain that category growth. And I think in North America, if you pick that as an example, that's really helped us on the volume side in Q4, as you saw from our results, our volume mix was up 1.7%. But on a 2-year stack basis in Q4, was up 3.6%. And then on the full year basis, in North America, volume mix was up in Q4, 2.1%. And on a 2-year stack basis, it was up 4.1%. And I agree with Mike 26 should probably be one of our best years for innovation, and we're going to continue executing that strategy and are optimistic we'll continue to be able to deliver what consumers are looking for.

Yes. And then, Bonnie, just to follow up on your -- on the final part of your question. I think our '26 kind of implies our category outlook is around 2% globally, plus or minus. And there's been -- if you look at the last 4 quarters, there's been a little choppiness around that. But -- if you think -- if you look specifically at our categories, we tend to be more resilient and demand tends to be a little bit more stable because of the categories that we're in. .

The next question will be from Lauren Lieberman from Barclays.

Just wanted to follow on, on some of those thoughts and particularly holding in on price and mix. In North America, we've seen pricing took another step back this quarter after being up in 3Q and mix persistently negative. I know you look at vol/mix, but price/mix is decelerating, not improving. So just wondered if you could comment on that. And because you've mentioned price investments a couple of places in the release. .

Let me take that one, Mike?

Yes. Go ahead.

So yes. I would say there's really 3 things going on there on the price mix. The first thing that I would say is there is a promo dynamic, if you recall, in the third quarter, call, we talked about the competitive activity in North America in the second half being some fairly significant promotional activity. And we, as a result of that, rephased some of our planned activation activity around innovation into the fourth quarter. So you're seeing that come through and specifically, just to remind you, as Mike said, we're in essential categories we don't believe that promo drives incremental consumption, but we will use it as a tactic to drive trial, especially related to innovation that is really sensorial. And we did have a strong agenda of innovation in 2025, and you probably saw some of that. For example, we -- we did move some of that programming on [indiscernible] Drive, which we have a great innovation. It's the softest [indiscernible] in the value tier. Our new generation 2 core, which provides better protection and more comfort it was named the #1 diaper good housekeeping, disposable diaper, great consumer reading. So we wanted to get that in the hands of consumers to drive trial.

We had other innovations as well, and we did that in the fourth quarter and those performed relatively well. I would say just last thing on the promo dynamic before I move on is our end market promotional activity for the year remains below the category and 2019 levels. And again, we expect that to flow with our innovation. The other 2 dynamics, I'll hit briefly. One is club mix. That's just the consumer moving channels, and that has come through a little bit in our pricing because they're buying larger pack sizes at a lower price per unit. So you see more volume, but a little bit of a drag on the pricing piece there. And again, that's our philosophy of just serving consumers in the channel that they want to shop in.

And then the last thing is we did talk about several times making strategic investments in pack sizes and choices to better align our good, better, best pricing value-adders across the channels, especially ahead of some of the innovation we have coming and we had made some choices to sharpen the competitiveness of our value proposition. So over the long term, we're going to stay focused on maintaining PNOC's discipline while growing volume and mix. profitably. And that will be led by innovation and the focus on category development. And we have a great lineup in '26 to that end. So that's kind of the direction we're headed and we're excited about it.

The next question will be from Nik Modi from RBC Capital Markets.

Just like a quick clarification. I didn't see anything in the release regarding any updates on closing timing or regulatory filing timing. So if you could provide any clarity on that, that would be helpful. But my main question is really just the state of the U.S. [indiscernible] category, especially the dynamics at play at Costco, given Procter is now entering after decades of exclusivity for [indiscernible]. So if you can provide any kind of thoughts on that? Is that kind of embedded in your outlook? How are you going to respond, et cetera, et cetera?

Okay. Nick, maybe I'll ask Russ, maybe you can talk about the U.S. diaper category, and then I'll come back, Nick, and answer your questions on the acquisition.

Yes, sure. Yes, in terms of diapers, again, we're growing by driving innovation and brand building that grows the category and cascading that to all tiers. And -- that model has worked well for us around the world in the United States before I get to the U.S., I'll just hit a couple of highlights around the world in the fourth quarter. We grew share in many of our key markets, including China, up 210 basis points; Korea up 30 basis points; Brazil, up 50 basis points; Indonesia, up 230 basis points. So that strategy that we're executing is working in North America as well. In the fourth quarter, we grew share about 100 basis points, and we've grown share in diapers 2 years in a row. But with -- just with respect to the club situation, the way we look at it is we're really focused on providing consumers with differentiated brand value propositions no matter what channel they're shopping in.

And we're widely available, so is our competition. However, we did see a major club player has moved away from branded exclusivity in our category. And so we'll see partial loss of diapers and pull-ups distribution in the North America Club channel and that will start in the first quarter here. And this is incorporated to your question in our full year expectation of growing, as Nelson mentioned, in line or to better than weighted average category growth. So we're focused on continuing to execute the strategy, and there might be some ebbs and flows over time, but we're very confident in the long term. We're going to continue to move in the right direction as our current performance indicates.

Just to clarify for what's built into the forecast, Nik. We -- as Russ mentioned, we expect this distribution loss to commence in Q1 -- it is reflected in our full year outlook, and it's a headwind of around 60 basis points for the full year.

And then, Nik, just regard to the Kenview process, we -- the shareholder vote is on the 29th of Thursday. I will tell you expect the vote to reflect the very positive feedback we've heard from our investors. And so through yesterday, pretty good chunk of shareholders have already voted and it's well in excess of 90% in favor. So we feel good about that. And then with regard to timing of close, we still expect somewhere in the back half. I think the regulatory process is on track and consistent with our initial expectations. And maybe you didn't ask this part, but I will tell you, our IFP transaction remains on track for a midyear closing this year, still subject to regulatory approvals.

And then we work closely with Kenview to file shortly after announcing the transaction, submitted the U.S. antitrust filing, and we'll complete filing all applicable international jurisdictions by early February. And so again, I think we're on track to close in the second half of this year.

The next question will be from Steve Powers from Deutsche Bank.

Maybe just to round out the top line conversation a bit. Just maybe a little bit more precision around how you expect the overall 2% category growth to shake out North America versus rest of world? And I guess in light of the 4Q dip that you noted and the overall choppiness we've seen, do you see that backdrop existing pretty steadily in 2016, I guess, inclusive of the first quarter? Or will it -- are you assuming that it takes more time to ramp. That would be helpful. And if I could, I know I'm supposed to have one question, but I'm going to try to get 2. .

Nelson, in the prepared remarks, you talked about visibility in achieving that 40% future adjusted gross margin before the end of the decade. I'm assuming that target existed before Kenview. So it's independent of Kenview contributions I guess. Maybe just an update on how are you seeing the primary drivers shaking out there? And then just how much progress roundabout you think you might be able to make in '26.

Let me just open with maybe just an overall comment on the sales outlook. And then Nelson kind of will give you a little more texture on the pace and then we can hit the margin thing, Steve. But one, I just wanted to kind of emphasize that our volume momentum, and I think Bonnie noted that the volumes were, in our minds, performing well. The volume momentum really this year -- or last year in '25 really reflects, I think, the compelling offering that we have. And as I mentioned earlier, we're even more bullish on our innovation and marketing initiatives this year. And so I think our focus on strengthening the value propositions at every tier has been very, very important. We have a very strong pipeline coming this year. And so we expect a meaningful step-up as we get through the year to support our new launches. And so we feel very good about the plan for this year. But I'll let Nelson, you may want to comment a little bit more on the pacing.

Sure, Mike. So a few things, Steve, and I'll unpack a little bit Q4. But to start with, for 2026, as Mike mentioned in his prepared remarks, I mean, we have a very strong, and I'd say the strongest pipeline of innovation and activation programs that we've had in quite a few years across all of our markets. And we are -- our plan is to continue to build the momentum on volume plus mix-led growth that we saw play out in 2024 with an acceleration in 2025. Now as you rightfully mentioned, for the fourth quarter of 2025 on the surface weighted global average category growth dropped to around 0.6%. And that compares to about 2% that we were staring at right around between Q1 and Q3 of last year. And there were a few discrete factors that weighed on this drop, particularly in North America. And as you know, we have the impact in '24 of Hurricane Helene, the port strikes, panic-related buying and to a lesser extent, in 2025, there was a little bit of pantry loading in North America diapers in Q3 or '25. So that all kind of played out into the weighted average growth of 0.6% for the category in the last quarter.

For the full year, as I mentioned, category grew weighted right around 2%, and our categories have remained resilient. As we think about the last 4 weeks data that we've got, we're hovering around that 2%. So we think that a good starting point for weighted average category growth for the start of the year is around that level. We are maintaining our disciplined approach to grow in the categories and the brands through the innovation, the differentiation, and we expect both North America and our international personal care business to grow in line or ahead of the categories for the full year.

In terms of net sales, we expect both the first half and the second half to be roughly 50-50, so pretty even. But when you look at the growth in terms of quarterly pacing, we are planning for the innovation and the brand support to ramp up as we progress through the first quarter and then into Q2 and the balance of the year. So I would expect, as we built our outlook to see organic growth to accelerate in the back half versus the first half of the year.

As it relates to the visibility of achieving the 40% before the end of the decade and the drivers and the progress, a couple of things. I mean, as we stated, Margin progression is not going to be linear quarterly or year-on-year. However, we've made very strong progress over the last 2 years. We take -- we took a little bit of a step back on gross margin in 2025, and that partly was impacted by, one, the inflationary elements that we were dealing with. As a reminder, we had around $200 million of input costs that we dealt with last year, and that included the headwinds, which were unexpected related to tariffs.

As we go into this year, though, we're not expecting that. I mean we're expecting costs actually to be largely flat. So that's one. Secondly, we are expecting to deliver very strong productivity in the year. Another year that will hover around 6%, building on what we achieved in 2024 and 2025. So all in, we expect to expand margins, both gross and operating profit margins in the year in 2026, putting us well on pace to achieve our objectives of at least 40% before the end of the decade for gross margin and at least 18% to 20% in operating profit before 2030. So well on pace to deliver that. And again, that excludes any favorability or impact as we carry out the integration of Kenview, Stephen?

The next question will be from Chris Carey from Wells Fargo Securities.

You gave some information just about the model from 2026 kind of through 2028 with phasing and obviously implied in there is some medium-term growth expectations as well. You also established some of these expectations in the S/4. And can you just help reconcile or clarify whether there's been any evolution in the expectations as of the S/4 relative to where we are today. And -- and maybe just because so much of this medium-term CAGR is anchored to an acceleration in 2028. Just help us understand the -- the visibility that you have and the confidence that you have that you can achieve those outcomes in a few years from now?

Sure. So from a modeling standpoint, let me walk walk you through what we had in the S/4 and what we have for 2026. And to your point, our visibility and confidence in getting to our ambitions before the end of the decade. So firstly, I mean, a couple of things. We've built into the outlook for this year, the momentum that we've got based on the innovation and all the activation plans that we've been building on through 2025 and what we have in place as we commence this year. There are two factors that are coming into the picture as we speak, for the outlook for the year, and they've come up in the past couple of months. The first one is we've had a bit of softer than anticipated fourth quarter in the demand in North America and enterprise markets. And this resulted in a lower base of volumes and EBITDA for 2025, and that's reflected in the outlook.

The second bit is really around the partial loss of the diapers and training pants distribution in the North America club channel that we just talked about, both Ross and myself, which we are not able to fully offset in 2026. And as I mentioned, that will be a headwind of around 60 basis points of growth on the year that is reflected in our outlook. And that, of course, will be a difference that you would see versus what we would have had in the S/4. That said, our ongoing business is well positioned to deliver results consistent with the long-term algorithm that we laid out in March of 2024. And these 2 factors are reflected in the outlook.

On the top line, we -- based on all the innovation plans that we have, the commercial plans, we expect to deliver growth that's at or above global weighted average category growth globally. We are aiming for operating profit growth that's at the higher end of our mid- to high single-digit range. And as we support a significant step-up in new product activation across key markets, in another year of gross productivity that will approach 6% of cost of goods sold, and we will maintain our discipline on SG&A savings that you've seen flow through in the last couple of years through our Powering Care transformation.

If you look at adjusted EPS, we expect to be in line with 2025 levels on a constant currency basis, Chris, and this will reflect 2 things: one, the underlying growth, which will be consistent with our long-term algorithm. But there will be an offset. And that's because of the reduction in income from discontinued operations, which we expect to be roughly half of what we saw in 2025 levels with a midyear projected close of the IFP transaction.

And then, Chris, I think you may not have asked us specifically, but I would say from the Kenview perspective, I'll tell you, and we've been getting [indiscernible] into the integration management process. I would tell you, we haven't seen anything that would change our view on the potential of this combination. Kenview, they're going to be set to report the results on the usual timing, I think, which is early to mid-February. And then if you looked at the S/4 pretty hard, we did take a fairly -- or a somewhat more conservative view of their outlook and near midterm financial profile. -- we plan to make pretty good investments into their brands and their portfolio and capabilities. And so we still see a generational value creation opportunity by putting these 2 companies together. Our focus is on making sure that both companies have great earnings capacity over the long term.

Yes, keep going.

Yes, you have a question on the visibility. Yes, you have the question on the visibility. And I'll reiterate that we have strong visibility into our plans on the productivity front to achieve the margin expansion and fund the brand investments that we have for the following years as well as on the top line, our ability to grow at or ahead of the categories, largely driven by the very strong innovation pipeline that we've got for the next few years as well as our executional plans across the globe.

The next question will be from Mike Lavery from Piper Sandler.

I just want to follow up a little bit, I guess, on Steve's bonus question on the margins. Just would love to understand you called out the significant reinvestment that you're expecting post deal. Just maybe how -- you said, of course, that it's not linear, but maybe how bumpy does it get? And we know some of the synergy pacing and how that plays out. But kind of just maybe how much more can you unpack the path to 40% gross margins and 18% EBIT.

Yes. Well, Michael, thanks for the question. Just a comment, I would say -- and I'm presuming you're talking about kind of our stand-alone on our path to 40%. I think we're -- overall, we feel like we're making strong progress. We have good -- very good visibility into our path to the 40% and 18% to 20% [indiscernible] aspiration by 2030. In fact, I think we're probably pacing slightly ahead of what we originally planned. Just to confirm or reiterate, Michael, these margin targets are milestones not a destination. And so we expect to kind of exceed that when we can. And then you'll note that the IFP transaction does create a onetime impact and a better business for both businesses longer term. And we'll update you on that as we get closer to close. But again, I think we feel very good about our productivity delivery. We feel very good about the innovation that we have in the pipeline that's enabling us to drive positive mix and premiumize at the top end of the category and then grow volume by cascading those features down through the tiers. So I'll pause there. I don't know if there's anything else we want to click on there.

The next question will be from Robert Moskow from TD Cowen.

Thanks for the question. Nelson, the argument for gross margin expanding this year, I think, reflects, you had $200 million of input costs last year you didn't expect. And then it's not going to happen this year. But if I look back at '25, I mean, one of the -- was that pricing turned negative the environment got a lot more competitive. What's to stop that from happening again in 2026. It seems like the environment continues to be really competitive. You're losing some distribution in Costco. You might have to take steps to defend your turf and other retailers. I mentioned the name of the club. I'm just speculating, of course. But so how much cushion do you have in the model in case it does get into that kind of environment again?

Yes. So a few things there, Ross. First, yes, as you rightfully say, as you unpack why we expect margins to expand. One, costs are projected to be neutral year-on-year versus 2 years in which we faced about $200 million of costs. Secondly, productivity, gross productivity is expected to be right around the 6% level, which will be at the high end of our 5% to 6% and again, another record productivity level for us in the year. And then on the pricing bid, I think it's very important to go back to what we chatted early last year on what Russ mentioned. We made some strategic price pack architecture and channel price investments, particularly in North America in -- towards the end of Q4 of 2024. So as you head into 2026, we're going to be lapping largely that. So that is going to be something that, again, based on what we've modeled and what we put together, that is one asset that will be different as we go into the year. So that changes year-on-year and it's reflected there. .

The channel mix and all that [indiscernible], that will continue to play out to some extent, but that's factored into the model, Rob. So hence, why we do see a little bit of a difference between '25 and '26 from that end and why we're at this stage, confident in our ability to expand margins in 2026 back to where we had modeled before.

And maybe, I'll [indiscernible] on Rob. I think part of it is also philosophically, we're really not interested in renting share through promotion. And especially, I think Russ mentioned it earlier on the call, which is -- it doesn't make sense in a category where consumption is relatively stable or almost fixed in a category like that tissue or diapers. And so what we're really focused on -- and I think we had this in our prepared remarks, is kind of having an operating model and a culture that's driving this notion of the elusive virtuous cycle, which we think is delivering great results. And that includes innovating at all runs of good, better, best, especially at the top end and pulling it through the value tiers. .

And then as you're kind of asking about, making sure that we can invest for impact. And I think we've done a very good job of increasing our investment over the last several years, but also improving our -- maybe the effectiveness of our advertising and our marketing. And for us, we feel like that's a much more powerful lever to pull than trade promotion. And so that's kind of where we've been investing, and we're really seeing great results. And I think that's leading to -- that's been a driver of our last couple of years of strong volume plus mix growth. And we feel very well positioned for more volume and mix growth in 2026.

At the same time, to get this virtuous cycle, we have to have leading productivity, which we're delivering. And so we're really proud of. And so I think that's our focus and that's how we're going to run the play in 26.

Yes. I got it. I guess my question is, Nelson, you said that price realization was lower in because of decisions you made in fourth quarter of '24. But with -- from our modeling, the pricing was weaker than expected during the course of '25 compared to the original guidance. Am I wrong? Or was a down year for pricing always part of the plan? It seems like it was weaker than you thought. That's all I was asking.

We always factored into the plan on the pricing actions that we were going to take at the end of the quarter in 2024. And there's always going to be a little bit of shift in programming, Rob, that place into in the year, and that comes up in actuals. But that was largely it. I mean there will be a bit of move across channels, as Russ referred to. But overall, based on what we're planning we wouldn't see what we saw in '25 at this stage.

And keep in mind, I think Russ had mentioned earlier that -- and we've talked about on last quarter's call, where because of competitive activity, we held back on some of our Q3 programming, and we shifted it into Q4. So that would explain some of what you're looking at on a sequential basis.

And the final question today is coming from Edward Lewis from Rothschild & Co.

Yes. I guess a quick one just looking at the international business. So good share gains. You note again and obviously a good end to the year there. And as I look at the results for 9 months on the international gross margins, there's around about a 7 percentage point gap between that and North America. So am I right in thinking that the international gross margin is a big opportunity? And what do you see as the drivers there.

Yes. Good to hear from you. Yes, international margins are an opportunity. It's something we're focused on improving. I'll let Russ talk a little bit more about it. We feel very good about the progress we're making in international especially our focus markets. .

Yes. Yes. I would say a few things. First, I do think that a key part to the equation for us growing is to meet consumer demand at every tier, and we talked a lot about the good and the better, but the best is a big opportunity for us. And we've seen that where we've expanded margins in international geographies is developing that premium segment. And we believe that there's very, very significant upside in that, especially in geographies where the consumer is still developing and GDP growth continues to allow people to have more money to spend. And so that's one.

I think the second thing is we've had no less of a focus on productivity internationally, and we've come up with some really great ways through the wiring that we've executed to be able to leverage our global scale that we've got in markets like North America and China and other geographies to help drive costs down. And so that's another big component. I would just note that we've been growing significantly, and we've seen that sequentially unfold for us in the markets outside of North America and China. Brazil diapers, organic growth, mid-single-digit. South Korea diapers positive organic growth. Indonesia, positive organic growth, gaining share in Australia. So infant care and adult care. So that's another element to it. It's just the leverage that we'll get as we continue to scale the business and looking forward to Kenview, we think that's another really big opportunity potentially for us. So that's kind of what I would say.

And then, Ed, I'm excited about our share momentum. I mean we did see significant growth across [indiscernible] markets in 2025. Just to give you a few examples. I mean, overall, our focus markets, our top 6 markets in IPC were up about weighted share 50 basis points. China was up 270 basis points on diapers. And then outside China, fem care in Indonesia was up almost 200 basis points. Korea was up 60%, Australia up 50%; Brazil, up 40. And so -- so I think we're making very good progress across the board. And then if you think about international in 2016, we expect to drive positive volume and mix-led growth ahead of the category. We are targeting weighted share growth again long by -- led by our strong innovation and premiumization and then expect operating profit dollar and margin gains reflecting the strong productivity and overhead management that we're doing. So thanks for the question, Ed.

Thank you. And that does conclude our Q&A session for today. I will now hand the call back to Chris Jakubik for closing remarks.

Great. Well, thanks, everybody, for joining us today for analysts who have follow-up questions, the Investor Relations team will be around all day to take them. So have a great day, and again, I appreciate the interest.

Thank you. This does conclude today's conference. You may disconnect your lines at this time. Thank you for your participation.

Good morning, everyone. Welcome back to day 2 of Morgan Stanley's Global Consumer and Retail Conference. I'm Dara Mohsenian, Morgan Stanley's Household Products and Beverage analyst. Just before we get started, a quick disclosure. Please see the Morgan Stanley research website at www.morganstanley.com for important research disclosures and contact your Morgan Stanley representative if you have any questions.

And with that, I'm very pleased to welcome Kimberly-Clark back to our conference. They're coming off a transformational acquisition announcement of Kenvue. So it's a great time to have you guys here as you take another step in your transformation in recent years. With us today on stage are Chairman and CEO, Mike Hsu; and CFO, Nelson Urdaneta; and Head of Investor Relations, Chris Jakubik. Thank you, guys, for being here today.

All right. Great to be here today.

Thank you.

So Mike, I thought, first, we could start off big picture around the Kenvue deal. It's obviously very topical right now. You've built real momentum at Kimberly-Clark over the last couple of years. Powering Care is working, productivity has picked up, you've accelerated organic sales growth, market share performance. Help us understand why now was the right time for Kimberly to take on something as large and complex as Kenvue versus continuing to pursue that lower risk strategy of executing on the base business, which seems to be working. So it creates a higher bar.

Yes. Great question. We feel great about our base business, and we can talk more about that later, but -- and the momentum that we've been building in our core business trajectory. But what we're really focused and excited about is building the preeminent personal wellness leader, right? And that's where we feel like we have a great opportunity in joining forces with Kenvue. And really, what we're trying to do is we see the opportunity to deliver extraordinary everyday care as a combined entity.

I would say, and as you point out, there, that our performance has been improving significantly over the last 10 years. We've built an operating model and I would say, an accountable culture that has been leading for the last, I would say, 2 years, industry-leading results, right? And that's really driven by -- I think that maybe you put in that note last quarter, we've really focused on having superior value propositions at every run of the good, better, best ladder, including the good tier. Even though our strategy long term has been to premiumize our categories, we made a shift and we're emphasizing the value tiers the last couple of years, and that's having great effect.

Secondly, we have really worked hard to improve our supply chain. We are putting up world-class or industry-leading productivity last year, this year as well. And then we've got an operating model that we think is different than a lot of companies, and we see it as -- we're trying to be lean, fast and agile. And so those are kind of the things that we bring. And then with Kenvue, though, we see kind of the crown jewel of health and wellness, right, a crown jewel portfolio with iconic brand portfolios, leading market positions.

And then I think really preeminent science, medical regulatory knowledge that really can catapult us in this space. And so together, we think -- well, we haven't done one of this magnitude since Scott tissue days and my predecessor, Tom Falk. But the 3 of us, Nelson, Chris and I, we were all at Kraft and what we observed at Kraft that worked well for us there was we call internally the plug-and-play approach, right?

You saw over time, things come in and out of Kraft or even the split between Kraft and Mondelez, the backbone of that was a really good management system that we could -- people could plug into or you could plug businesses in like Cadbury and then unplug from. And so we've worked really hard over the last couple of years to build a better plug-in-socket system with our management systems, and we think we have a very effective and efficient operating model and an efficient set of management systems to help do this.

Great. That's helpful. You ran through the attributes of Kimberly-Clark as well as the Kenvue's side and their iconic brands. What do you bring to each other in terms of incremental value?

Yes. Well, I think the biggest thing is our focus strategically has been to shift our mix to, as you probably observed, higher margin, higher-growth categories. We really want to shift our mix. And when you think about that, and we took an exhaustive look at all categories, this goes all the way back to 2017 when I became the Chief Operating Officer, we've constantly looked at all consumer categories in our space and then further out. But health and wellness always came to the top of the list.

And the biggest reason there, you're probably fully aware, we have exposure to an aging population through our adult care business, Poise and Depend. And we see the trends, not just in the U.S., which has been growing near double digits, the whole time I've been at KC. And that's because of the aging population in the U.S. But that population is not just aging in the U.S., it's all developed markets and then increasingly developing and emerging markets as well.

And so as the population continues to age, and I'm still fortunate enough, I have 4 parents still with us. They're all in their 90s. But as the population ages, the need for health and wellness products becomes more and more acute. And so -- and as Kirk and I -- the Kenvue CEO, Kirk Perry and I got together, we did feel like, there's going to be a unique opportunity to tap into that. And the combination of our portfolios, there were a couple of unique things. One is -- and Kirk recognized this from his Proctor days because he competed in all of our categories for most of his tenure there.

But what we would say is we tend to be daily use long duration, high frequency, high ring. And so because of that, consumers want a long-term relationship with our brands. And so we've invested a lot there in building digital social capability to have a continuous relationship with our consumers. We don't do the old-fashioned marketing acquisition anymore, right? We bring them in and they stay with us. I think a lot of other brands haven't done that, and it's been a little more difficult for some of the Kenvue brands to do that because the spend is not as great, right?

If you're buying Band-Aid, you're probably not spending $1,000 a year like you're spending on Huggies. And so we build those relationships, and we're able to bring other brands along like we're doing in some markets like, say, in the baby care life stage or in the women's life stage or in the senior care life stage, and so what we recognized is we serve the exact same life stages. We come at them from different ends, their pills and lotions and medicine. And then we come at with absorbing most of your bodily fluids, right? So it's a different angle, but we're really going after the same consumer. And so we felt like, gosh, we put their science and our engineering together, we can come up with some really great solves for the consumer.

Right. And as you've gone through more due diligence work, anything that's emerged that has excited you or maybe wasn't something that was on your radar screen as much originally?

Well, maybe the -- you may want to jump in, Nelson, but probably the biggest thing was the word geographic complementarity or the portfolio complementarity. I don't use 6-syllable words very often. I can barely say it.

Dangerous.

Right. But the degree of the complementarity of our portfolios is extremely high. I mean -- and the obvious one is on the geographic side. And from a revenue perspective, and it's funny, one of the directors said, well, I don't really usually put much stock in the revenue synergies, right? But this is one where it's pretty clear. You might say, hey, revenue synergies tend to be a little ephemeral. But our experience, and Nelson was in the Asia Pacific chair when Kraft bought Cadbury.

And in Asia, we had struggled with Oreo distribution in India and in China. But when the Cadbury came into the system and LU came into the system, which had great distribution, and you may want to talk about it, Chris, in China, those brands went from low, low, low double-digit millions of revenue to triple digits, pretty solid triple digits pretty quickly. And so for us, maybe the one that was shocking to us was in our largest markets, there was a high degree of complementarity.

So for example, on the Kenvue's side, Europe ends up being a pretty big market for them. After our spin of our international family professional business, we'll almost have no business in Europe. And so -- and not only are they strong in Europe, but they're also a multibillion-dollar business in Europe, but also really strong in the pharma channel, really strong in the medical channel, which is areas that we didn't have access as much to. So that's one.

Second, for them, India. We struggled -- we used to be in a joint venture with Unilever. We struggled on physical distribution since. We're doing fine online, but Kenvue is in 3.1 million out of 5 million points of distribution in India. And so that one is going to be an exciting opportunity that we all got excited about.

If you flip it around, where are we really big? KC de M xico is a $3 billion business. They're a couple of hundred million in Mexico. And so we've got all these markets where Korea for us is a very large business, it's smaller for them. China, we've been, as you know, doing very, very well, and they've been struggling a little bit in China. And so it just felt like there's a lot of fast opportunities to work really aggressively on driving distribution of the portfolio brands -- complementary portfolio brands to build both businesses.

Great. That's helpful. And Nelson, maybe we can turn to cost synergies from revenue synergies. The target as a percent of Kenvue's revenue sits at the high end of what we've typically seen in CPG transactions. Why should investors feel confident around that level of delivery, especially given the limited overlap between the 2 businesses? What really gives you confidence there? And what's sort of behind those numbers?

Sure. So a few things. We built our acquisition model on a set of conservative assumptions that were thoroughly validated through the due diligence process. The nature of the integration, as Mike was explaining, the plug and play as well as the high visibility to the synergies give us high confidence to be able to deliver the $1.9 billion of cost synergies throughout the 3 years following the close of the transaction.

If we look closely at the portfolio, there are a lot of commonalities actually between the 2 companies, as Mike was stating. First is the geographic bid. Just to highlight, we largely operate in the same markets. And actually, in 80% of the markets, we're bigger. Secondly, we are serving a very similar amount of customers, both brick-and-mortar and online. So there's a lot of synergies to be had on that end. And then thirdly, there's a lot of benefits to be realized by joining our supply chain.

If we look at the process that we followed to come up with the synergies, a few things. One, we spent the time together with the team at Kenvue to validate all the synergies, both from a country-by-country basis as well as functions. We triangulated with external sources, and then we did this bottoms-up validation as part of the due diligence. The other bit is we took a top-down approach. And we looked at, as you said, CPG benchmarks, which run in the 8% to 9% range. But if you look at consumer health, average deals have been more on the 13% level with a few deals actually higher than that.

So if we look at the landing of our assumption, which is about 12% of net sales at Kenvue, that's spot on where we'd expect to land. The other bit to take into account is we've set aside in our modeling about $2.5 billion of costs to deliver the $1.9 billion of cost synergies. That's about a 1.3x ratio, which lands pretty much where benchmarks are at.

Great. That's helpful. Maybe can you take us under the hood a bit more in terms of cost synergies? What are really the key buckets? What are the key areas you're going after functionally?

So let me peel the onion a bit. So it's going to be 3 buckets. that will help us deliver. And actually, our expectation is to be ahead of the cost synergies that we've been communicating. And we are confident that we'd be able to deliver about 80% of those synergies within the first 2 years after the merge. These buckets are as follows: One, it's G&A overhead, which will drive about 40% of the savings.

And as you think about the drivers of the G&A overhead savings, 3 things to take into consideration. One is merging, synergizing corporate as well as some of the centralized functions. The second bucket that we would be driving is going to be within G&A. The fact that we're going to be driving joint efforts around real estate, office space, et cetera, and that's going to be in that space. And then the third bucket is around non-people-related costs. Think of systems, HR, finance, all of that will be one.

The second bucket that drives these synergies will be procurement, and supply chain and distribution. So as you look at distribution and network design for the products that we distribute, take into account that, one, we have developed very strong digital tools that have been driving significant savings in our procurement organization.

Secondly, as you think about distributing products together, Kenvue's products tend to weigh out pretty quickly on a truck. Ours tend to cube out pretty quickly. So by optimizing mix, that's going to drive benefits. And then the other bit is that within supply chain, we've been driving over the last 2 years best-in-class productivity, as Mike mentioned. We've been delivering about 6% gross productivity in 2024 and 2025. And as we bring to bear these capabilities, that will support this delivery.

And then the last bucket of savings for the synergies is in sales and marketing, which will drive about 30% of those savings. And in their examples, you have, one, trade spend optimization. We've been doing a lot of revenue growth management buildups and capabilities in the last few years. We'll bring those capabilities to bear. Secondly, when you look at nonworking media spend, our ratio is about 20%, Kenvue's is 40%. So there is room for us to do savings there.

Thirdly, eliminating duplicate customer teams by bringing best of both in both sales and marketing. So as you look at that, those savings would be there. And then the last bit that I'd leave you with is we expect those savings to flow to the bottom line because as we did the modeling, the base plan for Kenvue, excluding synergies, we brought it down by around 200 basis points, the EBITDA margin for 2027 versus what you would have seen in consensus right up to the moment that we announced the transaction because we are planning on the base plan for Kenvue to step up investments in both R&D and marketing.

Okay. Great. You mentioned you're not necessarily stopping at your targets, right? You're looking to generate upside. Where do you see the potential areas of upside from a cost synergy standpoint? Is it mainly within the buckets you mentioned? Are there certain areas you're not putting into your original synergies? Just thinking about where there could be upside potentially.

And if I just interject with -- just the one thing I'll add leading up into that, Dara, and it applies across G&A and the cost of goods set of costs, which is the paradigm, we tend to operate in lower gross margin categories, right? And so because of that, we've held our organization standard to be the most efficient, right? And so we're proud of the fact that we operate on a very lean basis. Our G&A levels tend to be -- are mandated internally by us, I guess, to be top quartile, right?

And so -- and that's a very different perspective than what we learned in our discussions with Kenvue management on, they tend to be higher on that G&A form. Some of it because coming out of that spin, maybe their systems and staffing weren't as fully developed. But I think therein lies, I think, where some of that upside opportunity is going to come from because, again, you're marrying up a lean organization with one that is a little less lean, and we're going to find a way to get lean.

And just for reference, I think to kind of understand the order of magnitude on the G&A side, if you look at SG&A and you take out R&D and the marketing pieces, we tend to be in the 11.5% to 12% of revenue range. And I think they're closer to about...

17%.

17% right now. So there's a lot of space in there.

So it's in those buckets. I mean, at the end of the day, it's in those buckets, the benchmarks clearly point to the opportunity. And we -- as Mike said, we've been doing that for many years. We have lean structures that are able to operate very effectively. And that's why we feel that there's upside actually to the savings.

I think on the revenue piece as well, when you look at the revenue synergies that we've laid out, the complementarity is just -- geographic complementarity makes up the vast, vast majority of the revenue synergies that we've laid out. But as we look longer term in terms of bringing the R&D together and what you can do in terms of adjacencies and leveraging the know-how of each side, our expertise in materials, their expertise in more of the molecules, if you will, that really hasn't been built into the revenue synergy piece.

Great. Mike, you mentioned the great brands on the Kenvue side. They've had more of a tough time since the separation. What's your plan to revitalize the brands? And what gives you confidence in your ability to do so?

Confidence in the ability -- well, it's because I've been in the exact same shoes, probably worse. You were covering us in 2017, weren't you? Do you remember those days?

Yes. Yes.

Do you remember how bad that was for me?

Yes.

That was my first year as Chief Operating Officer. I think at the half, I think our business revenue -- revenue in North America was down 7% that year. There was a diaper war happening and all others, you may recall. But beyond that, I would say tough performance and worse than what Kenvue's performance is now. I think I said on our post-announcement call, I had 23 reporting units, P&L units reporting in at the time.

This is my second quarter as COO, 22 of them were declining, right? And so I kind of been exactly in these shoes. What was the core problem? I mean, one, there was a competitive issue, but that wasn't the biggest thing. I think the competitive issue knocks you off your plan, your game a little bit. And then what happens is the organization was kind of conditioned to deliver OP or EPS. The company is very focused on EPS growth.

And so when you are operating in that mode, some of the growth muscle goes away over time. And we've been operating in that mode for quite a long time. I think in our discussions with Kenvue, I would say the symptoms are the same, right, which is -- and you've covered them for a long time. I think internally, maybe there was more of a cash focus while they were under the corporate banner of the preceding company. But coming out of the spin, I think a pretty strong focus on the plan, EPS growth and all those things. And so I would say some of that growth muscle had eroded.

And so what became clear in our discussions that we had with the Kenvue management team is we have developed approach. I mean coming out of 2017, we said, hey, we got to found a way to grow the business profitably. And at the same time, we're going to build world-class consumer capability to kind of manage the business more effectively longer term. And so we talked about with the Kenvue team is, I'd say we have a readymade approach to get companies on a virtuous cycle and get off of that vicious cycle, right?

And so it becomes, what are those things? One, it starts, and this is probably the most important one, getting the organization into a growth and accountability mindset, right? They have to have clarity on who owns a number, what they're accountable for, and they -- you got to be able to count on them to deliver. And that's harder than it looks, but it's like the prerequisite for everything. You can't do anything until you get that.

Second big thing is that we talk a lot about is maybe taking the time to have the skill and the will to invest for impact. I mean, because people pop in investment on things and then you kind of wonder where it went. I think what we did, even in those darkest days of 2017, we made some big technology investments. We identified where the growth drivers in our personal care business is going to be, where the big demand spaces that consumers would feel like would be worth paying more for over time.

The reason we're winning right now in the last couple of years is because of this Gen 3 diaper that we've been talking about that we invested in initially back in 2017. That's when we laid the bet. And so it's like you have to have the conviction, you have to have the insight, you have to then set the money aside and let the teams work. And so I'd say we've developed that skill and will, not just in technology, but also in the marketing front, the sales execution front, the investments we made to build a great productivity -- world-class productivity pipeline.

So I think that's the second big thing. And then the last one is maybe the hardest one, but it's mostly his job in mine, which is then we have to set the right investor expectations and be willing to take a punch and maybe make you guys not so happy with us so that we can continue to invest and create that virtuous cycle.

Great. That's helpful. Maybe I can tie that back to revenue synergies a bit. Just I think one of the lessons we've learned historically, you go back decades in CPG, we all do on stage, is sometimes when you bring 2 entities together, there's incremental opportunities, but sometimes you get base business distraction. So how do you guard against that on the Kimberly-Clark side and the momentum you've created behind the innovation and the other areas that you mentioned?

Yes. Well, we're really excited about our plan. And I've been saying publicly, gosh, our innovation in the next 10 years is going to be way better than the last 10 years. And next year is going to be better than this year. And so we feel very good about our pipeline across the board. And that's pipeline of innovation, our pipeline of marketing ideas, our pipeline of productivity ideas. And so I think for the KC side, all we're asking our organization to do is just keep running that play, right?

And yes, we -- one of the key things, and we started just this week on our initial integration management office meetings with the Kenvue team -- our team and the Kenvue team, and one of the things we said is, "hey, they have a strong plan that they're excited about, we have a strong plan, we got to keep our teams from being distracted, right?" But the next sets of things is I think we have to be very surgical about realizing the cost synergies, which is a fact of life for what we're trying to do.

But we also want to get a great start on the revenue synergies. And we think, again, as I said, in the near term, there's some obvious brand distribution opportunities in markets like Mexico for the Kenvue brands, Korea for the Kenvue brand, India for us, leveraging the Kenvue capability. And so we want to really get behind those and prime the pump on those. Obviously, there's no gun jumping, so we won't be doing anything before the close, but we can plan for that.

Right, okay. And then on Tylenol, there's clearly been some external noise around the brand, and that's impacted consumer sentiment to some extent, got the talk, exposure in Europe. So just level of confidence around those risk points as you do due diligence here and what gives you confidence that those risk points are manageable?

Yes. So I've got a fairly experienced and seasoned Board, you might expect. So Sher McCoy, our Lead Director. She grew up in R&D at J&J Consumer. And then she was the Vice Chair of J&J Consumer. We have Deeptha Khanna, who ran the Global Baby business at J&J. I've got Joe Romanelli, who was at Merck in the pharma business, so he understands that side as well. And then Sylvia Burwell, who was the former Secretary of HHS.

So I'd say, given those players, they know the company to some extent and also know kind of the medical science world, their expectations for due diligence were pretty high. And so we retain what we would say are the foremost experts from a legal perspective, medical, regulatory perspective, we brought in Ted Boutrous from Gibson Dunn, who's typically considered one of the top litigators on these types of cases in the U.S., Arnold & Porter, who has a lot of regulatory experience, especially with the FDA and brought that to bear. We had Hilary Marston, who was the former Chief Medical Officer of the FDA advising us.

And so that team kind of put together, took a part, I would say, everything starting with the science. And I would say we felt convicted and staying with Kenvue that the science is clear, and we believe it's safe and the safest alternative, which I think the FDA has actually said in the last couple of weeks that remains the safest alternative for pregnant moms to use. And they also, I think, said that there has no -- not been a causal link established between autism and the use of acetaminophen. So we went clinically through the scientific research on a case-by-case basis. And so -- and I would say Dr. Marston was pretty clear in terms of her opinion on that side.

And then similarly, we went case by case on all the plaintiff cases that you could say are precedent type cases. And so the only thing -- I won't give you a number as to what we used in our calculations, hopefully, the investors would understand I would pick it up in the same way that you might, which is in my head, I'm calculating expected value, right? And so what I would tell you is that there's no scenario that we came across that where the liability would be greater than the synergy creation -- the value creation of the synergies.

Right. Great. That's helpful. So looking at the Kenvue portfolio, there is an underperforming tail piece of the portfolio. Obviously, there's some very large brands with great brand equity, but there's also a tail. Just as you think about the combined businesses and look out 5 to 10 years, is there further opportunity in your mind to sort of prune or reshape the portfolio, whether it's tail brands or potentially sort of unlocking value when you look at the Kenvue brand portfolio? How do you think about that holistically?

Yes. I can take that.

Yes.

So a few things there. I mean we remain very disciplined and focused on driving and creating long-term shareholder value. I think we've clearly demonstrated that over the last few years, Dara. So if you look at the moves we've made in our portfolio, starting with in 2023, we sold our Brazilian tissue and professional business. Last year, we sold our personal protective and equipment business, we've exited about $650 million ongoing private label business. So our exposure for the remaining portfolio in private label is going to be de minimis going forward.

We recently announced the creation of a joint venture with Suzano, which we expect to go into place right around midpoint of next year, which will leave us with a company that has exposure to higher growth and higher-margin categories. So we've been very disciplined. As you look at Kenvue, first, I want to be clear, we like the categories we're in, we like the brands that they have. Having said that, there's always opportunities to optimize the portfolio in order to be driving better shareholder value.

The team at Kenvue, as you point out, the leadership team is already executing a strategy on that regard. And what our conviction is as long as it's driven by driving and ensuring that long-term shareholder value is protected and created, that's the approach that should be taken. So no different to the playbook we have today.

We've spent a lot of time on Kenvue. So maybe let's get to the base business. First, just -- look, the consumer environment is difficult. We've heard that from CPG companies at this conference pretty consistently over the last couple of days. Just give us a little bit of update on what you're seeing from a consumer sentiment standpoint. You're obviously in pretty defensive categories, but also from a promotional standpoint as you look at the reaction from some of your peers that compete across HPC in the U.S. and if there are any international markets you would point out?

Yes. I'll start with one that -- we still see a long runway of growth by elevating and expanding our categories over time. And I will stipulate, hey, the current environment, especially here in the U.S. or North America is tougher than it has been in the past. But our categories, we still see a long runway of growth.

And I'll tell you a couple of reasons why. One, we did see that the impact on the American consumer, especially on household incomes of $100,000 and below, were going to be tougher. And you could do the research and see where inflation has impacted the market basket of goods, where, hey, the stimulus payments ran out and savings rates have actually dipped below where they were pre-COVID. So all those things have happened.

We saw that coming maybe 2 years ago. And so what we did, Dara, and this goes back to the note that you published last quarter, as we pivot our strategy, even though our long-term strategy is to premiumize our category, and we've made tremendous progress. I think in North America, we went from it being a 40% premium business to 70% premium business over 10 years. So that's the core strategy. But that said, we want to lead. And so what we said is we have to have a superior value proposition in every run of the good, better, best ladder, and that includes the good tier.

So for us, like in U.S. Huggies, that would be our Snug & Dry tier or our value tier brand. And so what we've done, and you know, we've made a lot of progress rolling out our Gen 3 diaper, it's behind what drove us to market leadership in China. It's taken our -- I think we've grown our share in Korea and Australia separately by 15 points each. We're now in the 60s on share in those markets. And so every market that we take that Gen 3 diaper into, our share really, really improves. And so we brought that into the U.S. on Snug & Dry first this year, our Tier 4 or our value tier product.

And so I think that's what's really behind our strong vol mix performance this year. It's mostly strong volumes because we've cascaded our best technologies into our value tiers. And so we're really proud of that. That notwithstanding, the promotion environment has ticked up. I know Nelson is going to want to comment on it, but I will tell you that promotion is not a growth driver for us.

We see promotion purely as a trial driver on the innovation that we want to get in the consumers' hands. And so -- and the reason we do it that way, our philosophy is that is you know our categories there they go with a biological cycle. And so promoting them isn't going to make anybody use the products more, right? And so that's our focus is on driving innovation to grow the category, not by promoting our way there. But...

Yes. Let me just add a little color to kind of the environment that we're facing today. And I'll start with for the last 7 quarters, talk about 2 years, we have been growing volume and mix because we're meeting consumers where they need us. We sensed and we saw the pressure on consumer purchasing power a couple of years ago. And we pivoted, as Mike said, and we don't see today a catalyst in the short term.

As it turns and looking at the categories, categories in the last few weeks have been softer than we expected. That includes the U.S. But I'd like to highlight a couple of things. Our tissue business in North America has been growing despite a tough comparison versus prior year. But if we look at the discounting activity, particularly in diapers in the U.S., which we saw in the value tiers in the third quarter, it's kind of rolled forward into the fourth quarter.

We have been holding share. However, we've chosen not to participate in kind by promoting. What this translates into is as we look at the fourth quarter, our expected organic growth for the quarter should be more in line with the growth of the weighted average of the categories globally, which is right around 2%, and for the year, that would put organic growth slightly at or below that level. But the important thing is we are growing volume and mix. Our profitability remains strong. We are executing our investments in line with our plan, and we remain fully focused on having the best performing products in the marketplace at the lowest cost at every price tier, and that is our winning platform.

Great. That's helpful. Maybe to wrap up, Mike, we've seen share price dislocation since the Kenvue announcement, obviously, not uncommon in large deals. How would you respond to that reaction just in terms of your viewpoint on Kimberly's ability to drive shareholder value from here going forward?

All right, Dara. Don't shoot me if it seems flip. I'm going to say, hey, it's a great buying opportunity.

Okay.

And why don't I say that one, I would say, hopefully, you get the conviction. We feel great about our base plan and our innovation and our marketing pipeline, our productivity, how money comes. So we feel very strong about that. I feel like the combination with Kenvue is going to give both companies together the opportunity to provide extraordinary everyday care.

But I would say a couple of years into the combination after close, we expect to be a company that's going to have top-tier margins in CPG and growth rates on the top and bottom lines that are as good as anyone's or better, right? And so -- and that would warrant, I think, a stronger valuation than where both companies sit today. And so we're really bullish on the whole premise of the logic of the transaction. We're very excited to partner with the Kenvue team to build a better business.

Great. That's very helpful. Well, with that, we're out of time. So we'll wrap up. But thank you so much, gentlemen, for being here. We appreciate it.

Thank you for having us.

Thank you. We appreciate it.

Good morning. Welcome to today's conference call to discuss Kimberly-Clark's acquisition of Kenvue. [Operator Instructions]. With that, I would now like to turn the call over to Chris Jakubik, Kimberly-Clark's Head of Investor Relations. Please go ahead.

Thank you, and good morning, everyone. This is Chris Jakubik, Head of Investor Relations at Kimberly-Clark and thank you for joining us on today's call to discuss Kimberly-Clark's acquisition of Kenvue. As a reminder, this call is being recorded and a press release and slide presentation regarding today's news are available at the Investor Relations sections of each company's website. Before we begin, I'd also like to remind everyone that all statements made during the call that relate to future results and events, including the proposed merger, are forward-looking statements that are based on current expectations.

Actual results and events could differ materially from those discussed, and we will discuss some non-GAAP financial measures during these remarks. These non-GAAP financial measures should be considered a replacement for and should be read together with results. Please refer to the information on the forward-looking statements slide here as well as the additional information contained in SEC filings for both companies. Presenters on today's call include Mike Hsu, Chairman of the Board and Chief Executive Officer of Kimberly-Clark; Kirk Perry, Chief Executive Officer and Board member of Kenvue; Sherry McCoy, Lead Independent Director of the Kimberly-Clark Board; and Nelson Urdaneta, Senior Vice President and Chief Financial Officer of Kimberly-Clark.

At this time, all participants are in listen-only mode. The call will be open for analyst questions following the presentation. With that, I'll turn the call over to Mike.

Okay. Thank you, Chris. Good morning, everyone. It's great to be here with all of you. I'm excited to announce a transformational transaction that will bring together 2 iconic American companies to create a global health and wellness leader. Throughout our century-plus history, 1 thing has remained constant for Kimberly-Clark, a focus on developing science and technology to provide extraordinary everyday care. Kimberly-Clark's and Kenvue's combined brands carry deep meaning for billions around the world. For so many parents, Huggies and Johnson's baby shampoo remind them of when their kids were born. Our collective brands help parents raise their children and continue to play an important role throughout consumers' lifetime in moments of need and vulnerability. Together, we will be the largest pure-play consumer health company, caring for even more people around the world and delivering even better solutions to their important everyday needs.

At Kimberly-Clark, we spent years positioning our business for this moment. Today, we are a faster, leaner, pure-play personal care company, and we have industry-leading operational and brand momentum. As we've executed Powering Care, both on the portfolio and operations side, we've had our eye on how we can take this transformation to the next level. We're wired now for this next major step forward. We have the playbook, the experience and the team in place. We're no strangers to driving discipline, quality, productivity and efficiency. It's what we focus on every day. We'll unite these brands and the best scientific minds in a new home that will drive a relentless focus on innovation and rigor.

Together, we will achieve sustained global leadership and create a durable long-term value for our combined shareholders and most importantly, better care for a better world. We have an incredible opportunity before us to create the preeminent consumer health and wellness company. Our portfolios are highly complementary across categories and geographies. Our combination will drive growth, innovation and commercial strength, backed by a powerful commercial engine and a playbook that can scale globally. Our complementary capabilities and greater scale will enable us to move faster and accelerate our capacity to serve customers and drive significant efficiency. Both companies bring strong talent, and we will leverage our respective strengths to ensure 1 plus 1 equals 3.

We're going to be built to win with a best-of-both approach to the combination and we're united by purpose-led, performance-driven cultures with shared values. Together, we'll advance our mission to create better care for a better world. The result is significant value creation opportunity for Kimberly-Clark and Kenvue's shareholders. On Slide 6, you'll see how we stack up against our peers on a pro forma basis. When you look at sheer scale together, we will be a leading global health and wellness player with the wherewithal to compete, drive significant investment and win. The right side of the slide illustrates how bringing these brands together creates a truly comprehensive offering of consumer-centric care.

Together, we'll serve a broader range of consumers through every stage of life. Many of our combined products are used on a daily basis and complementary, which means we can enhance lifetime value. We'll be there for our consumers at every turn, and we see particular growth opportunities in Baby Care, Women's Health and Active Aging. But now I'll turn it over to my great partner, Kirk Perry, Kenvue's CEO.

Thanks, Mike. Since launching as a stand-alone company, Kenvue has made important progress to strengthen our foundation. Thanks to the contributions of Kenvue's talented team, we are now well positioned to deliver on our tremendous potential as part of Kimberly-Clark. This transaction represents the culmination of our Board's month-long review of strategic alternatives for Kenvue and one that we believe is a truly fantastic outcome. We are delivering significant immediate value to our shareholders, who will have the potential to benefit from substantial upside as part of the combined company. I got to know Mike and the team very well during this process. It quickly became clear to our team that these companies have amazing strategic alignment. This transaction joins 2 highly complementary portfolios comprised of everyday essentials that people trust and count on throughout their lives and teams who share a passion for delivering science-backed solutions.

We are confident that bringing together Kenvue's and Kimberly-Clark's strengths, capabilities, resources and geographic reach will empower the combined company to innovate even faster and continue to grow our brands. As a combined global leader in health and wellness, we will unlock the full potential of our portfolio as we serve consumers at every stage of life. I have closely followed Kimberly-Clark's evolution. In fact, my last 15 years at Procter & Gamble competed head-to-head with them, and I'm excited about our ability to leverage the strong operating foundation that this team was built to unleash the full potential of Kenvue's brands. What's more, both Kenvue and Kimberly-Clark are driven by a deep commitment to caring for people and making a positive impact. And we expect the combined company to create new and different potential growth opportunities for our employees.

I am confident Kenvue has a very bright future with Kimberly-Clark, and I look forward to working together to successfully complete this transaction and bring the 2 companies together. Finally, I also want to note that we released our third quarter 2025 results this morning and reaffirmed our outlook for the year. In light of the transaction, we will not hold our previously scheduled earnings conference call, but we have posted remarks to our IR site. On this call, we're excited to talk about this compelling combination and we look forward to discussing our results separately with analysts and investors. With that, I'll hand it back to Mike.

All right. Thank you, Kirk. Before we get into the transaction in further detail, I've asked Kimberly-Clark's Lead Independent Director, Sherry McCoy, to say a few words as her deep experience in this space and involvement in this process from the store has been invaluable to us.

Thanks, Mike. Kimberly-Clark is a 150-year-old iconic American company built on tested everyday essentials. In my 7 years as a Kimberly-Clark Board member, I have seen firsthand the power of our brands and the team's commitment to driving quality innovation. This transaction is a significant opportunity and one that I am personally very excited about. Bringing these 2 companies together makes incredible sense, and we'll combine -- we'll position the combined company to achieve great things on behalf of consumers and shareholders. My confidence stems from my history with the Kenvue business. I spent 30 years at Johnson & Johnson and know the brands intimately. They are powerful and valuable for the billions of people around the world who need them. Consumers feel a deep emotional connection to them. I know these brands have found a great home at Kimberly-Clark.

I began my career as a scientist and approach every business decision through that lens. Our Board reviews this opportunity in the same way that Mike and the team run the business and the same way that our scientists invent every day with incredible rigor, thoughtfulness and discipline. We came away with deep conviction in the value creation potential of this combination. Mike has recruited a world-class leadership team. I've watched them transform the business over the past several years and they are firing on all cylinders. Through its transformation, Kimberly-Clark has built the foundation it needs to take this next step. And Mike and the team have the right platform in place to deliver on this opportunity.

This management team will be outstanding stewards to nurture and reinvigorate everything that makes Kenvue's brands essential. Hand in hand with the combined company's amazing scientific talent, they will apply the rigor and discipline these brands need to get to the next level. Together, these companies will serve billions of consumers across every stage of life, and create a global leader positioned for the next 150 years. So Mike, back to you.

Okay. Thank you, Sherry. Okay. Now on Slide 10, you're going to see a snapshot of what Kimberly-Clark is today, a truly global leader in personal care and hygiene. We have scale and reach with 6 brands that generate more than $1 billion in sales annually and serving more than 1/4 of the world on a daily basis. We have a strong global presence across our categories in key regions. We're also demonstrating an ability to continue excelling, led by great innovation. We're executing with discipline through an innovation-led volume plus mix driven growth model, the breadth and scale of our market position is a compelling advantage for us that will only be compounded by acquiring Kenvue.

I want to step back and highlight just how far we've come in the past few years. Less than a decade ago, when I took over as CEO, our results and the valuation of our stock suffered from below-average organic growth, margins that were lower than our peers and earnings that were more volatile than they needed to be. Since then, we've made significant progress in accelerating our growth, growing our gross margins beyond what had seemed a historical cap of 35% and significantly reducing our earnings volatility. Now we started by focusing on elevating our categories, expanding our markets and building a more consumer-centric culture. 18 months ago, we took that transformation to the next level with the launch of Powering Care.

We've accelerated pioneering innovation, building our engineering -- on our engineering heritage to bring category-bending science-based products to market faster than we ever have. We've made strong progress optimizing our cost structure enabled by an integrated margin management approach. We've rewired our organization to become better, faster and stronger and have taken decisive action to focus on right-to-win spaces. Importantly, we've done this while fostering a purpose-led, performance-driven culture. Today, Kimberly-Clark is a business with higher growth, higher margins and lower earnings volatility but what we've achieved is just a milestone, not an endpoint.

As we've executed on this transformation, we've always had our eye on how we can take it to the next level. We're constantly looking for opportunities to progress faster and deliver more for our brands, for our customers, our people and our shareholders. And we're confident that acquiring Kenvue will be a catalyst to achieving just that. Our transformation has yielded a powerful value creation model that leaves us uniquely positioned to unlock the immense potential of Kenvue's brands. Bringing together Kimberly-Clark and Kenvue is a special opportunity for our companies and our shareholders. Companies like these can't be built overnight. These assets are unparalleled and the brand equity is vast. We will deliver on this opportunity by leveraging our ability to out-innovate, out-market and out-activate, paired with our cost discipline and manufacturing expertise.

We're driving organic momentum and gaining steam across our business. Every day, our focus is on out-innovating, out-marketing and out-activating our peers. We're introducing new innovations and premiumizing our categories bringing standout features to drive consumer preference across the good, better, best spectrum, across the categories and geographies we compete. We've raised our marketing game to reinforce love for our iconic brands as we build industry-leading capabilities in digital engagement and creative development. And we earned a #1 advantage score for 3 consecutive years, demonstrating our value to our retail partners. All of this is underpinned by a growth and accountability mindset, which we work to embed across the entire organization.

So on Slide 13, you're going to see the fruits of their work to instill a culture of accountability, discipline and operating excellence. On productivity and cost discipline, we are generating tremendous savings across our supply chain and now expect to achieve more than $3 billion in cumulative cost of goods sold savings by 2030. Just last week, we reported our strongest quarterly productivity level yet delivering savings at a rate of 6.5% of adjusted cost of goods sold. We're successfully executing 3 key strategies that help us deliver the best products at the lowest cost. We're optimizing our value stream. We've revamped our product platforms, raw material sourcing and manufacturing processes.

We're optimizing our network, driving efficiency, speed and lower cost across manufacturing and distribution. Our global supply chain organization is working hand-in-hand with our local teams to automate and digitize our supply chain. Importantly, we're confident in our ability to sustain momentum for years to come and bring these best practices to optimize the Kenvue footprint. Finally, we've enhanced our focus on right-to-win spaces through our wiring for growth efforts. On Slide 15 are some specifics on the significant moves we've made in the past few years. This includes the exit of about $650 million of private label contracts in North America, which will bring private label production to less than 1% of our ongoing sales.

Most recently, our announced joint venture with Suzano will sharpen our focus on our core personal care categories and reduce our exposure to highly variable fiber costs. All these actions also optimize our capital intensity and they're centered around creating a higher-growth, higher-margin portfolio. Taken together, we've made tremendous progress in a short time, our team is performing at a very high level and are well equipped for this next powerful step in our transformation. The acquisition of Kenvue is that powerful next step. As you've heard today, the combination of these great categories and great brands creates a global health involvement leader. We will apply the Kimberly-Clark management system to Kenvue, a lean, fast, agile operating model, disciplined management system and world-class commercial and cost capability.

We've built a world-class team and world-class capability to compete effectively in the toughest categories in CPG. We're confident in Kimberly-Clark's long-term path and believe our technology and innovation pipeline will continue to get even better. We believe we can create tremendous shareholder value by applying our domain expertise to higher growth, higher-margin categories. We're confident we can help Kenvue improve execution, will serve consumers better. Our high geographic complementarity creates outsized revenue opportunity. Our lean operating mindset will drive significant cost synergies unlocking significant capacity to invest back into the business and create significant shareholder value.

Kenvue is very well situated at the intersection of CPG and healthcare. They have strong talent and amazing brands. We have tremendous complementarity across categories in critical markets. And together, we will create best-in-class consumer-driven company. Kimberly-Clark will enhance the potential and performance of Kenvue's portfolio, uniting our proven commercial activation engine and go-to-market playbook with Kenvue's beloved brands will accelerate growth. We will harness our combined global scale to accelerate our capacity to search consumers and deliver efficiencies. With a broader product range and greater reach, we will be better equipped to invest behind driving household penetration and we will realize exceptional synergies that will fuel a powerful financial algorithm.

From the start, we'll be a $32 billion powerhouse generating approximately $7 billion in EBITDA annually. We'll have 10 iconic billion-dollar brands that touch more than 1 billion people across every stage of life. Those brands will be fueled by science-backed pioneering innovation that will continue to deliver new technology for consumers. To get the most out of these brands, we will leverage Kimberly-Clark's brand building and commercial engine. We've already proven we can do it at Kimberly-Clark and we'll leverage that experience as we bring in Kenvue. All of this leads to an attractive financial profile with greater scale.

Now on this slide, you'll see the range of large, essential and highly complementary consumer categories that the combined company will serve. We'll have deep reach and strategic alignment to capture -- better capture growth from both further premiumization and, in some cases, huge demographic tailwinds that are possible across these categories on a global basis. We know that consumers are increasingly prioritizing health and wellness, which now comprises $800 billion of annual spending. Kenvue's brands are among the leaders in attractive categories delivering outsized market growth, including over-the-counter, Skin Care, Oral Care and Wound Care.

Kimberly-Clark has exposure to structural tailwinds across age cohorts within each of our categories with significant growth across Adult Care, Baby Care, Family Care and Feminine Care. Together, we'll be well positioned to lead category growth over time in each of these areas. Over the past 10 years, we've built world-class CPG executional capability. We built the engine, and we're eager to deploy it to Kenvue. We developed the skill and the will to invest for impact. In North America, we're an execution machine. In the Advantage survey, we went from 26 globally when I started at the company to third globally this year and #1 in North America 3 years in a row. We've built a winning playbook that's enabled us to double our revenue and triple our profitability in China, the world's largest and most competitive market for our categories.

Bringing that capability and experience together with Kenvue will create a health and wellness leader with scale in key categories. Here you can see the many areas of opportunity for us to apply that playbook and complement each other's respective geographic areas of strength. The transaction will fuel growth in Kenvue's brands globally as Kimberly-Clark's capabilities are applied across the combined product range, and our commercial playbook is activated in more markets, for example, Mexico, South Korea, India and China. In markets where Kenvue already has strong business, for example, India and Western Europe, applying our commercial playbook to our brands will take our combined market position to new heights. With that, I'm going to turn it over to Nelson and he'll review the transaction and financial details.

Thank you, Mike. I'll start by expressing how excited we are for both companies and the tremendous opportunity we have to create lasting value from this combination. We have a clear path to delivering exceptional cost and growth synergies that we expect to total $2.1 billion of EBITDA, net of a meaningful level of reinvestment back into the business. Our synergy's realization will be bolstered by the work we have already done to rewire our organization and to optimize our margins. Driving cost discipline, productivity and efficiency is what we are doing so effectively through Powering Care. We have built the capabilities for this moment. We have a fit-for-purpose operating model and high conviction in our ability to achieve these targets. This includes approximately $1.9 billion in cost synergies and approximately $500 million in incremental profit from revenue synergies, of which we will reinvest approximately $300 million. We expect to realize the cost synergies in the 3 years following closing, while revenue synergies are expected to be captured within 4 years.

Turning to the next slide. We show the breakdown of where we see opportunities to unlock cost savings across the combined enterprise. Through our diligence process, which included teams from both organizations, we've done an extensive bottoms-up analysis of every cost package, from procurement, to conversion, to sales, distribution and overheads. Result of this process is a well-balanced and robust set of opportunities across cost of goods, sales, marketing and trade spend as well as G&A.

In each of these areas, our Powering Care strategies have given us both a strong foundation of capabilities and momentum from which to build. In productivity, we will leverage our integrated margin management capability and discipline on pricing net of cost to drive industry-leading productivity, having already identified potential gains in procurement and distribution. In sales, marketing and trade spend, we'll leverage our commercial playbook and sales talent across categories, rationalizing and deduplicating systems and processes, so we run lean and fast. And as Mike mentioned, we will adopt our balanced matrix approach to the organizational design, to ensure that we have a fit-for-purpose set of global functions that are there to support local markets in executing with excellence and speed.

To drive these savings, we project onetime costs of approximately $2.5 billion in the first 2 years following the close of the transaction. As we bring together an exceptional portfolio across complementary geographies and consumer need states, we will accelerate growth for the combined entity. We will pursue opportunities across every stage of life where we will have excellent consumer value propositions, enhancing our ability to serve customers. We plan to reinvest a meaningful portion of the revenue-related profit synergies to fuel Kenvue's brands and drive market-leading growth. Mike shared, we see opportunities to scale each other's business in key geographies, where one of us has a stronger foothold. Turning to the next slide, The transaction values Kenvue at approximately $48.7 billion.

Upon closing, Kenvue's shareholders will receive $3.50 in cash and 0.14625 Kimberly-Clark shares for each Kenvue share, representing total consideration of $21.01 per share. The total consideration represents an acquisition multiple of approximately 4.3x Kenvue's last 12 months EBITDA or 8.8x including expected run rate synergies of $2.1 billion net of reinvestment. Current Kimberly-Clark shareholders are expected to own approximately 54% and current Kenvue shareholders are expected to own approximately 46% of the combined company on a fully diluted basis.

Upon closing, the Kimberly-Clark Board of Directors will add 3 members from Kenvue. We expect the transaction to close in the second half of 2026 subject to the receipt of Kenvue and Kimberly-Clark shareholder approvals, regulatory approvals and satisfaction of other customary closing conditions. The transaction is structured for financial flexibility, consistent with our long track record of disciplined capital management. The structure of this transaction is designed to allow us to delever on an accelerated basis to levels consistent with our current credit rating.

Importantly, as the vast majority of the consideration is in stock, we will be taking on a very manageable increase in leverage. In addition, we will deploy the meaningful upfront net cash proceeds from the formation of our international family and professional joint venture with Suzano to help fund part of the cash consideration. We are targeting a leverage ratio of approximately 2x EBITDA to be achieved within 24 months post close, which is consistent with our current credit rating. Until that target leverage is achieved, share repurchases will be limited to offsetting dilution from equity compensation.

Finally, this transaction will not only enhance our financial profile but it will unlock a powerful financial algorithm to drive significant shareholder value. We start from a strong foundation, built upon pro forma annual net revenues of approximately $32 billion and $7 billion of EBITDA presynergies. We've built our financial outlook on a conservative set of assumptions, including a gradual recovery in Kenvue organic growth, back towards its weighted average category growth, meaningful investment levels on the base business and 3-year and 4-year time horizons on cost and revenue synergies, respectively.

At the same time, the magnitude of synergies we expect to deliver should result in no more than mid-single-digit EPS dilution in year 1 and deliver solid EPS accretion in year 2 following the close of the transaction. And we will be well positioned for long-term sustainable returns thereafter, driven by adjusted organic growth ahead of the weighted average category growth in the markets in which we'll operate, adjusted top-tier operating profit margins. top-tier constant currency EPS growth, all of this resulting in double-digit total shareholder return.

Again, we see this as a tremendous opportunity to create value for both companies and our respective shareholders. I'll now turn it back to Mike for a few closing thoughts.

Okay. We believe that Kenvue is the perfect partner for Kimberly-Clark. We share common values and a common vision to deliver superior care for billions around the world. Our combined brands are enduring trust and carry deep meaning. This is at the heart of what will make this combination so powerful and why we have such high conviction that together will create significant value. For both companies, this is the right transaction at the right moment. I want to reiterate how deeply excited we are for the opportunities ahead for our shareholders, our consumers and customers, employees and our communities. We thank you all for joining us this morning. And with that, I'd like to open up the line for questions.

[Operator Instructions] And our first question for today will come from Nik Modi with RBC Capital Markets.

So I guess 1 question for you and 1 question for Kirk. Mike, can you just maybe help us understand as you're doing the due diligence, like what gives you the confidence that you can actually turn some of the Kenvue -- struggling Kenvue brands around? And if you can be specific in terms of kind of how we should think about it based on a lot of the capabilities that you've been building over the last 5 years or so. And then for Kirk, maybe just help us understand kind of organizational priorities between now and close. Just if you could just give us some direction on kind of how you're thinking about it.

Yes. Actually, Nik, I'm going to ask Kirk to help me answer the first part as well because that's the whole basis for the idea here. And we had an initial conversation and I proposed an idea, but I think we had to understand what -- I didn't exactly understand what was challenging the company, right? And so -- and I think in our discussion, I think what Kirk's kind of initial assessment of why the company was struggling was really centered around executional discipline. And I will tell you Nik, I would say executional discipline is our core strength. And hopefully, that you've seen with us improve in that area over the years. And I think in the last couple of years, I think we've been executing a very, very high level.

I just -- I did want to say, well, first of all, Kirk knows I think this -- I thought he did a fantastic job on his first earnings call with some difficult numbers. I will tell you, and I told this to Kirk, I've walked the marathon in his shoes because I was in the same boat on my second earnings call. Nik, you may remember July of 2017, and you guys don't know this, but I had at the time when I was the Chief Operating Officer was my second earnings call with Kimberly-Clark. I had 23 operating units reporting. We were down in 22 of them, and our largest operating unit, North American Baby Care was down 7% at the term. right?

So very tough times. Of course, when I met Kirk, I tried to blame him, but he told me he had already been long gone from P&G at the time. But in any case, hey, from those troubles, and you -- those numbers on an order of magnitude, those are more than what Kenvue's experiencing right now. I will tell you that we put our heads down -- and we said, "Hey, we're going to fix this plane while we're flying it. We're not working just to get a business performance result. We're going to build a world-class company." And so from there, one, we made long-term investments on breakthrough technologies, some of what you're seeing now like our Gen3 Core, but some is still coming, and that our customers know about, Kirk knows about, but we haven't shared broadly with investors yet.

I think we've shared at -- maybe the last -- a little bit more at the last couple of investor conferences, okay? Second, I'd say we've built an advantaged social marketing model that has really helped us double our revenue and share in China, the world's largest and competitive market for our categories. We've built, as you saw on the slide, a top-rated customer selling organization and that's been rated by our leading retailers. And then a supply chain as you see with our productivity that really is focused on delivering the best product at the lowest cost. So we have that capability. And on top of that, I would say the management systems, the information, the visibility and the growth in accountability mindset that I think in our discussions that I think Kirk saw value in. But maybe, Kirk, I'll let -- maybe I'll let you talk.

Thanks, Mike. I would tell you, Nik, on the first question, as we looked at this, there was such a significant wealth of capabilities that Kimberly-Clark had built over the last several years. As I mentioned earlier, I competed with these guys for 15 years head-to-head.

Nik, he was clear he was beating us when he ran.

Yes, I was beating them. But we -- so I saw it firsthand and now several years later, just the efficiency through which they have done this. And so as we think about the challenges we have at Kenvue around things like our go-to-market strategy in terms of what we have there, thinking about things like revenue growth management for one, Mike talked about category management with Advantage Solutions being the #1 rated company in North America, huge capability there, e-com, another capability. These guys are juggernauts in China. I mean it is a machine and their ability to drive that across the rest of the globe is very evident. That's another insights and brand building. And we talked about this on my first call in August, is really having that capability.

We have it in pockets, but not at scale. And so what this does enables us to significantly pull forward those capabilities into Kenvue brands. We'll talk more next separately on our Q3 results, but we had a really good October that really helps us feel confident that we're putting those things in place. And as we move to close on this transaction, we'll be even in a stronger place. But the second question was what are the priorities as we go forward. I mentioned in August, there were 4 things I was focused on: leadership, second was strategy, the third was our structure operating model and the fourth was execution. Those will not change.

In fact, today, we announced some leadership changes. I became the permanent CEO of Kenvue which means I'm going to carry this through the transaction to make sure that we're staying on course and delivering what we promised. Now it's Carlos De Jesus running our North American business; and John Halvorson taking over as our Chief Digital and Marketing Officer. Strategy. We're going to be super focused and strategic as we go forward. We're not going to be everything to everyone, but we'll talk more about that with you all in the analyst community in terms of what our strategy is. By the way, a great dovetail with where Kimberly-Clark is today.

Our structure operating model, we're going to make some changes, which make it crystal clear who the decision-makers are and making sure we have end-to-end accountability. Again, almost a perfect dovetail with where Kimberly-Clark is now and a relentless focus on our execution. So those are going to be the priorities that we have as we move from now to close to make sure that we're consistently delivering on the results that we should be delivering on with the core brands that we have.

Yes. Nik, maybe I'll add, Kirk, I maybe a little of -- we know and we're excited about Kirk being the permanent CEO because we know he will move in the right direction. I have many people that work for Kirk when he was at Procter and they always tell me, Kirk is the best leader they've ever worked for. Just so you guys get that. The other thing that should give you some reassurance, Nik, is if you listen to what Kirk is describing, it's exactly the challenges we had. I mean we're very similar companies historically. I'd say a lot of decentralization, which has a lot of pluses, but has its drawbacks, right? And so -- so decision-making historically dispersed. Lack of clarity on who owns the number, you heard Kirk mention that. We've been through that too. And then also the thing that we also talked about was like us, I think, Nik, you may remember us, we were probably a little too earnings focused in our past.

And I think Kenvue and maybe even within J&J and Consumer, had a similar perspective. And so what that -- you start to atrophy some of the growth capabilities when you do things that way. And so we've been -- and when I said I've walked a marathon on those shoes, it's exactly the whole journey that we've been on. And that's why I'm so confident that we can work together and really help the Kenvue brands really take off.

Next question will come from Lauren Lieberman with Barclays.

Two sets of questions. So first is just piggybacking off of just your discussion pointing out, Mike, some of the similarities between the companies historically. But there's also some interesting differences, right? Like Kimberly-Clark a much -- let me go back to historical, right, much more commodity exposed and sort of low gross margin, heavy CapEx, technical innovation and manufacturing, a very tight portfolio of brands, right? Kenvue's got a very long tail, I believe, that needs some cleaning up. I think Kimberly always had a pretty clear strategy, given the limited category footprint, right? So maybe been a little bit different by market. But at the end of the day, it was a pretty clear direction of travel given the categories in which you competes. Kenvue's very, very broad. So I wanted to talk about maybe some cleanup work that still needs to happen at Kenvue. How much, Kirk, do you think you can start to take on, I mean over the next 9 months, it might be a little tough. But I think that's a big topic because everything in the slide speaks to the big brands and arguably, maybe still too many geographies, but this is a very, very -- Kenvue was complex to begin with.

And now this becomes more complex for Kimberly-Clark to take on, which is a very different mode of operation, also, Mike, that you've been moving in, right? You've been trying to tighten things up. and now you're going to get very broad again. So -- and then I'll ask my second question.

Yes. Maybe Kirk, I'll start. I just -- the 1 thing I want to clarify is kind of like, hey, because this is kind of a different set of categories for us. That's clear. It's a different kind of pivot for us. I will tell you, Lauren, like everything that we've been doing in our transformation was designed to meet this moment. I mean that's really the focus like we've built a world-class team that's enabling us to win in the toughest Kirk, you would agree, the toughest categories. We're very confident in KC's organic path, right? And I'll be clear and you got some click further on this. I'm way more excited about our next 10 years and think our innovation for the next 10 years is way more than what we had in the last 10 years. And so I think we've got some big stuff coming on organically within Kimberly-Clark.

However, the strategic logic, Lauren, is I really wanted the company to have greater exposure to higher-growth, higher-margin categories. That's why we made some of the portfolio we moved with our international tissue business, private label, PPE, some of those things. But -- and then as we did an exhaustive diagnostic of the whole CPG universe and beyond the CPG universe. And I would say everything led us to health and wellness because the macro trends of the global population aging, right? So the U.S. population and developed markets are clearly aging. But even developing markets, are going to see that, and you're starting to see that impact.

And so for us, when you think of an aging global population, health and wellness has the biggest tailwind behind it. And it's just going to continue accelerating for the next 30 years, right, in that direction. So that was kind of some of the strategic logic. So then once you cross the bridge and say, oh, health and wellness. And I know you guys like have been under pressure and everything else. For you, for us, like Kenvue was always like the crown jewels, like the #1 name that we have been thinking about for a long time. And so -- and obviously, I think you know that the brands are so great. And so with that, I'll pause there and let maybe Kirk address some of your.

So on the brand question, you're 100% right. We talked about this back in August. We have 115 brands that are in the portfolio, 41 really are multiregional or global and represent the core of our business. And as we go forward, I think about it in terms of between now and close, back to my 4 priorities as I think about strategy and execution on the strategy front, we're going to be talking more to you all about this related to what it is we can really uniquely have a point of difference on with our brands, and that is around 3 things. One is the insights, true insights, not facts, not consumer -- accepted consumer but insights that open the hearts and minds of consumers that we build our innovation on and are marketing on. The second piece is claimable science-based advantages. And the third is healthcare professional recommendations. Those are our 3 nodes we call them, and we're going to be relentlessly focused on that.

If the brands don't fit into the ability to do that, obviously, we're going to look at ways to optimize our portfolio to make sure that we can focus on those 3 things as an example. Again, something we talked about our top 10 markets and top 10 brands in those markets represent north of 75% of our sales. So we're very concentrated. And we know that if we focus on them and we grow share on them, the rest will take care of itself. The other thing is from an executional standpoint, we know that and I mentioned this, our bottom 30% of SKUs that really bog us down operationally. We have -- we are actually implementing this now. We're reducing the bottom 30% of our SKUs in all of our core regions, which will allow us to focus on the bigger part of our portfolio and get a lot of the execution muck out of the way.

So we are going to continue to focus on that. So yes, there are things in the portfolio that won't fit long term. And as we get closer to close, we will obviously have more aggressive discussions about that.

Yes. I think, Lauren, I forgot to mention that part, which is the complexity, yes. I mean, I definitely see that Kenvue has a more complex product and geographic portfolio. The thing I'll also say as Kirk works through that prioritization process, Nelson and I are not strangers to portfolio complexity. We led the profit center, the biggest profit center at Kraft. In our grocery division, Nelson, we had, as I recall, 40 categories and 47 brands. And in our tenure, I would say, our performance of the division that when we were there was 4% top line and 10% bottom line. We knew we learned how to manage through that complexity. So I would say, yes. again, we want to have operational discipline look to have kind of an efficient portfolio, but there are ways to manage complexity efficiently as well.

Great. And then sorry, just 1 big follow-up or separate question really is just to talk about lawsuits and liabilities. So talk in the news more recently. I know with Tylenol, there's no new science, but there's certainly been headlines and noise. I just wanted to -- for you guys to comment perhaps on how that is factored into deal consideration and so on.

All right. Should I address the deal consider -- all right. I'll do that. I just want to make sure that, Lauren, that you know we reviewed this transaction in the same way that we run the business with incredible rigor, right, thoughtfulness and discipline. And so the Board carefully considered all of the risks and all the opportunities. And then we had multiple sessions with the Board, with the world's foremost scientific medical, regulatory and legal experts. And so going through that process multiple times, I think the worker firm that this is a generational value creation opportunity for both companies.

Yes. Well, I mean, Lauren, as you can expect, I'm limited in what I can say on litigation, but what I can say is there is nothing that is more important to us and the health of the people who use our products. And so on both the things you mentioned on talc and acetaminophen, we -- we've said this multiple times, it's on our website. We stay normally behind the science and the safety of our products. I mean, these things have been studied for decades, and we continue to stand by that science as the medical community does as well.

Our next question will come from Dara Mohsenian with Morgan Stanley.

So Mike, can you just give us a bit more insight for how this deal came together from a Kimberly-Clark standpoint? It's clearly a very sizable bet. As Kimberly been looking more for an entry into consumer health or another like growth for the company was looking for more global scale, a big focus? Is it more opportunity circumstances of the 2 companies coming together? Just trying to understand the decision-making process on your end and timing of when this deal came together. And the juxtaposition is versus the base business where you've been transforming the base business and seemingly a lower risk or more visible strategy there of sticking with the status quo. So it'd be helpful to understand more the motivation behind the deal from your standpoint on top of some of the attributes you're excited about going forward.

Yes. Dara, so great question. I will tell you definitely not opportunistic, definitely strategic. I was on with our top leaders at KC just before this call. I said, Hey, like this was always in the back of my mind, right? And -- and you could -- actually, you might see it's reflected in our Board composition and our leadership composition that I -- this has always been in the back of my mind. Not in the front, but maybe someday, right? And so this was always the -- Kenvue was always the bell of the ball for me. And so because of the great collection of brands and capabilities that the company has, as I mentioned earlier, we've been migrating our portfolio to focus on higher growth, higher margin personal care. And then within that, health and wellness to me was, by far, the most attractive aspect of personal care because of the macro trends of an aging population globally.

And so again, with the built-in tailwind, we wanted to increase our exposure and the other thing is -- and I think there's an important idea here, and this is something that I think Kirk sparked to the first time we talked, and I think it clicked with you right away, which is like the combination is going to enable us to provide comprehensive everyday care. And everyday is a Kenvue term was on adopting because I love it. The extraordinary power of everyday care is their purpose. And I wish I thought that myself. But we can deliver comprehensive everyday care way better than either of us can do on our own. Because the reality is, when Kirk and I got together was clear. We serve every important stage of life, and both of us do it from opposite sides of the category, right?

So if you think about it is our Baby Care and all things baby, women's care or feminine care. We do it through Kotex. They have a bunch of products that serve women. Family care more broadly. I think, Kirk, you guys probably would call that essential care, but it's essentially family care for us. It tends to be the tissue category for us, but much broader play. Active aging, which is the one that puts us on to the macro trend, right? These categories are continuing to double and the needs of aging seniors is going to continue to expand. So those are kind of like the big life stages that we really address. And there's probably more if we think harder about our portfolio.

But the interesting thing and where I think there's a powerful combination here is our brands in KC are very high penetration. If you're in the category, everybody is in it, right? They're high frequency, meaning you're using them every day, and then they're long duration. So if you're in Femcare, you're going to be using Kotex for 40 years. If you're in the pen, you're going to be using the pen for 40 years, right? Baby Care is probably the shortest but you're in our suite of products for maybe somewhere between 3 and 5 years, right? And so there is like long duration, frequency. There's a lot of expenditure for consumers. And so because of that, they want to have an ongoing relation with us. And that's why we really prioritize what Kirk was talking about, a digital, social, marketing approach where it's kind of a continuous loop that we have a direct connection with consumers. And so if you think about that social digital capability, we think by bringing more brands that address the same consumer segment that we can deliver a much higher standard of care. I don't know Kirk if you have any.

Well said.

Dara, I hope I didn't go off on the tangent there.

No, that was helpful. And then can we just touch on revenue synergies? How much confidence do you have there? You're both students of the CPG industry having been in the industry for decades what's made sense on paper in a number of deals in terms of revenue synergies has often proven more difficult than originally expected. So level of confidence there and really the key buckets within the revenue synergies and obtaining those synergies.

Yes. Dara, I can start and Mike jump in. I mean what was interesting is we sat down to go through the synergies, both on the cost side and the revenue side. I mean this is the first time I've had this happen where we had the entire leadership team sitting down and going through this, country by country, category by category. It became very clear because as you point out, revenue synergies are harder to execute than cost synergies because we've both been doing this a long time. But this is the first time I've ever honestly looked at it, where we started with a lower number, and we continue -- usually try to bring that 1 down for the reason you point out, but we continue to add to it because as we went country by country, category by category, the synergies were really terrific.

Just even as you think about our technical competencies in the background, us with molecules and Kimberly-Clark with paper and substrates and you bring those things together. That's just 1 example, and we don't want to give away all of our secrets in terms of revenue synergies, but they are low hanging and significant is what I would say.

Yes. I think there maybe a couple of things, and I was just telling my leadership group. We're going to be inventing new stuff to serve like this -- provide this comprehensive everyday care better, like better than we could because we were kind of trapped into our own different segments, right? But I think we can do a better job. So I think the products will evolve. I will say the immediate low-hanging fruit from a revenue synergy is the geographic complementary, right? We said it's a hard work for me to say, there's 5 syllables, I am a monosyllabic guy, but the thing about it, India, we struggled in India to build a distribution network. And so we're probably right around, let's say, $100 million in India, right? And they're a multitude of that. And they're -- I think, Kirk, I heard, as I recall, 3.1 million points of distribution in India, which is hard to build, right?

And so that will be great for Huggies and some of the other brands that we have. And so that's 1 example. The other example, it turns out are that I guess we have been -- Kimberly-Clark has high distribution and big businesses in a lot of markets where people still smoke a lot. And so I've never been so excited about smoking cessation and I think that's a good product to market. And that's what Kirk's CFO on it was like reading into my head, the whole discussion. And so -- because as you recall, like we have a large position in Indonesia. We have a large position in China, Korea, everything else. And so yes, there's a lot of -- those are just probably 2 minor examples, but we feel a lot of those opportunities.

The other thing I'll add is beyond the revenue synergies. And by the way, in our plan that we're presenting after Nelson laid out, we put in a pretty conservative number for the revenue synergies because we know the market tends to be a little more skeptical of those. So I would probably say, and Kirk, I don't know if you would agree we would intend to beat that And so that's on the revenue side. And then you didn't ask about the cost side, but I would say cost discipline. KC, we are a top quartile efficient overhead company, right? Our discipline is since our gross margins are a little lower than the average of the industry, we have to be the lowest on SG&A. And so we are, and we've always been that.

And so -- and I would say, and Kirk, you may comment coming out of a higher-margin pharma business, our observation, I think Kirk and Amit was that the cost structure for Kenvue is a little higher than for a CPG of the size. And so there's some opportunity there.

Yes, for sure. I mean our stand-alone focus would have been very much attacking that. But you're right. I mean we came out of a pharma industry where SG&A, COGS are just higher. And obviously, you all work in an industry where every penny matters. And so that combination is going to be fantastic.

And Dara, I think it's important also to highlight the fact that one, these synergies will be realized in the course of 4 years. And we are reinvesting close to 60% of the profit coming from these synergies back into the business. That's built into our business model. So to Mike's point, how -- the approach we've taken here, and as Kirk said, we spend time looking at each of the components, we are doing this reinvestment to also ensure that we're putting back money into the business to strengthen the overall profile as the 4 years progress.

Your next question will come from Chris Carey with Wells Fargo Securities.

Just 2 questions, please. So first, on Nelson, I think you mentioned mid-single-digit dilution. Is that inclusive of the proceeds that you'll be using from the IFP deal for this transaction. Said another way, does this change your expectations for the Suzano JV? Is that included in the mid-single digits? And then just secondly, can you just maybe balance this dynamic around the need to invest in relative to your confidence in the synergy target, how conservative or optimistic do you think the synergy target is? It's a fairly sizable percentage of acquired profitability. So just love a bit more detail on that front as well.

Sure. So let me address the dilution and the linkage to the Suzano transaction. So the linkage of the Suzano transaction, Chris, is solely because of the net proceeds that we project of $1.8 billion that when we announced the Suzano transaction, we were deploying the share buybacks. That's not going to happen because right now, with the transaction and in our approach, to being prudent on the balance sheet and the leverage and our commitment to our credit rating, we are going to deploy that to pay for the cash consideration. So that -- if you run the math, and we'll be happy to talk to you later, that is what's driving that bit of the dilution, but nothing else related to our assumptions on the Suzano transaction. That remains the same as what we had announced back in June.

Chris, you may want to repeat that. I think it was -- we didn't hear the second part of your comment.

Well, the second question was just confidence on the synergy number. It's a relatively big percentage of acquired profitability and just a bit more detail on some of the drivers.

So sure. So let me walk through the cost synergies. The cost synergies amount to $1.9 billion. And what we've done is a fairly detailed bottoms-up approach function by function. And this covers all elements of the P&L. So we've gone through distribution by market and we've come up with the synergies that this would drive. We've gone into SG&A line item by line item, looked at the structures of the 2 organizations and the geographies and come up with it. And the other bit is as you look at the overall phasing of the synergies, the cost synergies, we're doing these in -- throughout the first 3 years of the transaction, a little bit more of synergies coming in, in year 1, year 2, but the completion of the synergies would largely be achieved through the third year. As we compare it against further transactions, both in CPG and the healthcare space, all of the ratios that we had are right on benchmarks that have happened, and we looked at this in depth, both ourselves and with our advisers.

Next question will come from Javier Escalante with Evercore ISI.

A lot to digest here. I was expecting that Clorox would be complication today. So on the deal, right, the combined entity kind of like rough math, give you SG&A between 17% and 18%. And the portion of SG&A alone, right, which is about $750, takes SG&A to 15% around, which is still above the peer group. And I know that Nelson referred to the reinvestment. So I don't know whether this is -- given the scale of what you are doing, is this conservatism in terms of the savings target? Or this is net of reinvestment because it is not in the slide, this commentary that Nelson just made. So if you can clarify that? And then I have a question -- a common question to Sherry and Kirk because Sherry knows long time no speak. Sherry knows both companies and Kirk come from a highly centralized company like Proctor. So I would love to hear thoughts on that. But first on the pure math of the synergy, please.

I'm going to try. Nothing may have to correct me. But here's, I think, Kirk, where I think your analysis, Javier, is definitely correct and it's kind of our starting point. I think as we got into the due diligence phase, there are some things that they classify as SG&A that we didn't, we thought we were less addressable in that area. And so kind of our estimate here is based on an apples-to-apples, had a lineup of the P&L based on how we understand it.

Yes, that -- that's right. Yes, just different categorizations.

And then you mentioned also, it's related to this, but you mentioned also that there's going to be portfolio simplification. Is this portfolio sortification going to be on hold through next year because the transaction is not going to close in a while or it's going to start happening, say, the noncore assets like hair care, stuff like that is going to start being divested as we speak.

Yes, Javier. What I would tell you is we're going to continue to operate the 2 companies on a stand-alone basis until we close. And so whatever we need to do in the due course of business to make sure we deliver what we promise, we will do. So we're actively looking at the portfolio as we speak. And obviously, we were looking at multiple paths on this front. And so now that we've made this decision, we're moving forward with this. We will view it through that lens.

Okay. So the question is to Sherry and then for sure, Kirk, because you come from kind of like the opposite side of how conglomerates like this has been run, right? So Sherry, you know long time no speak, you come from Johnson & Johnson, right and is very decentralized. So was Kimberly-Clark and the whole point of both companies where they were trying to centralize to improve execution. So basically, when do you think that this decentralization helps to keep execution risk low? And then on the Kirk side, what do you see here, right, borrowing your knowledge from Procter that can be applied to this new entity, which is very interesting in itself.

Great to hear from you, Javier. As it relates to Kimberly-Clark and Kenvue, I think the similarities are that they are very consumer-oriented facing companies. People are very focused on in the market so that decentralization you talk about is still present in both companies. And I think it's important, and I think what Mike has done is really brought together a matrix approach where they have the right balance between ensuring that we understand what's going on in the market, the people are running their markets, but we're actually benefiting from the global scale and the capabilities in the center. And so I don't like to use the word centralization because I don't think -- I guess maybe because I grew up in J&J for 30 years, it's sort of like a bad word.

But I do think the idea of the power and the scale that you have by getting the capabilities at the center and then looking at how you wire the organization and have the connective tissue. So the people in the markets and running the categories understand how to drive that business is critical. But at the same time, they have the power internally in the central core. And I see that Kimberly-Clark perhaps, again, I haven't been close to Kenvue businesses in a while, but they may be further along in the journey in terms of getting that balance and getting that wiring right so that people can actually have the scale. Because to me, it's about having the customers the right science capabilities and then ensuring people can go off and do the right thing from a consumer product standpoint.

Yes. And I would say, Javier, for me, I've worked across very different models in CPG, tech and data and analytics. And any model can work. But to me, the models that work the best, and the principle I try to live by is as common as possible as different as necessary. And so there is a level of global scale that you get that benefits the entire company, but there is a customization locally that enables you to win at the local level. And so another concept that I've seen that works really well, and this is something we did at Procter, hard point soft points where you take those things that have to be common and they are just the law. But then the soft points are what has to happen locally to enable you to win. And I would tell you, 1 of our challenges at Kenvue right now is we're living in between, which is no place to live in the murky middle and so I think that's what Kimberly-Clark has done an amazing job of defining those hard point soft points that common as possible different as necessary focus that we're moving to now as we go toward the close of this merger so that when we come out on the other side, we will enable it to be a nice dovetail into what they've already done.

Javier, I know you're not asking me, but I can't resist to chime in a little bit. But if you look at our org chart, if you look at our org chart, it would probably look -- Kirk, -- it's a matrix. It's a regular matrix like everybody else so it probably looked pretty similar to P&G, right? I think the difference in ours is the spirit of ours, and I was explaining to Kirk, like our whole organization and this rewiring was designed to help the markets win. Like what we're prioritizing is like winning in the local market. And the markets have the P&Ls, they are the best to figure out how to win. But we want to leverage the scale as Sherry said. And so the functions are wired to help the markets win, but bring the best of what they see around the world at KC in to help that market win.

So again, we're not a centralized company, and we're not decentralized. We're kind of a little bit of a hybrid, but it's working for us because I'm seeing -- we're 18 months into our Powering Care and our rewire and everything else. The speed of which the transformation is taking place is a lot faster than I think any of us on our leadership team had foreseen.

And Kirk, remind me, the P&L responsibility in Kenvue was at the local level? Or was it at a brand level?

So it is at segment level. So we have 3 segments how your self-care, essential health and skin health and beauty.

Great. I think we're run past time here. So we'll end it there. Thanks for everybody for joining. And we'll be around to take any follow-up questions.

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.

Good day, everyone, and welcome to the Kimberly-Clark Third Quarter 2025 Earnings Call Question-and-answer Session. It is now my pleasure to hand the floor over to your host, Chris Jakubik, Vice President, Investor Relations. Sir, the floor is yours.

Thank you, and good morning, everyone. This is Chris Jakubik, Head of Investor Relations at Kimberly-Clark, and thank you for joining us. I would like to remind everyone that during our comments today, we will make some forward-looking statements that are based on how we see things today. Actual results may differ due to risks and uncertainties, and these are discussed in our earnings release and our filings with the SEC.

We will also discuss some non-GAAP financial measures during these remarks, and these non-GAAP financial measures should not be considered a replacement for and should be read together with GAAP results. And you can find the GAAP to non-GAAP reconciliations within our earnings release and the supplemental materials posted at investor.kimberly-clark.com.

With that, I will turn it over to Mike for a few opening comments.

Okay. Thank you, Chris. Good morning, everyone. Our third quarter results underscore the strong progress we're making to transform Kimberly-Clark into an industry-leading personal care company. Despite a dynamic external environment, Powering Care continues to power our performance. It's enabling us to deliver solid results and importantly, better care for a better world.

Our inflection to volume plus mix-led growth that began last year continued into the third quarter. Q3 marked Kimberly-Clark's seventh consecutive quarter of volume plus mix-led growth even as volume growth has been somewhat challenging to achieve across the broader CPG industry.

We're growing volume and mix because we're meeting consumers where they need us across the good, better, best spectrum, and we're well positioned to post similar growth in the fourth quarter. We held global weighted market share despite an uptick in competitive promotion activity in the quarter.

We're leveraging our scale to deliver more consistent profitability in a challenging environment. In the third quarter, we delivered consistent operating margin expansion and another quarter of industry-leading productivity, our strongest of the year to support reinvestment and profitable growth.

Our rewired organization is fast tracking the best of Kimberly-Clark across our markets. The promotion of Russ Torres to President and Chief Operating Officer is accelerating our momentum. I'm pleased to have Russ with us today for his first earnings call as Chief Operating Officer.

We're in the fourth quarter, and we're playing to win. We have sustainable momentum and the discipline and ingenuity to effectively execute our innovation-led volume plus mix-driven growth strategy. We're confident in our ability to unlock our long-term potential and deliver more value for our consumers, our team, our partners and our shareholders. So with that, I'd like to open the line for questions.

[Operator Instructions]

Your first question is coming from Javier Escalante from Evercore ISI.

Congrats on the strong results. I wonder whether you could give us an update on the competitive dynamics in U.S. diapers. When you spoke in early September, you indicated delays in marketing plans because of increased competition from retailers' private label and their Chinese imports despite tariff.

So did you resume marketing plans in Q4? What's the consumer and retailer reaction to it? And in a bigger sense, is there something you can do to steer the market away from a price war given that the U.S. diaper market will likely trend volumes flattish given low fertility rates?

Javier, great question. I would tell you, we saw increased competitive activity and uptick in activity earlier in the quarter. I would say our teams navigated it pretty well. And I would say your point around how we want to drive the business, I think I said it in my prepared remarks, our strategy is totally innovation-led. And so we're really focused on making our products better at every tier of the good, better, best spectrum. And I think that strategy, as you can see in our results, is paying off pretty well. But I'm going to ask Russ to comment because I think he's kind of closer to the action in North America and having just come out of that role. And so maybe, Russ, you may want to give him a little bit more detail.

Sure. Sure. Absolutely. Javier, Yes, I would say, overall, as the quarter played out, you're right, we did make the decision to move some promotional activity from the third quarter to late in the third quarter, mainly the fourth quarter. And so just the update on that is we are seeing solid performance in diapers in North America. And so I think that has worked out thus far.

So we gained 10 basis points of share in diapers in the third quarter, which frankly was maybe a little better than what we had expected, and we're up in share 90 basis points year-to-date. But I would maybe unpack a couple of topics just that I think are notable that may give you a little bit more insight to what you and everyone else might be seeing in the scanner data, and that's promotion activity and club would be the two things.

So let me start with the promotional activity. Just to remind everyone, I think we mainly see promotion as a tactic to drive trial for innovation. To Mike's point, we're very focused on driving innovation and brand building and cascading that innovation across every tier of the good, better, best spectrum. And we would say that overall promotion in -- across all of our categories within North America, and that includes diapers is well down versus our 2019 levels.

But you may see the promotional levels tick up as a result of that trial activity I talked about. And the reason for that is we've got a great lineup on innovation. We have probably the most active lineup we've had in quite some time across the good, better, best tiers. And just to remind everyone, we launched the blowout blocker earlier this year, HuggFit 360 and our Little Movers tier, which is doing quite well. And then, of course, we have a very significant improvement in the value proposition in our mainstream lineup in Snug & Dry where we've made great product improvements to improve softness and comfort and have introduced a superior core, Generation 2 core that will improve protection, and that's off to a great start from ratings.

So our strategy had been to really use promotion to drive trial because we know when people try the product, they're going to love it and come back. And so what you're seeing is probably an uptick in that promotional activity. But I would also point out that our promotional activity in general in diapers is lower than the category. And we'd expect that as we get through the trial period, that promo activity to normalize as we get through the fourth quarter and towards the end of the year. And so that's just a little bit of an explanation behind what you might be seeing there.

And then on the club mix piece, I just wanted to talk for a second about that. That you may see coming through as a little bit of negative mix headwind in U.S. diapers. And what's happening there, as everyone knows, is we've been experiencing double-digit growth in the club channel. And that really is in response to both the consumer shifting to the club channel as well as some changes in assortment that have positively impacted our business in certain retailers.

And so we are also, in parallel, driving premiumization. And so that's important, like the HuggFit 360 that I mentioned is going to drive continued premiumization and positive mix over time. So hopefully, that sheds a little bit more light on the situation.

Yes. Yes, it does. I have a follow-up.

You'll be proud to know that Chris' team sent me that chart that you drew up 3 times.

I'm sorry for that. But the one thing that I would love to hear is driving positive mix because this has been your focus for a long time, right? And from the retailer standpoint, what they're doing with the Chinese diapers is a positive mix, but not necessarily to you. So what are you seeing in terms of consumer reaction to the Chinese diapers versus your intro? Is there anything that you have learned so far that give you encouraging? Or is it makes it more challenging driving positive mix?

I may start.

Go ahead, Mike.

Just the one thing I'll say overall that we're starting to see is I think the brand interaction tends to interact more with private label. And so there's kind of a swap in and out at the same tier, but Russ, you may want to comment further.

Yes. I think we're doing a lot of things to drive positive mix. And I think overall, Javier, I would say we're very confident because of our experience around the world, including in China that we make great products and consumers respond to those. And that's what the testing data shows, and I believe that's what the market reaction to our current position is showing.

So while you may feel like -- I think retailers understand that they have to balance mix, but I think more broadly, what's happening is there's a value-seeking consumer out there, and the retailers are trying to adjust their assortment to help serve those needs, and so are we. And I think that's why we're seeing positive volume mix growth. And so I think we feel comfortable with our levers.

We're doing things on pack sizes and other areas. So we're still early on in the progression of that, though. So we're going to see how that plays out. And -- but I would say that given our experience globally and in North America, we're confident in our plan.

Yes. The confidence in our plan, Javier, comes from the fact that we're very confident in our technology and our product quality. We're competing with the low-cost diapers that you mentioned in other markets, particularly in Asia. And our products are superior, and we believe our costs are very, very competitive, if not better. So we feel good in our plan.

Your next question is coming from Lauren Lieberman from Barclays.

In the prepared remarks that you guys published this morning, you gave -- you opened the door a little bit to '26 and talked a little bit about momentum into next year. So I wanted to know if you could talk a little bit about the shape of the P&L in '26 and '27. I know you've spoken about the dilution assuming that the IFP JV kind of goes through as planned. But I think numbers are a little bit all over the place. So anything you could do to shed some light on shape of the P&L '26 and '27 would be really helpful.

Well, we're still in the throes of working through it, Lauren. So I don't -- I think it's premature for us to share too much, but I think Nelson probably can maybe make a few remarks here.

Sure. So Lauren, just to provide some perspective. And again, without getting into specifics on point estimates because we'll be providing a thorough outlook when we report our Q4 and full year results early next year. It is important to highlight that we continue to target organic growth ahead of our categories, consistent with our long-term algorithm.

At operating profit, we are in the midst, as Mike said, of building plans for the next few years that should deliver our long-term constant currency operating profit growth in line with what we committed to and looked at as our long-term algorithm. And this includes the mitigation of the stranded costs that will result from the IFP transaction that, again, we expect to close sometime middle of next year.

I'd also point out that we continue to be targeting to achieve our milestone on gross margin of at least 40% and an operating profit of at least 18% to 20% before the end of the decade, and we're tracking fairly well in that terms. And as you say, and as we get into the details of the outlook and how we think about it, first, EPS.

And in the next couple of years, we need to distinguish between EPS from continuing operations, which exclude discontinued operations from EPS attributable to total KC, which includes earnings from discontinued operations. So that's the first step. So for constant currency adjusted EPS growth from continuing operations in the next couple of years, all else equal and assuming that we close the transaction sometime middle of '26, we should see a step-up in growth in EPS, in EPS from continuing ops as income from equity companies would increase by approximately 30% year-on-year, and we'd also benefit from the use of proceeds for share buybacks.

Then the second item is adjusted EPS attributable to total KC, which, again, assuming that we close the transaction in mid-2026, then constant currency growth should be somewhat more muted as we see about half of the discontinued ops income go away. And then as we go into '27, all of it go away. In the near term, we're going to continue driving underlying growth consistent with the long-term algorithm, and we will see a partial offset because of the dilution that we've been talking about.

Your next question is coming from Peter Grom from UBS.

So I wanted to ask on North America. Just the performance in the quarter relative to what we can see in the track trends, it was a bit stronger. So I know in the prepared remarks, you talked about some hurricane shipment dynamics. But can you just talk about what drove the gap in the quarter? And then maybe as we look ahead, would you anticipate a similar gap as we continue to monitor the data here in the fourth quarter?

Peter, maybe that's a good topic because I would say in our discussions, I think the source of data you look at is very -- it tends to be very different from our data, and so I know there's different analysts use different sources. The thing about our business, we skew to a few larger customers that are untracked or not well tracked. So even if Russ, club is in the system, depending on what source you're using it, maybe panel data versus what Russ is getting as live feeds, right?

Absolutely.

And then let me maybe just unpack a little bit the numbers. And I think two things from there. I mean both scanner and the reported results, we are seeing sustained momentum from all the innovation and activation that we're doing across the markets in the U.S. and the categories.

Focusing specifically in North America, I think it's important to highlight that from a year-to-date standpoint, shipments are largely in line with consumption. And as we've said, you're always going to see some noise quarter-on-quarter. And specifically for Q3, as we stated in our prepared remarks, what you're seeing is two things playing out.

The first one is lapping last year's hurricane-related impacts on shipments, which drove around 50 basis points year-on-year. And then the second item, and we've been talking about it and Russ mentioned it a little earlier today, is the timing of the promotional expense, particularly year-on-year. And that drove a timing on the realization of those promotional activities. So those are largely the two items that would have had overall shipments or organic growth ahead of what we would have seen in consumption for the quarter, but the year-to-date numbers are largely in line.

Yes. And Nelson, if I could just tag on to that and build on what Mike was saying. I think we're focused on meeting consumers where they need us and at every price tier, but also in every channel. And what you're seeing is really, as Mike alluded to, is a significant migration of consumers to e-commerce and club.

And so if those are not as well tracked, there can be a disconnect there, and you're certainly missing some of the growth that's happening. And so I'll just bring that to life with an example. In digital channels in North America, 99% of our growth last year came from digital. And this year, it's 100%. And I would -- we have a 7-point share benefit.

Our share is higher by 7 points on digital versus brick-and-mortar. And so that can have a pretty significant skew. And so that tracking piece tends to be -- the volumes there also tend to be a little bit lumpy and somewhat volatile. And so that tracking piece, I can understand maybe creates an additional noise in tracking things. But it is strong growth, and we're focused on executing our plans and delivering for consumers in all channels.

Your next question is coming from Chris Carey from Wells Fargo.

So I wanted to come back to the promotional activity in North America and how you're responding. But I specifically wanted to dig a bit deeper on the comment that North America is kind of tracking well quarter-to-date. It's not really about a quarter-to-date question per se, but you've shifted promotional activity into Q4. I'd love to get a bit more detail on how you think that's doing? How is that improving your competitiveness? And Nelson, just any margin implications that we should be thinking about from this increased promotional activity?

Yes. I would start maybe with a broader statement there on just what's going on in North America overall. We're growing volume and mix, as you see in our results because we're focused on meeting consumers where they need us. And clearly, what you see right now is that consumers are really under pressure and their purchasing power is under pressure.

We don't really see candidly a catalyst for that to change anytime in the near term. However, our categories are essential categories with low substitution, and they're very important to people's lives. And so that's what I think why you see the demand remain relatively resilient.

And from a promotional standpoint, that's exactly why we tend to view promotion as a tactic to drive trial. It doesn't really expand our categories. I think our retail partners understand that as well. And so our focus is really on strengthening our offerings by investing in value propositions and differentiated innovation at every rung of the good, better, best ladder, especially cascading those innovations across the portfolio, and that's exactly kind of what we're doing.

So that shows up in the form of strengthening the value offerings like I just talked about with Snug & Dry a minute ago for value-seeking consumers, improving the product quality, so they're getting more value for money as well as elevating benefits to drive trade-up and premiumization. And we see the premium segment of the category healthy and still growing kind of across our portfolio.

And one more thing I would note is just the volume/mix growth in North America, I think, is the proof point that, that is working. If you look at North America, we're kind of getting volume/mix growth on top of volume/mix growth. So year-to-date, our volume/mix growth in North America was about 2.2%. And if you looked at that on a 2-year stack basis, it would be 2.9%. And so that really is kind of how things are unfolding. So the promotional dynamics, our strategy was really to really focus on executing the play that I just described.

Yes. And then maybe, Chris, I'll add. I think earlier in the quarter, we saw competitively some deeper discount, deeper than we had seen discounting. It probably didn't have as much of an impact as we had originally thought. So that's kind of one delta. And then the other delta then also is our trial driving on the -- on our new innovation.

And as Russ said earlier, we're really only promoting the brand to drive trial on the innovation. And so I think that is getting traction. So overall, I'd say our brands are very, very durable, especially in this environment.

And to your question, Chris, related to margins. I mean, a few things that we expect to unfold in Q4 as it relates to gross margin -- we -- because of the timing of some of our investments, both on the supply chain and the mitigating actions realization related to the tariffs, we actually would be expecting gross margins to get back to expanding as we head into the fourth quarter.

As you think about operating profit margin, though, we are stepping up investments marketing-wise sequentially in the quarter and not in an immaterial manner because we're supporting all of the initiatives that we have. So from an operating profit margin, we'd actually expect to be not too different from what we would have seen last year in the same quarter, delivering a full year expansion of gross margin -- of operating profit margin is kind of our expectation at this point.

Okay. One quick follow-up. I couldn't quite tell, but did your commodity outlook, if you exclude the impact of tariffs come up a bit today? Maybe I'm misreading that. And if so, what's driving that? And maybe just more broadly, how you see the cost outlook evolving here? If you'd like to add a bit of thoughts on how the tariff backdrop is evolving, that may also be helpful.

Yes. So before I get to tariffs, one thing is I think I said versus prior year. So versus prior year, we would see an expansion in operating profit as well. I was referring more to quarter-on-quarter, it would be not too dissimilar. It would be largely a little bit below because of the investments.

In any case, getting to tariffs, two things that have played out on tariffs. One, on the gross element of tariffs, we are down and improved about $70 million. So we were about $170 million. We're down to about $100 million gross tariffs. On the mitigating actions, we're still mitigating around $50 million because of the timing of that, and we do expect to be able to largely mitigate them all as we get through last year. So that should play out.

Obviously, on the tariffs front, there's a lot of moving pieces, Chris, and we're staying attuned to what's happening on that front. But overall, the good news is that we are seeing the mitigating actions coming through. We expect that to play through as we go into Q4 and early 2026 and our teams are activating all the elements in the toolkit to offset.

Your next question is coming from Nik Modi from RBC Capital Markets.

Mike, so just maybe you could just give some clarity on the full 2025 guide just on the top line. Obviously, over delivery this quarter, but it looks like there's a little bit of a step back in 4Q. So I just wanted to just understand, is there something you're seeing? Or is it just the environment is volatile, so you're just kind of appropriating your guidance accordingly? And then just I'll ask my follow-up now. Procter & Gamble talked about some exclusions on tariffs or some inputs. And I'm just curious if you're seeing that as well.

Yes. Maybe I'll just -- I'll comment briefly on the last. Yes, some, right? And so -- and importantly, you have to recognize some of our products are daily essentials. And so there is an exclusion for Brazilian eucalyptus. And so -- and that's obviously an important factor for us. So that's one big area that I think we're very pleased to have been able to receive. Do you want to comment on the?

I can go on the guide for the top line, Nik. So I think a few things to unpack. On a year-to-date basis, our organic sales are 1.6%. And we -- what we're seeing on the categories at this stage is that the categories will grow around 2%, and our expectation right now is to grow largely in line with the categories for the full year. So in essence, I mean, we would see an acceleration in Q4, if not at least at the same level of what we saw growth in Q3 based on all of our programs. Does that clarify?

Yes, that does, thank you, so much.

Nik, and one more thing I'll add is just, as you know, we always talk about driving the virtuous cycle in our business and so we have seen a little strength, and we started off the year well. Third quarter came in good. So we're going to continue to reinvest in our brands and make sure that we can drive ongoing momentum as we get into next year.

Your next question is coming from Anna Lizzul from Bank of America.

I was wondering if we could take a step back on the diaper category. We're seeing the category evolving here with certain ultra-premium players expanding the market on the top end. I was wondering how you see Kimberly competing in this environment where we're seeing growth but also increased competition at the mid-tier and value ranges, but more robust growth on the ultra-premium side with some newer brands in the U.S.

So I was wondering, is this an area in ultra-premium where Kimberly could compete through innovation or potentially through M&A? And then how do you see the overall category dynamics developing from here?

Yes. The great thing about the diaper category and also all of our categories that performance is what really, really matters. And so -- and Anna, we're very confident that we have the best technologies. We have a great pipeline of technology in our go-forward years. Next year's innovations will be better than this year's and '27 innovations will be better than '26. And so there's that.

I would say our strategy, as we've said kind of -- you've probably heard us say it a lot, hey, we want to win in every rung of the good, better, best ladder. And so -- and that's what's driven our business globally is really expansion, premiumization of the category through better features and products worth paying more for.

Just to give you an example, in North America, our shift over the last 10 years, 10 years or so, our premium mix has gone from 40% of our business in North America to just under 70%. In China, our premium mix has gone from 6% 5 years ago to well over 40%, right? And so that's kind of our underlying strategy.

However, in this environment, we also recognize we have to have a great value proposition in the value tiers. We don't want to be a niche premium brand, and so this is why Russ has talked about us cascading our best innovation, our best features into the, I would say, the mid-tiers and so that we can have a superior offering across the line. But maybe, Russ, you may want to add a few thoughts.

Yes. I'd just add something. You mentioned super premium. I think we're excited about that, and that's consistent with what we're seeing just because I think it illustrates that there's plenty of room for us to continue to premiumize the category. And you see that demand on the premium and super premium side is out there.

And so continue to look for us to both drive that, as Mike just talked about, the premiumization success we've had, both in the United States and other markets, including China. We're going to continue to focus on that in addition to bringing great value at the mainstream and premium tiers.

Great. And just one follow-up on the cost side. You did mention in early September, your expectation to reduce your volatility to fiber, and that would approach 0 following the JV agreement. So I was wondering if you could elaborate on that more and the efforts that you're making towards that so far.

Yes. Maybe I'll start Anna. I'd say one thing. I'd say -- yes, volatility is one of the big things that we've been working on because we recognize like that was one of the features of the KMB stock that was different from maybe some other companies. And so -- and one of the key sources of that volatility was fiber prices, right, or our cost of fiber was more volatile historically.

I'd say this transaction and partnership on our international family and professional business with Suzano really does a couple of things. One, it really kind of stabilizes the source of the fiber cost, partnering with one of the most efficient producers of fiber in the world has some strong advantages, and so I'd say that brings an advantage.

Obviously, the nature of the joint venture itself by reducing our stake in that business internationally inherently reduces our volatility, and then I would also say, by nature of our strong partnership with Suzano, we have since Nelson has joined us and brought some of our kind of, I would say, risk management mindset that he and I used to have at our prior company here, we have worked hard to smooth out and take out volatility in the input costs that we've had. And hopefully, you can see that in your models.

And just to build on what Mike is saying, the transition that we've been doing over the last 2.5, 3 years to integrated margin management, Anna, has really percolated across the entire organization. The notion of pricing net of cost at least neutral in the mid- to long term, is gaining hold across the organization, and that's really a way of working that has allowed us to have more proactive management of the volatility separate from all the other actions that we're taking.

So that is a big, big cultural change across the organization, and we're seeing that play out over the last 2 to 2.5 years, and that's what also gives us the confidence of being able to attain our milestone margin targets before the end of the decade, both on the gross margin and the operating margin as we continue to progress in this Powering Care transformation journey.

Okay. I think we'll end it there for today. For anybody that has any follow-up questions, the IR team will be around all day to take them. I know there are other calls that people need to get to. So thanks, everybody, for joining us, and have a great day.

Thank you. Everyone, this concludes today's event. You may disconnect at this time, and have a wonderful day. Thank you for your participation.